Clinical and Molecular Hepatology

"Liver transplant"

Research Letter

Non-infectivity of hepatitis B virus under nucleoside analog therapy revealed through auxiliary partial orthotopic liver transplantation: Xiaojie Chen, Guiwen Guan, Lin Wei, Jidong Jia, Xiangmei Chen, Fengmin Lu, Zhijun Zhu; Clin Mol Hepatol 2025;31(3):e263-e267.
Published online May 8, 2025; DOI: https://doi.org/10.3350/cmh.2025.0393

8,067 View
70 Download

Correspondences

Liver Transplantation

Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”: Soon Kyu Lee, Jong Young Choi; Clin Mol Hepatol 2025;31(2):e161-e162.
Published online February 13, 2025; DOI: https://doi.org/10.3350/cmh.2025.0121

5,400 View
34 Download

Liver Transplantation

Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”: Soon Kyu Lee, Jong Young Choi; Clin Mol Hepatol 2025;31(2):e212-e214.
Published online February 10, 2025; DOI: https://doi.org/10.3350/cmh.2025.0100

5,729 View
24 Download

Editorial

Liver Transplantation

Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”: Jongman Kim; Clin Mol Hepatol 2025;31(2):589-591.
Published online January 24, 2025; DOI: https://doi.org/10.3350/cmh.2025.0076

Citations

Citations to this article as recorded by

Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Soon Kyu Lee, Jong Young Choi
Clinical and Molecular Hepatology.2025; 31(2): e161. CrossRef

5,810 View
46 Download
1 Web of Science
Crossref

Letter to the Editor

Liver Transplantation

Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”: Rui Shi, Minghua Wang; Clin Mol Hepatol 2025;31(2):e137-e139.
Published online January 9, 2025; DOI: https://doi.org/10.3350/cmh.2024.1159

Citations

Citations to this article as recorded by

Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Soon Kyu Lee, Jong Young Choi
Clinical and Molecular Hepatology.2025; 31(2): e212. CrossRef

6,123 View
46 Download
1 Web of Science
Crossref

Review

Liver Transplantation

Prediction and management of small-for-size syndrome in living donor liver transplantation: Jia-hao Law, Alfred Wei-Chieh Kow; Clin Mol Hepatol 2025;31(Suppl):S301-S326.
Published online December 10, 2024; DOI: https://doi.org/10.3350/cmh.2024.0870

Abstract
PDF

Small-for-size syndrome (SFSS) remains a critical challenge in living donor liver transplantation (LDLT), characterized by graft insufficiency due to inadequate liver volume, leading to significant postoperative morbidity and mortality. As the global adoption of LDLT increases, the ability to predict and manage SFSS has become paramount in optimizing recipient outcomes. This review provides a comprehensive examination of the pathophysiology, risk factors, and strategies for managing SFSS across the pre-, intra-, and postoperative phases. The pathophysiology of SFSS has evolved from being solely volume-based to incorporating portal hemodynamics, now recognized as small-for-flow syndrome. Key risk factors include donor-related parameters like age and graft volume, recipient-related factors such as MELD score and portal hypertension, and intraoperative factors related to venous outflow and portal inflow modulation. Current strategies to mitigate SFSS include careful graft selection based on graft-to-recipient weight ratio and liver volumetry, surgical techniques to optimize portal hemodynamics, and novel interventions such as splenic artery ligation and hemiportocaval shunts. Pharmacological agents like somatostatin and terlipressin have also shown promise in modulating portal pressure. Advances in 3D imaging and artificial intelligence-based volumetry further aid in preoperative planning. This review emphasizes the importance of a multifaceted approach to prevent and manage SFSS, advocating for standardized definitions and grading systems. Through an integrated approach to surgical techniques, hemodynamic monitoring, and perioperative management, significant strides can be made in improving the outcomes of LDLT recipients. Further research is necessary to refine these strategies and expand the application of LDLT, especially in challenging cases involving small-for-size grafts.

Citations

Citations to this article as recorded by

Dual, Split and Multi-Graft Liver Transplantation: Surgical Strategies to Maximize Liver Utilization
Josip Basić, Ivan Romić, Juraj Kolak, Goran Pavlek, Hrvoje Silovski
Transplantology.2026; 7(1): 2. CrossRef
Simultaneous Splenic Artery Ligation During Adult Orthotopic Liver Transplantation Improves Surgical Outcomes
Zichen Wang, Zhan Qu, Fan Mu, Lexuan Xu, Liangshuo Hu, Bo Wang, Jianhua Shi
World Journal of Surgery.2025; 49(10): 2909. CrossRef
PORTAL FLOW MODULATION IN LIVING DONOR LIVER TRANSPLANTATION
M Tursynbay, M Doskhanov, Z Ospan, B Baimakhanov, S Kaniyev, S Tileuov, D Mukazhanov, A Chormanov
BULLETIN OF SURGERY OF KAZAKHSTAN.2025; 85(4): 73. CrossRef

8,603 View
194 Download
2 Web of Science
Crossref

Original Article

Liver Transplantation

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation: Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, Pil Soo Sung, Seung Kew Yoon, Jeong Won Jang, Jong Young Choi; Clin Mol Hepatol 2025;31(1):131-146.
Published online October 2, 2024; DOI: https://doi.org/10.3350/cmh.2024.0451

Background/Aims
This study aimed to identify the risk factors for chronic kidney disease (CKD) and end-stage renal disease (ESRD) following liver transplantation (LT), with a specific focus on tacrolimus levels and intrapatient variability (IPV).
Methods
Among the 1,076 patients who underwent LT between 2000 and 2018, 952 were included in the analysis. The tacrolimus doses and levels were recorded every 3 months, and the IPV was calculated using the coefficient of variability. The cumulative incidence rates of CKD and ESRD were calculated based on baseline kidney function at the time of LT. The impact of tacrolimus levels and their IPV on the development of CKD and ESRD was evaluated, and the significant risk factors were identified.
Results
Within a median follow-up of 97.3 months, the 5-year cumulative incidence rates of CKD (0.58 vs. 0.24) and ESRD (0.07 vs. 0.01) were significantly higher in the acute kidney injury group than in the normal glomerular filtration rate (GFR) group. In the normal GFR group, the tacrolimus levels were identified as a risk factor for CKD, with a level of ≤4.5 ng/mL suggested as optimal for minimizing the risk of CKD. Furthermore, the IPV of tacrolimus levels and doses emerged as a significant risk factor for CKD development in both groups (p<0.05), with tenofovir disoproxil fumarate also being a risk factor in HBV-infected patients. The IPV of tacrolimus levels was also a significant factor in ESRD development (p<0.05).
Conclusions
This study elucidated the optimal tacrolimus trough level and highlighted the impact of IPV on the CKD and ESRD development post-LT.

Citations

Citations to this article as recorded by

Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development foll
Jongman Kim
Clinical and Molecular Hepatology.2025; 31(2): 589. CrossRef
Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Soon Kyu Lee, Jong Young Choi
Clinical and Molecular Hepatology.2025; 31(2): e212. CrossRef
Clinical significance and gene prediction of a novel classification system based on tacrolimus concentration-to-dose ratio in the early post-liver transplant period
Junwei Fan, Peihao Wen, Liyun Yuan, Yan Xia, Shijie Hu, Xiaoqing Zhang, Zhihai Peng
Frontiers in Pharmacology.2025;[Epub] CrossRef
Chronic kidney disease at one year after liver transplantation: Role of changes in immunosuppression over three decades
Alejandro Muñoz-Serrano, María Jesús Citores, Andrea Gutiérrez-Villanueva, Víctor Moreno-Torres, Jorge V López-Ibor, Natalia Vicente, Valentín Cuervas-Mons
World Journal of Transplantation.2025;[Epub] CrossRef

9,724 View
217 Download
5 Web of Science
Crossref

Review

Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation: Meng Sha, Jun Wang, Jie Cao, Zhi-Hui Zou, Xiao-ye Qu, Zhi-feng Xi, Chuan Shen, Ying Tong, Jian-jun Zhang, Seogsong Jeong, Qiang Xia; Clin Mol Hepatol 2025;31(Suppl):S285-S300.
Published online August 19, 2024; DOI: https://doi.org/10.3350/cmh.2024.0323

Abstract
PDF

Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated death globally. Liver transplantation (LT) has emerged as a key treatment for patients with HCC, and the Milan criteria have been adopted as the cornerstone of the selection policy. To allow more patients to benefit from LT, a number of expanded criteria have been proposed, many of which use radiologic morphological characteristics with larger and more tumors as surrogates to predict outcomes. Other groups developed indices incorporating biological variables and dynamic markers of response to locoregional treatment. These expanded selection criteria achieved satisfactory results with limited liver supplies. In addition, a number of prognostic models have been developed using clinicopathological characteristics, imaging radiomics features, genetic data, and advanced techniques such as artificial intelligence. These models could improve prognostic estimation, establish surveillance strategies, and bolster long-term outcomes in patients with HCC. In this study, we reviewed the latest findings and achievements regarding the selection criteria and post-transplant prognostic models for LT in patients with HCC.

Citations

Citations to this article as recorded by

A systematic review of MicroRNA (miRNA) biomarkers in the diagnosis and prognosis of hepatocellular carcinoma
J. M. John Britto, T Beula Bell
Irish Journal of Medical Science (1971 -).2026;[Epub] CrossRef
Correspondence to editorial on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”
Soon Sun Kim, Hyung Seok Kim, Jae Youn Cheong, Jung Woo Eun
Clinical and Molecular Hepatology.2026; 32(1): e72. CrossRef
Artificial Intelligence Applications in the Diagnosis, Treatment, and Prognosis of Hepatocellular Carcinoma
Ming-Ying Lu, Jacky Chung-Hao Wu, Henry Horng-Shing Lu, Mohammed Eslam, Ming-Lung Yu
Gut and Liver.2026; 20(1): 5. CrossRef
Current strategies in managing metabolic complications following liver transplantation
Soon Kyu Lee
Annals of Liver Transplantation.2025; 5(1): 3. CrossRef
Artificial intelligence in gastrointestinal surgery: A minireview of predictive models and clinical applications
Himanshu Agrawal, Nikhil Gupta, Himanshu Tanwar, Natasha Panesar
Artificial Intelligence in Gastroenterology.2025;[Epub] CrossRef
Machine Learning–Based Selection of Resection vs Transplant and Survival in Hepatocellular Carcinoma
Hyun Uk Kim, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You
JAMA Network Open.2025; 8(9): e2532353. CrossRef
Prognostic Significance of Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Liver Transplantation for Hepatocellular Carcinoma
Imam Bakir Bati, Umut Tuysuz, Elif Eygi
Current Oncology.2025; 32(8): 464. CrossRef
Advancing Hepatocellular Carcinoma Therapy with Next-Generation Molecular and Immunotherapeutics
Mudassir Hassan, Ijaz Hussain, Kafeel Ahmad, Saima Zafar, Adeel Khalid, Muhammad Haseeb, Nazim Hussain, Muhammad Adeel Ghafar
Journal of Hepatocellular Carcinoma.2025; Volume 12: 2907. CrossRef
Liver transplantation for alcohol-related liver disease in Korea: The need for patient management guidelines
Soon Kyu Lee
Annals of Liver Transplantation.2024; 4(2): 40. CrossRef

9,089 View
211 Download
4 Web of Science
Crossref

Original Article

Liver Transplantation

Ischemia-free liver transplantation improves the prognosis of recipients using functionally marginal liver grafts: Shuai Wang, Xiaohong Lin, Yunhua Tang, Yichen Liang, Min Zhang, Zhonghao Xie, Yiwen Guo, Yuqi Dong, Qiang Zhao, Zhiyong Guo, Dongping Wang, Xiaoshun He, Weiqiang Ju, Maogen Chen; Clin Mol Hepatol 2024;30(3):421-435.
Published online April 11, 2024; DOI: https://doi.org/10.3350/cmh.2024.0139

Background/Aims
The shortage of donor liver hinders the development of liver transplantation. This study aimed to clarify the poor outcomes of functionally marginal liver grafts (FMLs) and provide evidence for the improvement of ischemia-free liver transplantation (IFLT) after FML transplantation.
Methods
Propensity score matching was used to control for confounding factors. The outcomes of the control group and FML group were compared to demonstrate the negative impact of FMLs on liver transplantation patients. We compared the clinical improvements of the different surgical types. To elucidate the underlying mechanism, we conducted bioinformatic analysis based on transcriptome and single-cell profiles.
Results
FMLs had a significantly greater hazard ratio (HR: 1.969, P=0.018) than did other marginal livers. A worse 90-day survival (Mortality: 12.3% vs. 5.0%, P=0.007) was observed in patients who underwent FML transplantation. Patients who received FMLs had a significant improvement in overall survival after IFLT (Mortality: 10.4% vs 31.3%, P=0.006). Pyroptosis and inflammation were inhibited in patients who underwent IFLT. The infiltration of natural killer cells was lower in liver grafts from these patients. Bulk transcriptome profiles revealed a positive relationship between IL-32 and Caspase 1 (R=0.73, P=0.01) and between IL-32 and Gasdermin D (R=0.84, P=0.0012).
Conclusions
FML is a more important negative prognostic parameter than other marginal liver parameters. IFLT might ameliorate liver injury in FMLs by inhibiting the infiltration of NK cells, consequently leading to the abortion of IL-32, which drives pyroptosis in monocytes and macrophages.

Citations

Citations to this article as recorded by

Shortening the recipient warm ischemia time could be a strategy for expanding the liver donor pool
Jia-Wei Yu, Lin-Biao Xiang, Xiao-Juan Dong, Chen-Xi Yang, Lei Wang, Xiao-Yu Liu, Yi-Hong Song, Xian-Jie Bai, Jing-Wen Xiao, Lu Ren, Qin-Hong Xu, Gang-Hua Yang, Yi Lv, Qiang Lu
World Journal of Gastroenterology.2025;[Epub] CrossRef
Ischemia-free liver transplantation improves long-term outcomes in a 5-year follow-up study
Zehua Jia, Jiaxing Zhu, Jiayi Zhang, Jian Zhang, Changjun Huang, Niancun Zhang, Songming Li, Yuqi Dong, Yao Liu, Ping Zeng, Tielong Wang, Zhitao Chen, Yunhua Tang, Qiang Zhao, Maogen Chen, Yinghua Chen, Anbin Hu, Weiqiang Ju, Yi Ma, Dongping Wang, Xiaofen
JHEP Reports.2025; 7(7): 101393. CrossRef
Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease
Shaoyang Qin, Xiaochen Bo, Hongyuan Liu, Zhishuo Zhang, Zhicong Zhao, Qiang Xia
Hepatology.2025;[Epub] CrossRef
Economic impact of graft’s cold ischemia time on infection and post-liver transplant costs
DEYVID FERNANDO MATTEI DA-SILVA, OTÁVIO MONTEIRO BECKER JÚNIOR, JANINE SCHIRMER, NACIME SALOMÃO MANSUR, ELIZABETH AKEMI NISHIO, BARTIRA DE AGUIAR ROZA
Revista do Colégio Brasileiro de Cirurgiões.2025;[Epub] CrossRef
Avaliação econômica do impacto do tempo de isquemia fria do enxerto na infecção pós-operatória e nos custos pós-transplante hepático
DEYVID FERNANDO MATTEI DA-SILVA, OTÁVIO MONTEIRO BECKER JÚNIOR, JANINE SCHIRMER, NACIME SALOMÃO MANSUR, ELIZABETH AKEMI NISHIO, BARTIRA DE AGUIAR ROZA
Revista do Colégio Brasileiro de Cirurgiões.2025;[Epub] CrossRef
Ischemia-free Liver Transplantation: 7-y Experience From a Single-center Cohort in China
Qingze Meng, Honghui Chen, Jiahao Li, Meiting Qin, Jinbo Huang, Mingxi Zhang, Chengzhi Wang, Jitian He, Ruilin Cai, Huadi Chen, Yongqi Yang, Tielong Wang, Yefu Li, Maogen Chen, Weiqiang Ju, Dongping Wang, Zhiyong Guo, Yunhua Tang, Xiaoshun He, Qiang Zhao
Transplantation.2025;[Epub] CrossRef
The impact of ischemia-free liver transplantation on improving the prognosis of recipients using functionally marginal liver grafts: Editorial on “Ischemia-free liver transplantation improves the prognosis of recipients using functionally marginal liver g
Ho Joong Choi
Clinical and Molecular Hepatology.2024; 30(4): 702. CrossRef

8,349 View
181 Download
5 Web of Science
Crossref

Editorial

Steatotic liver disease

How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease: Byeong Geun Song, Dong Hyun Sinn; Clin Mol Hepatol 2023;29(2):411-413.
Published online March 6, 2023; DOI: https://doi.org/10.3350/cmh.2023.0058

Citations

Citations to this article as recorded by

Microemulsion co-delivering curcumin and DHA-rich algal oil alleviates nonalcoholic fatty liver disease
Jianlin He, Weizhu Chen, Sisi Chen, Menglei Shi, Ling Lin, Yiping Zhang, Bihong Hong
Journal of Functional Foods.2024; 112: 105998. CrossRef
Liver transplantation for alcohol-related liver disease in Korea: The need for patient management guidelines
Soon Kyu Lee
Annals of Liver Transplantation.2024; 4(2): 40. CrossRef

6,560 View
60 Download
1 Web of Science
Crossref

Reviews

Hepatic neoplasm

Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective: Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, Victor Ho-Fun Lee, Wai-Kay Seto, Man-Fung Yuen; Clin Mol Hepatol 2023;29(2):217-229.
Published online December 28, 2022; DOI: https://doi.org/10.3350/cmh.2022.0399

Abstract
PDF

Hepatocellular carcinoma (HCC) is a major public health burden in Hong Kong, and chronic hepatitis B is the most common HCC etiology in our region. With the high case load, extensive local expertise on HCC has been accumulated. This article summarized local guidelines and real-life practice on HCC management in Hong Kong. For HCC surveillance, liver ultrasound and serum alpha-fetoprotein for periodic screening is recommended in viral hepatitis or cirrhotic patients, and this is adhered to in clinical practice. HCC diagnosis is not covered in local guidelines, yet our practice is in-line with regional guidelines, where diagnosis is usually achieved by cross-sectional imaging and without the need for histology. Our guidelines recommend using the Hong Kong Liver Cancer Staging for pre-treatment staging, yet we routinely use other widely-adopted systems such as the Barcelona Clinic Liver Cancer Staging and the Tumor-Node-Metastasis Staging as well. Our local guidelines have provided clear treatment algorithms for the whole range of HCC therapies, including resection, ablation, transplant, transarterial chemoembolization, transarterial radioembolization, stereotactic body radiation therapy, targeted therapy, and immunotherapy. Real-life treatment choices are largely in line with the guidelines, although treatment protocols are individualized, and availability of specific therapies can vary between centers. Overall, HCC guidelines in Hong Kong are tailored based on local expertise and our unique patient population. The guidelines are up-to-date and provide practical pathways to assist our routine practice. Regular updates of local guidelines are warranted to account for the rapidly evolving paradigm of HCC management.

Citations

Citations to this article as recorded by

Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure
Rex Wan-Hin Hui, Trevor Kwan-Hung Wu, Karen Cheuk-Ying Ho, Ryan Hin-Man Leung, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Lung Yi Mak, Man-Fung Yuen
Gut.2026; 75(1): 119. CrossRef
A systematic review of MicroRNA (miRNA) biomarkers in the diagnosis and prognosis of hepatocellular carcinoma
J. M. John Britto, T Beula Bell
Irish Journal of Medical Science (1971 -).2026;[Epub] CrossRef
Advancements in locoregional therapy for advanced hepatocellular carcinoma: Emerging perspectives on combined treatment strategies
Qi Liu, Renjie Zhang, Weixi Shen
European Journal of Surgical Oncology.2025; 51(2): 109502. CrossRef
Investigational RNA Interference Agents for Hepatitis B
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
BioDrugs.2025; 39(1): 21. CrossRef
Gold(I) complexes bearing EGFR-inhibiting ligands as anti-HCC agents through dual targeting of EGFR and TrxR
Yawen Wang, Xiaoyan Ma, Xuejie Chen, Zhenfan Wen, Chunyang Bi, Zhongren Xu, Wukun Liu
European Journal of Medicinal Chemistry.2025; 283: 117137. CrossRef
Multimodal multiphasic preoperative image-based deep-learning predicts HCC outcomes after curative surgery
Rex Wan-Hin Hui, Keith Wan-Hang Chiu, I-Cheng Lee, Chenlu Wang, Ho-Ming Cheng, Jianliang Lu, Xianhua Mao, Sarah Yu, Lok-Ka Lam, Lung-Yi Mak, Tan-To Cheung, Nam-Hung Chia, Chin-Cheung Cheung, Wai-Kuen Kan, Tiffany Cho-Lam Wong, Albert Chi-Yan Chan, Yi-Hsia
Hepatology.2025; 82(2): 344. CrossRef
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?
Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen
Hepatology International.2025; 19(2): 304. CrossRef
Prospect of emerging treatments for hepatitis B virus functional cure
Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen
Clinical and Molecular Hepatology.2025; 31(Suppl): S165. CrossRef
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies
Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak
Hepatology International.2025; 19(4): 704. CrossRef
Comparative prognostic performance of staging systems for hepatocellular carcinoma: Evidence from a Vietnamese cohort study
Tuong-Anh Mai-Phan, Trong-Kha Nguyen, Tri-Nhan Pham, Minh-Quang Tran, Kim-Long Le
World Journal of Hepatology.2025;[Epub] CrossRef
The Prevailing Role of Diabetes Mellitus Among Cardiometabolic Risk Factors in Metabolic Dysfunction-associated Steatotic Liver Disease Prognostication
Karen Cheuk-Ying Ho, Lung-Yi Mak
Journal of Clinical and Experimental Hepatology.2025; 15(5): 103119. CrossRef
15-Year Trends in Hepatocellular Carcinoma: Epidemiology, Treatment, and Outcomes from a Hospital-Based Registry
Songgyung Kim, Jina Park, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Ki-Hun Kim, Jonggi Choi
Gut and Liver.2025; 19(5): 746. CrossRef
Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip
Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Disparate patterns of disease time burden in patients with HCC on immunotherapy or tyrosine kinase inhibitors
Rex Wan-Hin Hui, Matthew Shing-Hin Chung, Lu Li, Xianhua Mao, Chi-Leung Chiang, Carlos King-Ho Wong, Ian Chi-Kei Wong, Ka-Shing Cheung, Man-Fung Yuen, Wai-Kay Seto, Lung-Yi Mak
JHEP Reports.2025; 7(11): 101578. CrossRef
Development of a novel routine blood-based AI model for hepatocellular carcinoma screening—a territory-wide study
K.-N. Kwok, K.-M. Chueng, S.J.-L. Lam, M. Seo, C.Y. Lau, P.Y.-M. Woo, H.-S. Lam, S.-M. Yip, S. Lam, O.-P. Chiu, W.W.Y. Sung, H.H.-W. Liu, K.K.-H. Bao, J.C.-H. Chow, S.K.-K. Ng, H.H.-Y. Yiu, D.C.C. Lam
ESMO Gastrointestinal Oncology.2025; 10: 100241. CrossRef
Transarterial Radioembolization (TARE) in Patients with Hepatocellular Carcinoma: A Comparison of Palliative with Bridging-to-Transplant Concepts
Jacqueline Schönherr, Philipp Seifert, Falk Gühne, Thomas Winkens, Falk Rauchfuß, Utz Settmacher, Martin Freesmeyer, Robert Drescher
Cancers.2024; 16(1): 235. CrossRef
Hepatocellular carcinoma: Advances in systemic therapies
Trevor Kwan-Hung Wu, Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen
F1000Research.2024; 13: 104. CrossRef
ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B
Ryan Hin-Man Leung, Rex Wan-Hin Hui, Lung-Yi Mak, Xianhua Mao, Kevin Sze-Hang Liu, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Man-Fung Yuen
Journal of Hepatology.2024; 81(2): 218. CrossRef
Hepatocellular carcinoma: Advances in systemic therapies
Trevor Kwan-Hung Wu, Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen
F1000Research.2024; 13: 104. CrossRef
Bioequivalence Study of Velpatasvir/Sofosbuvir Oral Coated Tablets in Healthy Volunteers Under Fasting Conditions
Sergei Noskov, Anna Arefeva, Kseniia Radaeva, Igor Makarenko, Maria Gefen, Roman Drai
Clinical Pharmacology in Drug Development.2024; 13(10): 1123. CrossRef
Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen, James Fung
Expert Review of Gastroenterology & Hepatology.2023; 17(5): 443. CrossRef
The prime time for management of hepatocellular carcinoma in Hong Kong
Landon L. Chan, Stephen L. Chan
Clinical and Molecular Hepatology.2023; 29(2): 345. CrossRef
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clinical and Molecular Hepatology.2023; 29(2): 252. CrossRef
World Hepatitis Day 2023: Are we close to the target?
Rex Wan-Hin Hui, James Fung
Indian Journal of Medical Research.2023; 158(1): 1. CrossRef
Global trends of targeted therapy for hepatocellular carcinoma: A bibliometric and visualized study from 2008 to 2022
Xuan-Ang Yang, Rong Jin, Lei-Ming Zhang, Dong-Jian Ying
Medicine.2023; 102(34): e34932. CrossRef

11,851 View
283 Download
25 Web of Science
Crossref

Steatotic liver disease

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management: Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra; Clin Mol Hepatol 2023;29(Suppl):S286-S301.
Published online December 28, 2022; DOI: https://doi.org/10.3350/cmh.2022.0392

Abstract
PDF

Non-alcoholic fatty liver disease (NAFLD) is currently the fastest growing indication to liver transplantation (LT) in Western Countries, both for end stage liver disease and hepatocellular carcinoma. NAFLD/non-alcoholic steatohepatitis (NASH) is often expression of a systemic metabolic syndrome; therefore, NAFLD/NASH patients require a multidisciplinary approach for a proper pre-surgical evaluation, which is important to achieve a post-transplant outcome comparable to that of other indications to LT. NAFLD/NASH patients are also at higher risk of post-transplant cardiovascular events, diabetes, dyslipidemia, obesity, renal impairment and recurrent NASH. Lifestyle modifications, included diet and physical activity, are key to improve survival and quality of life after transplantation. A tailored immunosuppressive regimen may be proposed in selected patients. Development of new drugs for the treatment of recurrent NASH is awaited.

Citations

Citations to this article as recorded by

Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019
Jacob Romano, Jessica Burnside, Giada Sebastiani, Alnoor Ramji, Keyur Patel, Mark Swain, Sahar Saeed
Annals of Hepatology.2025; 30(1): 101757. CrossRef
Macronutrient Modulation in Metabolic Dysfunction-Associated Steatotic Liver Disease—the Molecular Role of Fatty Acids compared with Sugars in Human Metabolism and Disease Progression
Sinéad M Mullin, Aidan J Kelly, Méabh B Ní Chathail, Suzanne Norris, Christopher E Shannon, Helen M Roche
Advances in Nutrition.2025; 16(3): 100375. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk
Vlad Alexandru Ionescu, Gina Gheorghe, Nicolae Bacalbasa, Camelia Cristina Diaconu
Biomolecules.2025; 15(2): 163. CrossRef
Metabolic dysfunction-associated steatotic liver disease correlates with higher lower graft survival in liver transplant recipients with hepatocellular carcinoma
Marwan Alsaqa, Leandro Sierra, Ana Marenco-Flores, Ximena Parraga, Romelia Barba, Daniela Goyes, N. Begum Ozturk, Michael P. Curry, Alan Bonder, Behnam Saberi
European Journal of Gastroenterology & Hepatology.2025; 37(4): 497. CrossRef
Clinical and Economic Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Spanish Mediterranean Region: A Population-Based Study
Javier Díaz Carnicero, Inma Saurí-Ferrer, Josep Redon, Jorge Navarro, Gonzalo Fernández, Carlos Hurtado, Karine Ferreira, Carolina Alvarez-Ortega, Antón Gómez, Carlos J. Martos-Rodríguez, David Martí-Aguado, Desamparados Escudero, Marta Cedenilla
Journal of Clinical Medicine.2025; 14(7): 2441. CrossRef
MASLD or MAFLD: fatty liver by any name will pose the same challenge
Anil Chandra Anand, Dibyalochan Praharaj
Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Cardiac Remodeling and Arrhythmic Burden in Pre-Transplant Cirrhotic Patients: Pathophysiological Mechanisms and Management Strategies
Charilila-Loukia Ververeli, Yannis Dimitroglou, Stergios Soulaidopoulos, Evangelos Cholongitas, Constantina Aggeli, Konstantinos Tsioufis, Dimitris Tousoulis
Biomedicines.2025; 13(4): 812. CrossRef
Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Soon Kyu Lee, Jong Young Choi
Clinical and Molecular Hepatology.2025; 31(2): e212. CrossRef
Risk Factors Related to the Development of Nonalcoholic Fatty Liver: A Systematic Review
Omaira Valencia, Carolina López, Esteban Vanegas-Duarte, Carolina Fillizola, Diana Fernanda Bejarano Ramírez, Nicolás Andrés Cortés Mejía, Alonso Vera Torres, Kevork M. Peltekian
Canadian Journal of Gastroenterology and Hepatology.2025;[Epub] CrossRef
Safety, efficacy, and outcomes of invasive coronary angiography in liver transplant candidates
Carme Ginard, Giulia Pagano, Salvatore Brugaletta, Annabel Blasi, Marta Sánchez-Ric, Ander Regueiro, Roger Pujol, Sergio Rodriguez-Tajes, Pablo Ruiz, Jordi Colmenero, Gonzalo Crespo
JHEP Reports.2025; 7(7): 101428. CrossRef
The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort
Qi Feng, Chioma N Izzi-Engbeaya, Andrea D Branch, Benjamin H Mullish, Pinelopi Manousou, Mark Woodward
The Journal of Clinical Endocrinology & Metabolism.2025; 111(1): e58. CrossRef
MAFLD as a Cardiovascular Risk Factor: An Extended Retrospective Study with a Control Group
Małgorzata Szymala-Pędzik, Marcin Piersiak, Maciej Pachana, Karolina Lindner-Pawłowicz, Wioletta Szczepaniak, Małgorzata Sobieszczańska
Journal of Clinical Medicine.2025; 14(12): 4181. CrossRef
Metabolic-associated fatty liver disease: Noninvasive diagnosis and assessment of liver fibrosis
O. O. Karshina, I. S. Sabirov
Meditsinskiy sovet = Medical Council.2025; (8): 72. CrossRef
Are we standing on the shifting sands of post-transplant metabolic-associated steatotic liver disease?
Renata Zatta, Luana S da Silva, Guilherme Felga, Carolina FMG Pimentel
World Journal of Hepatology.2025;[Epub] CrossRef
Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States
Marika Hancock, Cayden Beyer, Michael Fuchs, Mukesh Harisinghani, Prasun Jalal, Michael Ndaa, Niharika Samala, Jose D. Vargas, Arjun Jayaswal
Journal of Medical Economics.2025; 28(1): 1370. CrossRef
Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards
Faisal Abaalkhail, Faisal M. Sanai, Khalid AlSwat, Adnan Alzanbagi, Ahmed Aljedai, Ali Alshehri, Assim Alfadda, Hamdan Alghamdi, Majid Almadi, Mohammad Aleissa, Mona Ismail, Saud Alsifri, Turki Alzahrani, Saleh Alqahtani, Waleed Al Hamoudi
Saudi Journal of Gastroenterology.2025;[Epub] CrossRef
Integrated Genomic Analysis Reveals the Synergistic Role of PNPLA3 and ABCC8 Variants in Diabetic MASLD in Pakistan
Asma Shabbir, Ambrina Khatoon, Zaigham Abbas, Sucheta Srivastava, Talat Mirza
Medical Sciences.2025; 13(3): 178. CrossRef
Sex-Stratified Prediction Models for 5-Year Nonalcoholic Fatty Liver Disease Risk in Thyroid Cancer Patients: A Nationwide Cohort Study
Young Bin Cho, Kyoung Sik Park
Biomedicines.2025; 13(9): 2250. CrossRef
Genome-Based Mexican Diet Bioactives Target Molecular Pathways in HBV, HCV, and MASLD: A Bioinformatic Approach for Liver Disease Prevention
Leonardo Leal-Mercado, Arturo Panduro, Alexis José-Abrego, Sonia Roman
International Journal of Molecular Sciences.2025; 26(18): 8977. CrossRef
Validation of MELD 3.0 and ReMELD-Na scoring systems: a German clinical cohort study
Aghnia J. Putri, Decan Jiang, Zoltan Czigany, Arianeb Mehrabi, Markus Wolfgang Buechler, Uta Merle, Christoph Michalski, Peri Husen
Langenbeck's Archives of Surgery.2025;[Epub] CrossRef
How best to combine liver transplantation and bariatric surgery?—Results from a global, web‐based survey
Jeannette Widmer, Janina Eden, Fariba Abbassi, Roberta Angelico, Fabian Rössler, Beat Müllhaupt, Philipp Dutkowski, Marco Bueter, Andrea Schlegel
Liver International.2024; 44(2): 566. CrossRef
Exploring the effects of epigallocatechin gallate on lipid metabolism in the rat steatotic liver during normothermic machine perfusion: Insights from lipidomics and RNA sequencing
Shuxuan Li, Yao Zhi, Wentao Mu, Mingqian Li, Guoyue Lv
European Journal of Pharmacology.2024; 964: 176300. CrossRef
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond
Allison Soto, Colby Spongberg, Alessandro Martinino, Francesco Giovinazzo
Biomedicines.2024; 12(2): 397. CrossRef
Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
Arghya Samanta, Moinak Sen Sarma
World Journal of Hepatology.2024; 16(4): 511. CrossRef
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients
David Pérez Compte, Lucas Etourneau, Anne-Marie Hesse, Alexandra Kraut, Justine Barthelon, Nathalie Sturm, Hélène Borges, Salomé Biennier, Marie Courçon, Marc de Saint Loup, Victoria Mignot, Charlotte Costentin, Thomas Burger, Yohann Couté, Christophe Bru
Biomarker Research.2024;[Epub] CrossRef
Cardiac abnormalities pre- and post-liver transplantation for metabolic dysfunction-associated steatohepatitis – Evidence and special considerations
Steven M. Elzein, Elizabeth W. Brombosz, Sudha Kodali
Journal of Liver Transplantation.2024; 15: 100228. CrossRef
Serum Creatinine as an Independent Predictor of Moderate to Severe Fibrosis in Chinese American Non-obese Metabolic Dysfunction-Associated Steatotic Liver Disease
Michael Sun, Vincent J Yao, Aivi A Rahman, Kevin Liu, Saud Rehman, Amber Sun, Alan C Yao
Cureus.2024;[Epub] CrossRef
Recent trends and new developments in liver transplantation
Yasuhiko Sugawara, Taizo Hibi
BioScience Trends.2024; 18(3): 206. CrossRef
Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice
Guanliang Chen, Yanwen Yu, Yuqin Zhu, Mayumi Nagashimada, Yajiao Wang, Naoto Nagata, Liang Xu
Endocrinology.2024;[Epub] CrossRef
Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review
Matthew L. Basa, Danielle S. Cha, David P. Mitchell, Daniel L. Chan
Metabolism and Target Organ Damage.2024;[Epub] CrossRef
The interrelation of cardiometabolic risk factors and metabolic dysfunction-associated steatotic liver disease subtypes
A. Yu. Ishchenko, M. Yu. Galushko, I. G. Bakulin
Meditsinskiy sovet = Medical Council.2024; (15): 146. CrossRef
Cardio-metabolic disorders in a patient with non-alcoholic fatty liver disease and normal body weight
Svetlana V. Turkina, Mikhail E. Statsenko, Irina A. Tyshchenko, Marina N. Titarenko, Marina A. Kosivtsova, Elena E. Gorbacheva
Journal of Volgograd State Medical University.2024; 21(3): 109. CrossRef
Exploring the knowledge and attitudes towards metabolic dysfunction associated fatty liver disease (MAFLD): Validation and correlations of MAFLD-knowledge questionnaire and MAFLD-attitude questionnaire
Samah Al Tawil, Mohamad Abdelkhalik, Adam El Fouani, Nour Allakiss, Lama Mattar, Wissam H. Faour, Rajaa Chatila
Heliyon.2024; 10(22): e40217. CrossRef
Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study
José Ignacio Martínez-Montoro, Isabel Arranz-Salas, Carolina Gutiérrez-Repiso, Ana Sánchez-García, Luis Ocaña-Wilhelmi, José M. Pinazo-Bandera, Diego Fernández-García, Araceli Muñoz-Garach, Dieter Morales-García, Miren García-Cortés, Eduardo García-Fuente
Nutrients.2024; 16(22): 3857. CrossRef
Liver transplantation for alcohol-related liver disease in Korea: The need for patient management guidelines
Soon Kyu Lee
Annals of Liver Transplantation.2024; 4(2): 40. CrossRef
Post-transplant complications in alcohol- and metabolic-associated steatotic liver disease
Shekhar Singh Jadaun, Sanjiv Saigal
Metabolism and Target Organ Damage.2024;[Epub] CrossRef
How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
Byeong Geun Song, Dong Hyun Sinn
Clinical and Molecular Hepatology.2023; 29(2): 411. CrossRef
Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
Qingfu Dong, Haolin Bao, Jiangang Wang, Wujiang Shi, Xinlei Zou, Jialin Sheng, Jianjun Gao, Canghai Guan, Haoming Xia, Jinglin Li, Pengcheng Kang, Yi Xu, Yunfu Cui, Xiangyu Zhong
Frontiers in Medicine.2023;[Epub] CrossRef
Diabetes and Metabolic Disorders: Their Impact on Cardiovascular Events in Liver Transplant Patients
Simone Di Cola, Giulia Cusi, Lucia Lapenna, Jakub Gazda, Stefano Fonte, Marco Mattana, Gianluca Mennini, Patrizio Pasqualetti, Manuela Merli, Xingshun Qi
Canadian Journal of Gastroenterology and Hepatology.2023; 2023: 1. CrossRef
Evaluation and Management of Nutritional Consequences of Chronic Liver Diseases
Silvia Espina, Diego Casas-Deza, Vanesa Bernal-Monterde, María José Domper-Arnal, Sandra García-Mateo, Alberto Lué
Nutrients.2023; 15(15): 3487. CrossRef
New Developments and Challenges in Liver Transplantation
Amjad Khalil, Alberto Quaglia, Pierre Gélat, Nader Saffari, Hassan Rashidi, Brian Davidson
Journal of Clinical Medicine.2023; 12(17): 5586. CrossRef
Outcomes in elderly patients undergoing hepatic resection compared to liver transplant for hepatocellular carcinoma
Sameer A. Khan, Fasih A. Ahmed, Muhammad S. Hafeez, Lawrence R. Feng, Abhinav Seth, Yong K. Kwon, Hassan Aziz
Journal of Surgical Oncology.2023; 128(8): 1320. CrossRef

13,287 View
300 Download
39 Web of Science
Crossref

Snapshot

Microbiome and metabolomics in alcoholic liver disease: Raja Ganesan, Ki Tae Suk; Clin Mol Hepatol 2022;28(3):580-582.
Published online July 1, 2022; DOI: https://doi.org/10.3350/cmh.2022.0171

Citations

Citations to this article as recorded by

Navigating liver health with metabolomics: A comprehensive review
Preetpal Singh, Ravinder Singh, Chirag Pasricha, Pratima Kumari
Clinica Chimica Acta.2025; 566: 120038. CrossRef
Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers: Editorial on “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”
Soon Kyu Lee, Jong Young Choi
Clinical and Molecular Hepatology.2025; 31(1): 301. CrossRef
Correspondence to editorial on: “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”
Satya Priya Sharma, Ki Tae Suk
Clinical and Molecular Hepatology.2025; 31(1): e74. CrossRef
Hepatoprotective Effects of Citri reticulatae Pericarpium and Chaenomelese speciosa (Sweet) Nakai Extracts in Alcohol-Related Liver Injury: Modulation of Oxidative Stress, Lipid Metabolism, and Gut Microbiota
Shuangshuang Ma, Lingtao Kang, Zhipeng Gao, Zhaoping Pan, Lvhong Huang, Jiaxu Chen, Yanfang Liao, Jiajing Guo, Fuhua Fu
Antioxidants.2025; 14(3): 343. CrossRef
Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease
Raja Ganesan, Haripriya Gupta, Jin-Ju Jeong, Satya Priya Sharma, Sung-Min Won, Ki-Kwang Oh, Sang Jun Yoon, Sang Hak Han, Young Joo Yang, Gwang Ho Baik, Chang Seok Bang, Dong Joon Kim, Ki Tae Suk
Hepatology International.2024; 18(2): 486. CrossRef
Expansion of effector regulatory T cells in steroid responders of severe alcohol-associated hepatitis
Min Woo Kang, Soon Kyu Lee, Eun Ji Jang, Jong Geun Park, Deok Hwa Seo, Ji Won Han, Jae Sung Yoo, Jung Hyun Kwon, Soon Woo Nam, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung
Liver Transplantation.2024; 30(9): 877. CrossRef
Letter: Risks of proton pump inhibitor treatment in cirrhotic patients—Authors' reply
Jun Sik Yoon, Jeong‐Hoon Lee
Alimentary Pharmacology & Therapeutics.2024; 60(4): 546. CrossRef
Therapeutic effects of fecal microbial transplantation on alcoholic liver injury in rat models
Yue Zhang, Pengfei Li, Bo Chen, Ruipeng Zheng
Clinics and Research in Hepatology and Gastroenterology.2024; 48(9): 102478. CrossRef
Stage dependent microbial dynamics in hepatocellular carcinoma and adjacent normal liver tissues
Hee Eun Jo, Sophallika Khom, Sumi Lee, Su Hyeon Cho, Shin Young Park, Ga Ram You, Hyosin Kim, Nah Ihm Kim, Jae-Ho Jeong, Jae Hyun Yoon, Misun Yun
Scientific Reports.2024;[Epub] CrossRef
Rice Protein Peptides Alleviate Alcoholic Liver Disease via the PPARγ Signaling Pathway: Through Liver Metabolomics and Gut Microbiota Analysis
Yue Tian, Yangzheng He, Hua Xiong, Yong Sun
Journal of Agricultural and Food Chemistry.2024; 72(43): 23790. CrossRef
Molecular Toxicology and Pathophysiology of Comorbid Alcohol Use Disorder and Post-Traumatic Stress Disorder Associated with Traumatic Brain Injury
Zufeng Wang, Chengliang Luo, Edward W. Zhou, Aaron F. Sandhu, Xiaojing Yuan, George E. Williams, Jialu Cheng, Bharati Sinha, Mohammed Akbar, Pallab Bhattacharya, Shuanhu Zhou, Byoung-Joon Song, Xin Wang
International Journal of Molecular Sciences.2023; 24(10): 8805. CrossRef
Therapeutic Potential of Human Microbiome-Based Short-Chain Fatty Acids and Bile Acids in Liver Disease
Raja Ganesan, Ki Tae Suk
Livers.2022; 2(3): 139. CrossRef
Diagnostic and molecular portraits of microbiome and metabolomics of short-chain fatty acids and bile acids in liver disease
Raja Ganesan, Ki Tae Suk
Process Biochemistry.2022; 123: 70. CrossRef

12,605 View
194 Download
15 Web of Science
Crossref

Review

Liver fibrosis, cirrhosis, and portal hypertension

Management of refractory ascites: Florence Wong; Clin Mol Hepatol 2023;29(1):16-32.
Published online June 9, 2022; DOI: https://doi.org/10.3350/cmh.2022.0104

Abstract
PDF

The development of refractory ascites in approximately 10% of patients with decompensated cirrhosis heralds the progression to a more advanced stage of cirrhosis. Its pathogenesis is related to significant hemodynamic changes, initiated by portal hypertension, but ultimately leading to renal hypoperfusion and avid sodium retention. Inflammation can also contribute to the pathogenesis of refractory ascites by causing portal microthrombi, perpetuating the portal hypertension. Many complications accompany the development of refractory ascites, but renal dysfunction is most common. Management starts with continuation of sodium restriction, which needs frequent reviews for adherence; and regular large volume paracentesis of 5 L or more with albumin infusions to prevent the development of paracentesisinduced circulatory dysfunction. Albumin infusions independent of paracentesis may have a role in the management of these patients. The insertion of a covered, smaller diameter, transjugular intrahepatic porto-systemic stent shunt (TIPS) in the appropriate patients with reasonable liver reserve can bring about improvement in quality of life and improved survival after ascites clearance. Devices such as an automated low-flow ascites pump may be available in the future for ascites treatment. Patients with refractory ascites should be referred for liver transplant, as their prognosis is poor. In patients with refractory ascites and concomitant chronic kidney disease of more than stage 3b, assessment should be referred for dual liver-kidney transplants. In patients with very advanced cirrhosis not suitable for any definitive treatment for ascites control, palliative care should be involved to improve the quality of life of these patients.

Citations

Citations to this article as recorded by

Outcomes following nurse-led day-case paracentesis
Mahir Yousuff, Pramudi Wijayasiri, Renee Ma, Rabiat Umar, Ripak Purbe, Nicola J. Monahan, Helen L. Garrity, Beverley J. Aram, Naaventhan Palaniyappan, Emilie Wilkes, Aloysious D. Aravinthan
Clinical Medicine.2026; 26(1): 100538. CrossRef
Integrated analysis of gut microbiota structure and metabolic function in patients with cirrhosis and refractory ascites
Dianyan Chen, Sandu Liu, Ka Zhang, Ke Pan, Linsu Zhang, Deyun Shu, Jin Zhang, Dingyao Ren
Biomedical Reports.2026; 24(2): 1. CrossRef
Proximal splenic artery embolization for treatment of refractory ascites, a single‐center experience
Abdul Rehman Mustafa, Raneem Atta, Russell P. Goodman, Vincent Wu, Zubin Irani, Omar Zurkiya, Emily D. Bethea, Kei Yamada, Eric P. Wehrenberg‐Klee
Hepatology Research.2025; 55(2): 219. CrossRef
Sex Differences in Patient-Reported Outcomes and Perception of Ascites Burden Among Outpatients With Decompensated Cirrhosis and Ascites
Florence Wong, K. Rajender Reddy, Puneeta Tandon, Jennifer C. Lai, Guadalupe Garcia-Tsao, Jacqueline G. O'Leary, Scott W. Biggins, Hugo E. Vargas, Leroy Thacker, Patrick S. Kamath, Jasmohan S. Bajaj
American Journal of Gastroenterology.2025; 120(8): 1791. CrossRef
Midodrine and Weekly Albumin Therapy in Patients With Cirrhosis and Diuretic Intractable or Recurrent Ascites: A Case-Control Study
Gourav J Borah, Gaurav Pande, Sayan Malakar, S Rakesh Kumar, Rajanikant R Yadav, Samir Mohindra
Cureus.2025;[Epub] CrossRef
The use of virtual reality-assisted interventions on psychological well-being and treatment adherence among kidney transplant recipients: A randomized controlled study
Chao Zhong, Lin Yao, Lanlan Chen, Xiaofen Wang, Xiaohui Zhu, Yihong Wen, Lei Deng, Jiafu Chen, Jialiang Hui, Lisha Shi, Lijuan You
Acta Psychologica.2025; 253: 104700. CrossRef
Comparison of clinical outcomes in patients with refractory ascites treated with either TIPS, tunneled peritoneal catheter, or ascites pump
Sarah L. Schütte, Anja Tiede, Jim B. Mauz, Hannah Rieland, Martin Kabelitz, Robin Iker, Nicolas Richter, Bernhard Meyer, Benjamin Heidrich, Heiner Wedemeyer, Benjamin Maasoumy, Tammo L. Tergast
Hepatology Communications.2025;[Epub] CrossRef
Identification of optimal portal pressure decrease to control ascites while minimizing HE after TIPS: A multicenter study
Martin A. Kabelitz, Lukas Hartl, Golda Schaub, Anja Tiede, Hannah Rieland, Andrea Kornfehl, Peter Hübener, Mathias Jachs, Jan Hinrichs, Sarah L. Schütte, Christoph Riedel, Jim B. Mauz, Tammo L. Tergast, Bernhard C. Meyer, Peter Bannas, Julia Kappel, Heine
Hepatology.2025; 82(5): 1172. CrossRef
The Effects of Alfapump on Ascites Control and Quality of Life in Patients With Cirrhosis and Recurrent or Refractory Ascites
Florence Wong, Hugo E. Vagas, K. Rajender Reddy, Mangesh R. Pagadala, Christine Pocha, Vinay Sundaram, Jasmohan S. Bajaj, Eran Shlomovitz, Emily Bendel, Jeroen Capel, Patrick S. Kamath
American Journal of Gastroenterology.2025; 120(10): 2291. CrossRef
Comparison of clinical outcomes of transjugular intrahepatic portosystemic shunt for refractory ascites and recurrent nonrefractory ascites
Shi-Hua Luo, Hui-Fang Zhang, Wei Liu, Jian-Guo Chu, Jian-Yong Chen
World Journal of Hepatology.2025;[Epub] CrossRef
Reinfusion of Malignant Ascites through an Extracorporeal Peritoneal Venous Shunt to Avoid Complications and Assess the Safety of a Denver Shunt: A Case Report
Keisuke Baba, Tomoki Tanie, Yasuo Matsubara, Yoshihiro Hirata, Hiroaki Ikematsu, Narikazu Boku
Case Reports in Oncology.2025; 18(1): 286. CrossRef
Pharmacological Treatment of Ascites: Challenges and Controversies
Jimmy Che-To Lai, Junlong Dai, Lilian Yan Liang, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
Pharmaceuticals.2025; 18(3): 339. CrossRef
A model predicting the 6-year all cause mortality of patients with advanced schistosomiasis after discharge: Derived from a large population-based cohort study
Lanyue Pan, Chunmei Wu, Ping Li, Jiaquan Huang, Yizhi Wu, Guo Li, Aysegul Taylan Ozkan
PLOS Neglected Tropical Diseases.2025; 19(5): e0013134. CrossRef
Investigation of bending angle algorithm and path planning for puncture needles in transjugular intrahepatic portosystemic shunt
Qinmei Liao, Bing Li, Xihao Hu, Xiaoyun Huang, Jiacheng Guo, Yuanzhong Zhu, Wenjing He
BioMedical Engineering OnLine.2025;[Epub] CrossRef
Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Cirrhosis Taking Diuretics—A Promising Step Toward Fewer Serious Liver Events
Mohamed I. Elsaid
JAMA Network Open.2025; 8(6): e2518478. CrossRef
Jabor A., Březina A.: Analysis od less common body fluids: Part 2 - peritoneal fluid and ascites
A Jabor, A Březina
Klinická biochemie a metabolismus.2025; 33(2): 34. CrossRef
TIPS in Patients With Refractory Ascites: Review of Literature and Current Recommendations
Matthew Abad-Santos, James Jeffries, Charles Hua, Guy E. Johnson
Techniques in Vascular and Interventional Radiology.2025; : 101057. CrossRef
Impacts of salt restriction on nutritional status, sarcopenia, and mortality of cirrhotic patients with ascites
Maha Elsabaawy, Mohammed Ragab, Madiha Naguib, Eman Kamal, Maymona Al-Khalifa, Khaled Gamil, Marwa Elfayoumy
BMC Gastroenterology.2025;[Epub] CrossRef
Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites
Jasmohan S. Bajaj, Ethan M. Weinberg, K. Rajender Reddy, Andrew P. Keaveny, Michael K. Porayko, David Koch, Paul J. Thuluvath, Douglas A. Simonetto, Paolo Angeli, Sujit V. Janardhan, Eric S. Orman, Jeffrey Zhang, Susan Clausen, Elisa Dauphinée, Joseph M.
Liver Transplantation.2025; 31(10): 1202. CrossRef
Refractory Ascites in Patients With Cirrhosis
Madhumita Premkumar
JGH Open.2025;[Epub] CrossRef
Future research direction of portal hypertension based on Baveno VII
Xuefeng Luo, Guangchuan Wang, Li Yang, Virginia Hernandez-Gea
Chinese Medical Journal.2025; 138(18): 2268. CrossRef
New insights into gut-liver axis in advanced liver diseases: A promising therapeutic target
Yunqi Xing, Yanghao Ou, Yujie Wang, Luming Hou, Junfeng Zhu
Biochemical Pharmacology.2025; 242: 117284. CrossRef
Managing Ascites and Kidney Dysfunction in Decompensated Advanced Chronic Liver Disease: From “One Size Fits All” to a Multidisciplinary-Tailored Approach
Mario Romeo, Carmine Napolitano, Paolo Vaia, Fiammetta Di Nardo, Silvio Borrelli, Carlo Garofalo, Luca De Nicola, Alessandro Federico, Marcello Dallio
Livers.2025; 5(3): 46. CrossRef
Predicting severe renal dysfunction in alcohol-associated cirrhosis: Comparative performance of liver function scores and machine learning models
Julian Müller-Kühnle, Moritz Schanz, Severin Schricker, Christian Benignus, Julia Todoroff, Jörg Latus, Wolfram Zoller, Dominik Marschner, Zhaoqing Du
PLOS One.2025; 20(9): e0332840. CrossRef
Decompensated cirrhosis but low MELD—Should we wait or refer for liver transplantation?
Noreen Singh, Yu Jun Wong, Patrizia Burra, Nazia Selzner, Aldo J. Montano-Loza
Liver Transplantation.2025; 31(11): 1423. CrossRef
Management of intractable ascites in cirrhosis: a review article
I. Dewa Ayu Made Dian Lestari, Ketut Suryana
International Journal of Advances in Medicine.2025; 13(1): 56. CrossRef
Acute kidney injury after TIPS in decompensated cirrhosis patients: a retrospective cohort study
Meng Jia, Yi-Dan Guo, Peng-Peng Ye, Xiao-Ling Zhou, Yang Luo
BMC Nephrology.2025;[Epub] CrossRef
Managing cirrhosis with limited resources: perspectives from sub-Saharan Africa
Mark W Sonderup, Patrick S Kamath, Yaw A Awuku, Hailemichael Desalegn, Neliswa Gogela, Leolin Katsidzira, Christian Tzeuton, Bilal Bobat, Chris Kassianides, C Wendy Spearman
The Lancet Gastroenterology & Hepatology.2024; 9(2): 170. CrossRef
Recent developments in the management of ascites in cirrhosis
Tian Lan, Ming Chen, Chengwei Tang, Pierre Deltenre
United European Gastroenterology Journal.2024; 12(2): 261. CrossRef
A new strategy for the treatment of refractory ascites in patients with hepatitis B-related liver cirrhosis
Wenjing Xu, Gang Wang
Asian Journal of Surgery.2024; 47(6): 2761. CrossRef
Chronological Course and Clinical Features after Denver Peritoneovenous Shunt Placement in Decompensated Liver Cirrhosis
Shingo Koyama, Asako Nogami, Masato Yoneda, Shihyao Cheng, Yuya Koike, Yuka Takeuchi, Michihiro Iwaki, Takashi Kobayashi, Satoru Saito, Daisuke Utsunomiya, Atsushi Nakajima
Tomography.2024; 10(4): 471. CrossRef
Review article: Recent advances in ascites and acute kidney injury management in cirrhosis
Danielle Adebayo, Florence Wong
Alimentary Pharmacology & Therapeutics.2024; 59(10): 1196. CrossRef
Treatment of portal hypertension complicated by variceal bleeding
M.I. Tutchenko, D.V. Rudyk, І.V. Klyuzko, M.S. Besedinskyi, S.L. Chub, О.А. Sirenko
EMERGENCY MEDICINE.2024; 20(3): 180. CrossRef
External treatment of refractory ascites induced by liver cirrhosis using traditional Chinese medicine
Xuerong Wang, Xiaoqin Zeng, Gang Wang
Asian Journal of Surgery.2024; 47(10): 4429. CrossRef
Shunt dysfunction and mortality after transjugular intrahepatic portosystemic shunt (TIPS) in patients with portal hypertension
Laura Büttner, Lisa Pick, Martin Jonczyk, Uli Fehrenbach, Federico Collettini, Timo Alexander Auer, Dirk Schnapauff, Maximilian De Bucourt, Gero Wieners, Bernhard Gebauer, Annette Aigner, Georg Böning
Insights into Imaging.2024;[Epub] CrossRef
Advancements in ascites management: a comprehensive narrative review of the Alfa Pump system
Muhammad Asim, Nabiha Naqvi, Vikash Kumar Karmani, Aima Tahir, Umm E. Salma Shabbar Banatwala, Shahzeb Rehman, Minha Aslam, Aleena Majeed, Farhan Khan
Egyptian Liver Journal.2024;[Epub] CrossRef
Drainage of ascites in cirrhosis
Jia-Xing Yang, Yue-Ming Peng, Hao-Tian Zeng, Xi-Min Lin, Zheng-Lei Xu
World Journal of Hepatology.2024; 16(9): 1245. CrossRef
Outpatient management after hospitalisation for acute decompensation of cirrhosis: A practical guide
Adonis A Protopapas, Alexandra Tsankof, Ioanna Papagiouvanni, Georgia Kaiafa, Lemonia Skoura, Christos Savopoulos, Ioannis Goulis
World Journal of Hepatology.2024; 16(12): 1377. CrossRef
A safe and effective treatment for refractory malignant ascites: the use of pigtail catheters
Akif Doğan, Ömer Aydıner
Polish Journal of Radiology.2024; 89: 561. CrossRef
Daily Low-Volume Paracentesis and Clinical Complications in Patients With Refractory Ascites
Tammo L. Tergast, Marie Griemsmann, Lena Stockhoff, Kerstin Port, Benjamin Heidrich, Markus Cornberg, Heiner Wedemeyer, Henrike Lenzen, Nicolas Richter, Elmar Jaeckel, Benjamin Maasoumy
JAMA Network Open.2023; 6(7): e2322048. CrossRef
Effect of different infusion approaches on safety and efficacy of terlipressin: Current controversies
Yong He, Lu Chai, Han Chen, Xing-Shun Qi
World Chinese Journal of Digestology.2023; 31(17): 705. CrossRef
Evidence-based hyponatremia management in liver disease
Ji Young Ryu, Seon Ha Baek, Sejoong Kim
Clinical and Molecular Hepatology.2023; 29(4): 924. CrossRef
Prevalence and risk factors of lymphatic dysfunction in cirrhosis patients with refractory ascites: An often unconsidered mechanism
Rahul Arya, Ramesh Kumar, Tarun Kumar, Sudhir Kumar, Utpal Anand, Rajeev Nayan Priyadarshi, Tanmoy Maji
World Journal of Hepatology.2023; 15(10): 1140. CrossRef
Pulmonary Complications in Patients with Liver Cirrhosis
Seul Ki Han, Soon Koo Baik, Moon Young Kim
The Korean Journal of Gastroenterology.2023; 82(5): 213. CrossRef
Post-Transjugular Intrahepatic Portosystemic Shunt (TIPS) Hepatic Encephalopathy—A Review of the Past Decade’s Literature Focusing on Incidence, Risk Factors, and Prophylaxis
Karina Holm Friis, Karen Louise Thomsen, Wim Laleman, Sara Montagnese, Hendrik Vilstrup, Mette Munk Lauridsen
Journal of Clinical Medicine.2023; 13(1): 14. CrossRef

19,471 View
1,112 Download
43 Web of Science
Crossref

Original Article

COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis: Ka Shing Cheung, Chiu Hang Mok, Xianhua Mao, Ruiqi Zhang, Ivan FN Hung, Wai Kay Seto, Man Fung Yuen; Clin Mol Hepatol 2022;28(4):890-911.
Published online June 3, 2022; DOI: https://doi.org/10.3350/cmh.2022.0087

Background/Aims
Data of coronavirus disease 2019 (COVID-19) vaccine immunogenicity among chronic liver disease (CLD) and liver transplant (LT) patients are conflicting. We performed meta-analysis to examine vaccine immunogenicity regarding etiology, cirrhosis status, vaccine platform and type of antibody.
Methods
We collected data via three databases from inception to February 16, 2022, and reported pooled seroconversion rate, T cell response and safety data after two vaccine doses.
Results
Twenty-eight (CLD only: 5; LT only: 18; both: 2; LT with third dose: 3) observational studies of 3,945 patients were included. For CLD patients, seroconversion rate ranged between 84% (95% confidence interval [CI], 76–90%) and 91% (95% CI, 83–95%), based predominantly on neutralizing antibody and anti-spike antibody, respectively. Seroconversion rate was 81% (95% CI, 76–86%) in chronic hepatitis B, 96% (95% CI, 93–97%) in non-alcoholic fatty liver disease, 85% (95% CI, 75–91%) in cirrhosis and 85% (95% CI, 78–90%) in non-cirrhosis, 86% (95% CI, 78–92%) for inactivated vaccine and 89% (95% CI, 71–96%) for mRNA vaccine. The pooled seroconversion rate of anti-spike antibody was 66% (95% CI, 55–75%) after two doses of mRNA vaccines and 88% (95% CI, 58–98%) after third dose among LT recipients. T cell response rate was 65% (95% CI, 30–89%). Prevalence of adverse events was 27% (95% CI, 18–38%) and 63% (95% CI, 39–82%) among CLD and LT groups, respectively.
Conclusions
CLD patients had good humoral response to COVID-19 vaccine, while LT recipients had lower response.

Citations

Citations to this article as recorded by

High Rate of Antibody Response to Multiple Doses of the COVID-19 Vaccine in Liver Transplant Recipients: Analysis of Predictive Factors
Nunzio Zignani, Andrea Costantino, Michele Sagasta, Clara Dibenedetto, Riccardo Perbellini, Sara Uceda Renteria, Pietro Lampertico, Maria Francesca Donato
Vaccines.2025; 13(4): 352. CrossRef
Examining Vaccination Coverage in Patients with Diagnosis of Chronic Liver Disease and Cirrhosis: A Cross-Sectional Study in Greece
Paschalina Dafnou, Ioannis Elefsiniotis, Theodoula Adamakidou, Nikoletta Margari, Stelios Parissopoulos, Lambrini Kourkouta, Konstantinos Giakoumidakis, Eleni Dokoutsidou
Livers.2025; 5(4): 68. CrossRef
Clinical application of COVID-19 vaccine in liver transplant recipients
Feng-Chao Liu, Man Xie, Wei Rao
Hepatobiliary & Pancreatic Diseases International.2024; 23(4): 339. CrossRef
Clinical characteristics and outcomes of liver transplant recipients infected by Omicron during the opening up of the dynamic zero-coronavirus disease policy in China: A prospective, observational study
Wei Zhang, Rongrong Wang, Pingbo Jin, Xinyu Yu, Weili Wang, Yuntao Zhang, Xueli Bai, Tingbo Liang
American Journal of Transplantation.2024; 24(4): 631. CrossRef
Ursodeoxycholic acid does not affect the clinical outcome of SARS‐CoV‐2 infection: A retrospective study of propensity score‐matched cohorts
Giuseppe Marrone, Marcello Covino, Giuseppe Merra, Andrea Piccioni, Annamaria Amodeo, Angela Novelli, Rita Murri, Maurizio Pompili, Antonio Gasbarrini, Francesco Franceschi
Liver International.2024; 44(1): 83. CrossRef
Effect of ursodeoxycholic acid on preventing SARS-CoV-2 infection in patients with liver transplantation: a multicenter retrospective cohort study
L Hu, H Zhang, C Huang, T Shen, Z Feng, F Mu, L Xu, Y Lin, C Yue, K Guo, M Tian, J Shi, C Zhang, P Wen, S Cao, Y Wang, J Zhang, X Shi, Z Wang, Y He, X Zhang, X Liu, Y Lv, Z Liu, W Guo, B Wang
QJM: An International Journal of Medicine.2024; 117(5): 339. CrossRef
Advancements in Vaccine Strategies for Chronic Liver Disease Patients: Navigating Post-COVID Challenges and Opportunities
Samer Al-Dury, Nelly Kanberg
Vaccines.2024; 12(2): 197. CrossRef
Third vaccine boosters and anti‐S‐IgG levels: A comparison of homologous and heterologous responses and poor immunogenicity in hepatocellular carcinoma
Chih‐Wen Wang, Chung‐Feng Huang, Tyng‐Yuan Jang, Ming‐Lun Yeh, Po‐Cheng Liang, Yu‐Ju Wei, Po‐Yao Hsu, Ching‐I. Huang, Ming‐Yen Hsieh, Yi‐Hung Lin, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu
The Kaohsiung Journal of Medical Sciences.2024; 40(5): 477. CrossRef
Klinische Verläufe und Kosten für Hospitalisierungen von COVID-19-Patienten mit potenziell eingeschränktem Immunsystem in Deutschland
Dennis Häckl, Marc Pignot, Phi Long Dang, Victoria Lauenroth, Fungwe Jah, Clemens-Martin Wendtner
DMW - Deutsche Medizinische Wochenschrift.2024; 149(07): e38. CrossRef
Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis
Lichen Ouyang, Gang Lei, Yeli Gong
Human Vaccines & Immunotherapeutics.2024;[Epub] CrossRef
Association between Gut Microbiota Composition and Long-Term Vaccine Immunogenicity following Three Doses of CoronaVac
Li-Na Zhang, Jing-Tong Tan, Ho-Yu Ng, Yun-Shi Liao, Rui-Qi Zhang, Kwok-Hung Chan, Ivan Fan-Ngai Hung, Tommy Tsan-Yuk Lam, Ka-Shing Cheung
Vaccines.2024; 12(4): 365. CrossRef
Proton pump inhibitors associated with severe COVID‐19 among two‐dose but not three‐dose vaccine recipients
Ka Shing Cheung, Vincent K C Yan, Xuxiao Ye, Ivan F N Hung, Esther W Chan, Wai K Leung
Journal of Gastroenterology and Hepatology.2024; 39(9): 1837. CrossRef
Serological responses to COVID-19 vaccination in patients with chronic liver diseases
Yu-Shan Huang, Szu-Min Hsieh, Feng-Chiao Tsai, Chien-Chih Tung, Hung-Chih Yang, Sui-Yuan Chang, Jann-Tay Wang, Chun-Jen Liu, Tung-Hung Su, Jia-Horng Kao
Journal of the Formosan Medical Association.2024; 123(11): 1194. CrossRef
Effect of metabolic dysfunction‐associated steatotic liver disease on BNT162b2 immunogenicity against the severe acute respiratory syndrome coronavirus 2 omicron variant
Lok Ka Lam, Jing Tong Tan, Poh Hwa Ooi, Ruiqi Zhang, Kwok Hung Chan, Xianhua Mao, Ivan F N Hung, Wai Kay Seto, Man Fung Yuen, Ka Shing Cheung
Journal of Gastroenterology and Hepatology.2024; 39(11): 2386. CrossRef
Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
Clinical and Molecular Hepatology.2023; 29(1): 168. CrossRef
Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”
Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen
Clinical and Molecular Hepatology.2023; 29(1): 176. CrossRef
Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination
Riccardo Nevola, Livio Criscuolo, Domenico Beccia, Augusto Delle Femine, Rachele Ruocco, Simona Imbriani, Maria Alfano, Angela Villani, Antonio Russo, Pasquale Perillo, Raffaele Marfella, Luigi Elio Adinolfi, Ferdinando Carlo Sasso, Aldo Marrone, Luca Rin
World Journal of Gastroenterology.2023; 29(5): 800. CrossRef
Association between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity
Ho Yu Ng, Wai K. Leung, Ka Shing Cheung
Microorganisms.2023; 11(2): 452. CrossRef
Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients
Ka Shing Cheung, Lok Ka Lam, Xianhua Mao, Jing Tong Tan, Poh Hwa Ooi, Ruiqi Zhang, Kwok Hung Chan, Ivan F. N. Hung, Wai Kay Seto, Man Fung Yuen
Vaccines.2023; 11(3): 497. CrossRef
Analysis of Antibody Responses After COVID-19 Vaccination in Liver Transplant Recipients: A Single-Center Study
Young Ju Oh, Jongman Kim, Eun-Suk Kang, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh
Journal of Korean Medical Science.2023;[Epub] CrossRef
Research Progress of Novel Coronavirus Vac-cine in Patients with Chronic Liver Disease
露王
Advances in Clinical Medicine.2023; 13(04): 6745. CrossRef
Humoral Immune Response after COVID-19 mRNA Vaccination in Patients with Liver Cirrhosis: A Prospective Real-Life Single Center Study
Elisa Biliotti, Alessandro Caioli, Chiara Sorace, Raffaella Lionetti, Eugenia Milozzi, Chiara Taibi, Ubaldo Visco Comandini, Fabrizio Maggi, Vincenzo Puro, Gianpiero D’Offizi
Biomedicines.2023; 11(5): 1320. CrossRef
COVID‑19 vaccination in liver transplant recipients (Review)
Aikaterini Gkoufa, Maria Saridaki, Vasiliki Georgakopoulou, Demetrios Spandidos, Evangelos Cholongitas
Experimental and Therapeutic Medicine.2023;[Epub] CrossRef
Meta‐analysis of the immunogenicity of standard and booster SARS‐CoV‐2 vaccination in patients with chronic liver disease and post‐liver transplantation
Wen‐Xin Wang, Jitao Wang, Rui Jia, Silvia Martini, Jiaye Liu, Yifei Huang, Fu‐Sheng Wang, Xiaolong Qi, Junliang Fu
Portal Hypertension & Cirrhosis.2023; 2(2): 61. CrossRef
Mycophenolate Interruption Restores Anti-SARS-CoV-2 Vaccine Immunogenicity in Unresponsive Liver Transplant Recipients
Pierluigi Toniutto, Annarosa Cussigh, Sara Cmet, Martina Fabris, Francesco Curcio, Davide Bitetto, Ezio Fornasiere, Elisa Fumolo, Edmondo Falleti
Vaccines.2023; 11(7): 1165. CrossRef
The vaccine-response in patients with cirrhosis after COVID-19 vaccination: A systematic analysis of 168,245 patients with cirrhosis
Zheng Li, Yue Hu, Bingwen Zou
Journal of Hepatology.2023; 79(4): e157. CrossRef
Research landscape on COVID-19 and liver dysfunction: A bibliometric analysis
Sa'ed H Zyoud
World Journal of Gastroenterology.2023; 29(27): 4356. CrossRef
Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants
Vijay Subramanian
The Journal of Infectious Diseases.2023; 228(Supplement): S34. CrossRef
Metabolic Associated Fatty Liver Disease (MAFLD) and COVID-19 Infection: An Independent Predictor of Poor Disease Outcome?
Vladimir Milivojević, Jelena Bogdanović, Ivana Babić, Nevena Todorović, Ivan Ranković
Medicina.2023; 59(8): 1438. CrossRef
Antibiotic Use Prior to COVID-19 Vaccine Is Associated with Higher Risk of COVID-19 and Adverse Outcomes: A Propensity-Scored Matched Territory-Wide Cohort
Ka Shing Cheung, Vincent K. C. Yan, Lok Ka Lam, Xuxiao Ye, Ivan F. N. Hung, Esther W. Chan, Wai K. Leung
Vaccines.2023; 11(8): 1341. CrossRef
COVID-19 and Liver Disease: An Evolving Landscape
Kai Zhu, Olivia Tsai, Daljeet Chahal, Trana Hussaini, Eric M. Yoshida
Seminars in Liver Disease.2023; 43(03): 351. CrossRef
Factors influencing immunogenicity and safety of SARS-CoV-2 vaccine in liver transplantation recipients: a systematic review and meta-analysis
Xinyi Luo, Fabrice Yves Ndjana Lessomo, Zhimin Yu, Yong Xie
Frontiers in Immunology.2023;[Epub] CrossRef
Impact of SARS-CoV-2 Infection on Humoral and Cellular Immunity in a Cohort of Vaccinated Solid Organ Transplant Recipients
Bernardo Ayala-Borges, Miguel Escobedo, Natalia Egri, Sabina Herrera, Marta Crespo, Sonia Mirabet, Carlos Arias-Cabrales, Anna Vilella, Eduard Palou, María M. Mosquera, Mariona Pascal, Jordi Colmenero, Marta Farrero, Marta Bodro
Vaccines.2023; 11(12): 1845. CrossRef
COVID-19 vaccine and hepatitis: A mini review
Beuy Joob, Viroj Wiwanitkit
Indian Journal of Allergy, Asthma and Immunology.2023; 37(2): 37. CrossRef
COVID-19 Vaccination in Patients with Chronic Liver Disease
Georgios Schinas, Eleni Polyzou, Fevronia Mitropetrou, Aristotelis Pazionis, Charalambos Gogos, Christos Triantos, Karolina Akinosoglou
Viruses.2022; 14(12): 2778. CrossRef

9,693 View
194 Download
36 Web of Science
Crossref

Review

Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review: Sang Jin Kim, Jong Man Kim; Clin Mol Hepatol 2022;28(4):739-753.
Published online April 26, 2022; DOI: https://doi.org/10.3350/cmh.2022.0060

Liver transplantation (LT) is one of the most effective treatments for hepatocellular carcinoma (HCC). Although LT eliminates HCC and greatly reduces recurrence, some patients experience recurrence after LT. Criteria and models for screening patients with a high probability of HCC recurrence after LT, starting with the Milan criteria, have been published. These models have changed over time, but a standard has not been established. We summarized HCC prediction models after LT by focusing on the application of radiologic, serologic, and pathologic factors and recent trends. This review will look at studies that are based on living donor LT and deceased donor LT, as well as studies that downstaging procedures have been performed preoperatively. This ultimately aims to help make decisions for evaluating the HCC state and selecting candidates for LT according to the circumstances of each transplantation center.

Citations

Citations to this article as recorded by

Lack of progress in cancer-related outcomes after liver transplantation: Mitigating risk and identifying future needs to move this needle
Alex Liu, Wei Rao, Kymberly D. Watt
Liver Transplantation.2026; 32(1): 107. CrossRef
Rapamycin-loaded nanoparticles elicit local liver immunosuppressive and remote anti-tumor efficacy
Yiyang Sun, Yanpeng Liu, Siyu Chen, Yidan Shen, Yangla Xie, Jing Zhang, Zhengxing Lian, Haiyang Xie, Sunbin Ling, Chang Xie, Haitao Hu, Huigang Li, Youqing Shen, Xiao Xu, Nasha Qiu
Nano Today.2025; 61: 102589. CrossRef
Comparative Validation of Prediction Models for HCC Outcomes in Living Donor Liver Transplantation: Superiority of Tumor Markers to Imaging Study
Hwa‐Hee Koh, Minyu Kang, Deok‐Gie Kim, Jae Hyon Park, Eun‐Ki Min, Jae Geun Lee, Myoung Soo Kim, Dong Jin Joo
Journal of Gastroenterology and Hepatology.2025; 40(3): 626. CrossRef
Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation
Meng Sha, Jun Wang, Jie Cao, Zhi-Hui Zou, Xiao-ye Qu, Zhi-feng Xi, Chuan Shen, Ying Tong, Jian-jun Zhang, Seogsong Jeong, Qiang Xia
Clinical and Molecular Hepatology.2025; 31(Suppl): S285. CrossRef
α-Fetoprotein model versus Milan criteria in predicting outcomes after hepatic resection for hepatocellular carcinoma: multicentre study
Chao Li, Yong-Kang Diao, Yi-Fan Li, Shao-Dong Lv, Xian-Ming Wang, Xue-Dong Wang, Qi-Xuan Zheng, Hong Wang, Han Liu, Kong-Ying Lin, Ying-Jian Liang, Ya-Hao Zhou, Wei-Min Gu, Ming-Da Wang, Lan-Qing Yao, Xin-Fei Xu, Jia-Hao Xu, Li-Hui Gu, Timothy M Pawlik, F
BJS Open.2025;[Epub] CrossRef
Comparison of initial treatments for resectable hepatocellular carcinoma within Milan criteria: an observational study based on a nationwide survey
Sang Jin Kim, Woo Kyoung Jeong, Hyung-Joon Han, Gyu-Seong Choi, Kyun-Hwan Kim, Jongman Kim
Annals of Surgical Treatment and Research.2025; 108(5): 279. CrossRef
Traditional herbal medicine as an adjuvant therapy for preventing the recurrence of hepatocellular carcinoma after radical resection: Development and validation of a machine learning prediction model
Xinyu Yue, Meihuan Fu, Song Yu, Huayue Shi, Simo Cheng, Xiaofeng Zhai
European Journal of Integrative Medicine.2025; 78: 102535. CrossRef
Experimental and Clinical Transplantation.2025;[Epub] CrossRef
Integrating Alpha‐Fetoprotein and Protein Induced by Vitamin K Antagonist‐II as Surveillance Tools After Liver Transplantation for Hepatocellular Carcinoma: A Novel Protocol for Early Detection of Tumor Recurrence
Jiyoung Kim, Kwang‐Woong Lee, Jae‐Yoon Kim, Jaewon Lee, Hyun Hwa Choi, Su young Hong, Jeong‐Moo Lee, Suk Kyun Hong, YoungRok Choi, Nam‐Joon Yi, Kyung‐Suk Suh
Clinical Transplantation.2025;[Epub] CrossRef
A non-invasive decision tree predicting recurrence-free survival after liver transplantation for hepatocellular carcinoma
Mo-Dan Yang, Jian-Yong Zhuo, Guo-Ying Wang, Li Zhuang, Xiao Xu, Shu-Sen Zheng, Yang Yang, Di Lu
Hepatobiliary & Pancreatic Diseases International.2025;[Epub] CrossRef
Activating transcription factor 4-mediated upregulation of Heat Shock Protein Family A Member 4 promotes hepatocellular carcinoma progression through activation of Wnt/β-catenin/EMT signaling pathway
Ruixi Li, Kunnan Wang, Naijing Hou, Yu Tian, Biyan Gong, Min Tang
International Journal of Biological Macromolecules.2025; 333: 148850. CrossRef
Mesenchymal Stem Cell-Mediated Targeted Drug Delivery Systems for Hepatocellular Carcinoma: Current Advances and Future Directions
Yang Gao, Jian-Ping Wang, De-Fei Hong, Chang Yang, Hua Naranmandura
Bioengineering.2025; 12(11): 1206. CrossRef
Prognostic significance of MRI features in patients with solitary large hepatocellular carcinoma following surgical resection
Kyowon Gu, Ji Hye Min, Jeong Hyun Lee, Jaeseung Shin, Woo Kyoung Jeong, Young Kon Kim, Honsoul Kim, Sun-Young Baek, Jong Man Kim, Gyu Seong Choi, Jinsoo Rhu, Sang Yun Ha
European Radiology.2024; 34(11): 7002. CrossRef
From prediction to prevention: Machine learning revolutionizes hepatocellular carcinoma recurrence monitoring
Mariana Michelle Ramírez-Mejía, Nahum Méndez-Sánchez
World Journal of Gastroenterology.2024; 30(7): 631. CrossRef
Risk assessment in liver transplantation for hepatocellular carcinoma: long-term follow-up of a two-centre experience
Chase J. Wehrle, Roma Raj, Marianna Maspero, Sangeeta Satish, Bijan Eghtesad, Alejandro Pita, Jaekeun Kim, Mazhar Khalil, Esteban Calderon, Danny Orabi, Bobby Zervos, Jamak Modaresi Esfeh, Maureen Whitsett Linganna, Teresa Diago-Uso, Masato Fujiki, Cristi
International Journal of Surgery.2024; 110(5): 2818. CrossRef
Challenges related to clinical decision-making in hepatocellular carcinoma recurrence post-liver transplantation: Is there a hope?
Nourhan Badwei
World Journal of Transplantation.2024;[Epub] CrossRef
Advances in Understanding Hepatocellular Carcinoma Vasculature: Implications for Diagnosis, Prognostication, and Treatment
Hyungjin Rhee, Young Nyun Park, Jin-Young Choi
Korean Journal of Radiology.2024; 25(10): 887. CrossRef
An inflammatory liquid fingerprint predicting tumor recurrence after liver transplantation for hepatocellular carcinoma
Modan Yang, Zuyuan Lin, Li Zhuang, Linhui Pan, Rui Wang, Hao Chen, Zhihang Hu, Wei Shen, Jianyong Zhuo, Xinyu Yang, Huigang Li, Chiyu He, Zhe Yang, Qinfen Xie, Siyi Dong, Junli Chen, Renyi Su, Xuyong Wei, Junjie Yin, Shusen Zheng, Di Lu, Xiao Xu
MedComm.2024;[Epub] CrossRef
New prognostic model for liver transplantation outcomes in hepatocellular carcinoma
S. E. Voskanyan, V. S. Rudakov, A. I. Sushkov, M. V. Popov, A. N. Bashkov, K. K. Gubarev, A. I. Artemyev, I. Yu. Kolyshev, M. Muktazhan, A. N. Pashkov, E. V. Naydenov, D. S. Svetlakova
Transplantologiya. The Russian Journal of Transplantation.2024; 16(3): 278. CrossRef
Chitinase-3 like-protein-1, a prognostic biomarker in patients with hepatocellular carcinoma and concomitant myosteatosis
Chiyu He, Zhihang Hu, Zuyuan Lin, Hao Chen, Chenghao Cao, Jinyan Chen, Xudong Yang, Huigang Li, Wei Shen, Xuyong Wei, Li Zhuang, Shusen Zheng, Xiao Xu, Di Lu
BMC Cancer.2024;[Epub] CrossRef
Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis: Editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging”
Abdelrahman M Attia, Hasmik Adetyan, Ju Dong Yang
Clinical and Molecular Hepatology.2024; 30(4): 653. CrossRef
Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation
Jianming Yang, Yewu Chen, Haobin Sun, Xijian Zhang, Jianfeng Wang, Zhixing Liang, Binsheng Fu, Tong Zhang, Shuhong Yi, Yinan Deng, Yang Yang
Infectious Agents and Cancer.2023;[Epub] CrossRef
Molecular Clues for Prediction of Hepatocellular Carcinoma Recurrence After Liver Transplantation
Nourhan Badwei
Journal of Clinical and Experimental Hepatology.2023; 13(5): 804. CrossRef
Persistently Elevated HBV Viral-Host Junction DNA in Urine as a Biomarker for Hepatocellular Carcinoma Minimum Residual Disease and Recurrence: A Pilot Study
Selena Y. Lin, Dina Halegoua-DeMarzio, Peter Block, Yu-Lan Kao, Jesse Civan, Fwu-Shan Shieh, Wei Song, Hie-Won Hann, Ying-Hsiu Su
Diagnostics.2023; 13(9): 1537. CrossRef
Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging
Yoon Jung Hwang, Jae Seok Bae, Youngeun Lee, Bo Yun Hur, Dong Ho Lee, Haeryoung Kim
Clinical and Molecular Hepatology.2023; 29(3): 733. CrossRef
Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients
Xiaoning Wu, Xiaoqian Xu, Jialing Zhou, Yameng Sun, Huiguo Ding, Wen Xie, Guofeng Chen, Anlin Ma, HongXin Piao, Bingqiong Wang, Shuyan Chen, Tongtong Meng, Xiaojuan Ou, Hwai-I Yang, Jidong Jia, Yuanyuan Kong, Hong You
Clinical and Molecular Hepatology.2023; 29(3): 747. CrossRef
Sequential regorafenib or nivolumab therapy in recurrent hepatocellular carcinoma with sorafenib failure in liver transplant patients does not improve prognosis
Jieun Kwon, Jongman Kim, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh
Annals of Liver Transplantation.2023; 3(2): 104. CrossRef
Neutrophil extracellular traps and complications of liver transplantation
Yanyao Liu, Ping Yan, Yue Bin, Xiaoyan Qin, Zhongjun Wu
Frontiers in Immunology.2022;[Epub] CrossRef

11,320 View
207 Download
27 Web of Science
Crossref

Snapshot

Liver Transplantation

Current status and outcome of liver transplantation in South Korea: Ho Joong Choi; Clin Mol Hepatol 2022;28(1):117-119.
Published online December 7, 2021; DOI: https://doi.org/10.3350/cmh.2021.0381

Citations

Citations to this article as recorded by

Outcomes of Highly Urgent ABO-Incompatible Living Donor Liver Transplantation in National Databases
Jongman Kim, Sang Jin Kim, Boram Park, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Seung Heui Hong, Soon-Young Kim, Jungbun Park, Youngwon Hwang, Dong-Hwan Jung
Journal of Korean Medical Science.2026;[Epub] CrossRef
Robust Predictive Performance of the SALT‐M Score for Clinical Outcomes in Asian Patients With Acute‐on‐Chronic Liver Failure
Kunhee Kim, Seung Hyuk Yim, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim, Jun Yong Park, Sang Hoon Ahn, Deok‐Gie Kim, Hye Won Lee
Alimentary Pharmacology & Therapeutics.2025; 61(1): 168. CrossRef
Impact of Chronic Hepatitis C Virus on Acute Kidney Injury After Living Donor Liver Transplantation
Jae Hwan Kim, Kyoung-Sun Kim, Hye-Mee Kwon, Sung-Hoon Kim, In-Gu Jun, Jun-Gol Song, Gyu-Sam Hwang
Anesthesia & Analgesia.2025; 141(3): 608. CrossRef
Appropriate timing and interval for surveillance colonoscopy after liver transplantation based on a single-centre experience
Dae Gon Ryu, Hongqun Liu, Samuel S Lee, Ki Tae Yoon, Mayur Brahmania
Canadian Liver Journal.2025; 8(1): 39. CrossRef
Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Soon Kyu Lee, Jong Young Choi
Clinical and Molecular Hepatology.2025; 31(2): e212. CrossRef
Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Soon Kyu Lee, Jong Young Choi
Clinical and Molecular Hepatology.2025; 31(2): e161. CrossRef
Emergency living donor liver transplantation
Jongman Kim
Annals of Liver Transplantation.2025; 5(1): 27. CrossRef
Number of Pretransplant Therapeutic Plasma Exchange Sessions Increase the Recurrence Risk of Hepatocellular Carcinoma in ABO-Incompatible Living Donor Liver Transplantation
Young Jin Yoo, Deok-Gie Kim, Eun-Ki Min, Seung Hyuk Yim, Mun Chae Choi, Hwa-Hee Koh, Minyu Kang, Jae Geun Lee, Myoung Soo Kim, Dong Jin Joo
Transplant International.2025;[Epub] CrossRef
Predicting risk factors for waiting mortality in adult emergent living donor liver transplantation based on Korean national data
Sang Jin Kim, Jongman Kim, Kyunga Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
Annals of Liver Transplantation.2025; 5(2): 107. CrossRef
Living versus deceased donor liver transplantation in highly urgent patients using Korean national data
Jongman Kim, Sang Jin Kim, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
Annals of Liver Transplantation.2025; 5(2): 115. CrossRef
Liver Transplantation at a Small Volume Center—The Role of Network System
Chang Ho Seo, Ho Joong Choi, Gun Hyung Na
Transplantation Proceedings.2024; 56(3): 653. CrossRef
Approach to Liver Transplantation: Is There a Difference between East and West?
Nazli Begum Ozturk, Nathanial Bartosek, Merih Deniz Toruner, Aymen Mumtaz, Cem Simsek, Doan Dao, Behnam Saberi, Ahmet Gurakar
Journal of Clinical Medicine.2024; 13(7): 1890. CrossRef
Anastomosis selection in liver transplantation for recipients with unusable recipient hepatic arteries: a bayesian network meta-analysis
Warsinggih, Citra Aryanti, Julianus Aboyaman Uwuratuw, Erwin Syarifuddin, Ronald Erasio Lusikooy, Muhammad Faruk
BMC Surgery.2024;[Epub] CrossRef
Mortality and associated factors among patients who underwent liver transplantation in South Korea from 2017 to 2021: a retrospective observational study
Tak Kyu Oh, In-Ae Song
Annals of Surgical Treatment and Research.2024; 107(5): 245. CrossRef
Chronological improvements of living donor liver transplantation for hepatocellular carcinoma in Seoul National University Hospital
Saran Ochir Gongor, Kwang-Woong Lee, Nam-Joon Yi, YoungRok Choi, Suk Kyun Hong, Jeong-Moo Lee, Jae-Yoon Kim, Kyung-Suk Suh
Annals of Liver Transplantation.2024; 4(2): 71. CrossRef
Outcomes of living donor liver transplantation in patients with concurrent extrahepatic malignancy
John Hee Park, Jongman Kim, Sunghyo An, Namkee Oh, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh
Annals of Liver Transplantation.2024; 4(2): 102. CrossRef
How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
Byeong Geun Song, Dong Hyun Sinn
Clinical and Molecular Hepatology.2023; 29(2): 411. CrossRef
Validation of MELD 3.0 scoring system in East Asian patients with cirrhosis awaiting liver transplantation
Jeong-Ju Yoo, Jong-In Chang, Ji Eun Moon, Dong Hyun Sinn, Sang Gyune Kim, Young Seok Kim
Liver Transplantation.2023; 29(10): 1029. CrossRef
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
Clinical and Molecular Hepatology.2023; 29(3): 593. CrossRef
The Effect of Model for End-Stage Liver Disease 3.0 on Disparities between Patients with and without Hepatocellular Carcinoma in Korea
Kunhee Kim, Deok-Gie Kim, Jae Geun Lee, Dong Jin Joo, Hye Won Lee
Yonsei Medical Journal.2023; 64(11): 647. CrossRef
Comparison of Fibrinogen Concentrate and Cryoprecipitate on Major Thromboembolic Events after Living Donor Liver Transplantation
Jae-Hwan Kim, Kyoung-Sun Kim, Hye-Mee Kwon, Sung-Hoon Kim, In-Gu Jun, Jun-Gol Song, Gyu-Sam Hwang
Journal of Clinical Medicine.2023; 12(23): 7496. CrossRef
The first successful report of liver transplantation from category III donation after circulatory death in South Korea: a case report
Incheon Kang, Jae-myeong Lee, Jae Geun Lee
Korean Journal of Transplantation.2022; 36(4): 294. CrossRef

14,149 View
106 Download
19 Web of Science
Crossref

Review

Hepatic neoplasm

The management of post-transplantation recurrence of hepatocellular carcinoma: Luckshi Rajendran, Tommy Ivanics, Marco PAW Claasen, Hala Muaddi, Gonzalo Sapisochin; Clin Mol Hepatol 2022;28(1):1-16.
Published online October 5, 2021; DOI: https://doi.org/10.3350/cmh.2021.0217

Abstract
PDF

The annual incidence of hepatocellular carcinoma (HCC) continues to rise. Over the last two decades, liver transplantation (LT) has become the preferable treatment of HCC, when feasible and strict selection criteria are met. With the rise in HCC-related LT, compounded by downstaging techniques and expansion of transplant selection criteria, a parallel increase in number of post-transplantation HCC recurrence is expected. Additionally, in the context of an immunosuppressed transplant host, recurrences may behave aggressively and more challenging to manage, resulting in poor prognosis. Despite this, no consensus or best practice guidelines for post-transplantation cancer surveillance and recurrence management for HCC currently exist. Studies with adequate population sizes and high-level evidence are lacking, and the role of systemic and locoregional therapies for graft and extrahepatic recurrences remains under debate. This review seeks to summarize the existing literature on post-transplant HCC surveillance and recurrence management. It highlights the value of early tumour detection, re-evaluating the immunosuppression regimen, and staging to differentiate disseminated recurrence from intrahepatic or extrahepatic oligo-recurrence. This ultimately guides decision-making and maximizes treatment effect. Treatment recommendations specific to recurrence type are provided based on currently available locoregional and systemic therapies.

Citations

Citations to this article as recorded by

Comparison of repeat hepatectomy with radiofrequency ablation for the survival of hepatocellular carcinoma with solitary intrahepatic recurrence after hepatectomy
Jialu Fu, Jiafeng Chen, Lei Jin, Junfeng Huang, Shengwei Mao, Xuhui Zhao, Weifeng Qu, Rui Yang, Yi Wang, Yichao Bu, Zhiqi Guan, Jun Gao, Xiaoling Wu, Qianfu Zhao, Tianhao Chu, Guiqi Zhu, Yuan Fang, Yinghong Shi, Weiren Liu
Clinics and Research in Hepatology and Gastroenterology.2026; 50(2): 102750. CrossRef
Lycorine suppresses hepatocellular carcinoma via the reprogramming of myeloid and epithelial cells
Xinyu Gu, Fuqiang Ma, Yafeng Liu, Shujun Zhang, Wenjuan Chen, Lifan Zhang, Lele Zhang, Juan Lu, Xinjun Hu
Phytomedicine.2026; 150: 157657. CrossRef
CTTN overexpression on circulating tumor cells promotes hepatocellular carcinoma recurrence via enhancing the proliferation and clonality of circulating tumor cells
Yongzhi Liu, Zhidong Fu, Lihui Jiang, Yang Chen, Feng Jiang, Chuanling Zhang, Tieming Zhu
Cytotechnology.2026;[Epub] CrossRef
Integrating CyTOF with scRNA-seq reveals that Cyclovirobuxine D inhibits HCC progression through hepatic immune microenvironment remodeling
Fuqiang Ma, Lele Zhang, Yitao Fan, Ziyi Xu, Yuhua He, Jiachun Sun, Juan Lu, Xinyu Gu
Phytomedicine.2026; 150: 157751. CrossRef
A systematic review of MicroRNA (miRNA) biomarkers in the diagnosis and prognosis of hepatocellular carcinoma
J. M. John Britto, T Beula Bell
Irish Journal of Medical Science (1971 -).2026;[Epub] CrossRef
Organ Transplantation: Current Status, Challenges, and Future Prospects
Xinqiang Li, Ruidong Ding, Jinzhen Cai
MedComm.2026;[Epub] CrossRef
Recipient blood group does not affect hepatocellular carcinoma recurrence after living donor liver transplantation in Korea
Sung-Min Kim, Shin Hwang, Gi-Won Song, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, Woo-Hyoung Kang, Sang-Hoon Kim, Sung-Gyu Lee
Surgery Today.2025; 55(1): 99. CrossRef
Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Satohiro Masuda, Florian Lemaitre, Markus J. Barten, Stein Bergan, Maria Shipkova, Teun van Gelder, Sander Vinks, Eberhard Wieland, Kirsten Bornemann-Kolatzki, Mercè Brunet, Brenda de Winter, Maja-Theresa Dieterlen, Laure Elens, Taihei Ito, Kamisha Johnso
Therapeutic Drug Monitoring.2025; 47(1): 4. CrossRef
New Scenarios in Liver Transplantation for Hepatocellular Carcinoma
Ezequiel Mauro, Manuel Rodríguez‐Perálvarez, Antonio D'Alessio, Gonzalo Crespo, Federico Piñero, Eleonora De Martin, Jordi Colmenero, David James Pinato, Alejandro Forner
Liver International.2025;[Epub] CrossRef
Analysis of treatment benefits and prognostic factors for posttransplant HCC recurrence in a large Euro-American-Asian cohort
Zhihao Li, Itsuko Chih-Yi Chen, Leonardo Centonze, Christian T.J. Magyar, Woo Jin Choi, Sachin Shah, Grainne M. O’Kane, Arndt Vogel, Luciano De Carlis, Jan Lerut, Quirino Lai, Neil Mehta, Chao-Long Chen, Gonzalo Sapisochin
Liver Transplantation.2025; 31(4): 450. CrossRef
Prognosis predictors of hepatocellular carcinoma after hepatectomy following conversion therapy
Shaoru Liu, Zongfeng Wu, Chenwei Wang, Liang Qiao, Zhenkun Huang, Yichuan Yuan, Ruhai Zou, Wei He, Binkui Li, Yunfei Yuan, Jiliang Qiu
European Journal of Surgical Oncology.2025; 51(1): 109375. CrossRef
Comparative Outcome Analysis of Lenvatinib Versus Sorafenib for Recurrence of Hepatocellular Carcinoma After Liver Transplantation
Christian T. J. Magyar, Sheron Perera, Luckshi Rajendran, Zhihao Li, Fahad A. Almugbel, Sophie Feng, Woo Jin Choi, Laia Aceituno, Arndt Vogel, Robert C. Grant, Nazia Selzner, Elmar Jaeckel, Nazanin Falla-Rad, Jennifer J. Knox, Eric X. Chen, Gonzalo Sapiso
Transplantation.2025; 109(4): 681. CrossRef
Rapamycin-loaded nanoparticles elicit local liver immunosuppressive and remote anti-tumor efficacy
Yiyang Sun, Yanpeng Liu, Siyu Chen, Yidan Shen, Yangla Xie, Jing Zhang, Zhengxing Lian, Haiyang Xie, Sunbin Ling, Chang Xie, Haitao Hu, Huigang Li, Youqing Shen, Xiao Xu, Nasha Qiu
Nano Today.2025; 61: 102589. CrossRef
Comparative Validation of Prediction Models for HCC Outcomes in Living Donor Liver Transplantation: Superiority of Tumor Markers to Imaging Study
Hwa‐Hee Koh, Minyu Kang, Deok‐Gie Kim, Jae Hyon Park, Eun‐Ki Min, Jae Geun Lee, Myoung Soo Kim, Dong Jin Joo
Journal of Gastroenterology and Hepatology.2025; 40(3): 626. CrossRef
Renal metastasis of hepatocellular carcinoma after living donor liver transplantation
Yo Nakamura, Jun Kamei, Ryo Tanaka, Yoichi Yasunaga, Nobuhisa Akamatsu, Satoru Taguchi, Shigenori Kakutani, Yuta Yamada, Aya Niimi, Daisuke Yamada, Haruki Kume
IJU Case Reports.2025; 8(2): 133. CrossRef
Construction and Validation of a Novel Butyrylation-Related Gene Signature Related to Prognosis, Clinical Implications, and Immune Microenvironment Characterization of Hepatocellular Carcinoma
Weiping Su, Yangying Zhou, Xuanxuan Li, Kuo Kang, Hui Nie
ACS Omega.2025; 10(4): 3375. CrossRef
ZNF384 and m6A methylation promote the progression of hepatocellular carcinoma by regulating the interaction between LINC00342 and DAPK1
Shujia Kong, Jiaxun Li, Xin Pan, Chen Zhao, Yanwen Li
Cellular Signalling.2025; 129: 111666. CrossRef
A prospective multicenter validation of RETREAT for posttransplantation HCC recurrence prediction
P. Jonathan Li, Parissa Tabrizian, Darine Daher, Felipe Gaviria, Veeral Ajmera, Eleazar E. Montalvan-Sanchez, Julio A. Gutierrez, Kali Zhou, Fanny Delebecque, Nicole Garcia, Bethany Barrick, Christopher Wong, Lauren Nephew, John Holden, Shravan Dave, Gabr
Hepatology.2025; 82(6): 1450. CrossRef
Long non-coding rnas as key modulators of the immune microenvironment in hepatocellular carcinoma: implications for Immunotherapy
Siqi Zhao, Fei Chen, Lingyu Hu, Xiaoping Li, Zhaofeng Gao, Minjie Chen, Xiaoguang Wang, Zhengwei Song
Frontiers in Immunology.2025;[Epub] CrossRef
Locoregional and Surgical Treatment of Single-Nodule Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and a Meta-Analysis
Marco Maria Pascale, Camilla Marandola, Francesco Frongillo, Erida Nure, Salvatore Agnes
Cancers.2025; 17(9): 1501. CrossRef
Stereotactic Body Radiation Therapy for Intrahepatic Graft Recurrences of Hepatocellular Carcinoma After Liver Transplantation: A Report of Two Cases
Alexander Piening, Alyssa Capizzi, Jeevin Shahi
Cureus.2025;[Epub] CrossRef
Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma
Maen Abdelrahim, Alejandro Mejia, Abdullah Esmail, Juan Carlos Barrera Gutierrez, Mahmoud Ouf, Joseph W. Franses, Irun Bhan, Sudha Kodali, Ashish Saharia, Amit Mahipal, Nikolas Naleid, Catherine Bridges, Antony Tin, Chris M. Brewer, Vasily N. Aushev, Arka
JCO Precision Oncology.2025;[Epub] CrossRef
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: The Blind Spot of HCC Management
M. Ningarhari, G. Lassailly, S. Dharancy, C. Moreno, E. Trépo
United European Gastroenterology Journal.2025; 13(7): 1069. CrossRef
Confirmation of the donor origin of de novo hepatocellular carcinoma after liver transplant using microsatellite analysis
Wei Zhang, Jane Houldsworth, Thomas D Schiano, M Isabel Fiel
American Journal of Clinical Pathology.2025; 164(3): 492. CrossRef
Exploration Biomarkers for Recurrence of Hepatocellular Carcinoma After Liver Transplantation Based on Bioinformatics Analysis
Guangyi Zhu, Shijian Li, Ziyang Luo, Ning Wen, Haibin Li, Yang Fu, Weixuan Li, Jihua Wu, Xuyong Sun
Biochemical Genetics.2025;[Epub] CrossRef
Adding dendritic cell-immunotherapy for post-transplant hepatocellular carcinoma recurrence
Wei-Chen Lee, Chih-Hsien Cheng, Tsung-Han Wu, Yu-Chao Wang, Jin-Chiao Lee, Hao-Chien Hung, Chen-Fang Lee, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan
Frontiers in Immunology.2025;[Epub] CrossRef
Experimental and Clinical Transplantation.2025;[Epub] CrossRef
Integrated microbiome-metabolome profiling unveils a predictive signature for early recurrence in hepatocellular carcinoma
Qiqi Chen, Yi Wang, Daoyuan Wu, He Zhang, Qingxin Xia, Dingding Qu
Frontiers in Microbiology.2025;[Epub] CrossRef
Comprehensive Bioinformatic Analysis Reveals an Autophagy-related Gene Signature for Predicting Outcome, Immune Status, and Drug Sensitivity in Hepatocellular Carcinoma
Peng Liu, Yan Zhou, Shun Zeng, Xiangjuan Chen
Recent Patents on Anti-Cancer Drug Discovery.2025; 20(3): 397. CrossRef
pH-responsive doxorubicin-loaded Artemisia argyi carbon dots: enhanced targeted therapy for hepatocellular carcinoma
Ruilong Jia, Ping Liu, Yanli Gong, Yuting Gao, Yajun Xiong, Xiaoyong Song, Jinglin Peng, Meiqi Lan, Xinli Shi
RSC Advances.2025; 15(45): 37645. CrossRef
Activating transcription factor 4-mediated upregulation of Heat Shock Protein Family A Member 4 promotes hepatocellular carcinoma progression through activation of Wnt/β-catenin/EMT signaling pathway
Ruixi Li, Kunnan Wang, Naijing Hou, Yu Tian, Biyan Gong, Min Tang
International Journal of Biological Macromolecules.2025; 333: 148850. CrossRef
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi‐Center Real‐World Study
Federica Lo Prinzi, Federico Rossari, Antonio De Rosa, Caterina Vivaldi, Masatoshi Kudo, Shigeo Shimose, Goki Suda, Silvia Camera, Silvia Foti, Mario Domenico Rizzato, Francesca Salani, Naoshi Nishida, Tomotake Shirono, Naoya Sakamoto, Laura Passeri, Mich
Hepatology Research.2025;[Epub] CrossRef
NAP1L4 in hepatocellular carcinoma progression and treatment from gene expression to clinical impact
Junjie Lin, Hehe Yin, Zihan Xie, Meihui Liu, Lulu Kong, Ruixuan Yao, Guang Chen, Yuyao Li, Jiaojiao Shen, Qingling Wang, Kexing Han, Honghai Xu, Yufeng Gao
Discover Oncology.2025;[Epub] CrossRef
SURVEILLANCE AND MANAGEMENT OF POST-TRANSPLANT HEPATOCELLULAR CARCINOMA RECURRENCE
Valerio Giannelli, Margherita Spigaroli, Nicola Guglielmo, Gianmauro Berardi, Marco Colasanti, Claudia Telesca, Shirin Demma, Giuseppe Maria Ettorre, Adriano Pellicelli
European Journal of Transplantation.2025; 3(2): 77. CrossRef
2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations
Ashish Kumar, Subrat K. Acharya, Shivaram P. Singh, Ajay Duseja, Kaushal Madan, Akash Shukla, Anil Arora, Anil C. Anand, Ankur Bahl, Arvinder S. Soin, Bhawna Sirohi, Debnarayan Dutta, Dinesh Jothimani, Dipanjan Panda, Gagan Saini, Joy Varghese, Karan Kuma
Journal of Clinical and Experimental Hepatology.2024; 14(1): 101269. CrossRef
Three molecular subtypes and a five‐gene signature for hepatocellular carcinoma based on m7G‐related classification
Yuan Yue, Jie Tao, Dan An, Lei Shi
The Journal of Gene Medicine.2024;[Epub] CrossRef
Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea
Sojung Han, Do Young Kim, Ho Yeong Lim, Jung-Hwan Yoon, Baek-Yeol Ryoo, Yujeong Kim, Kookhee Kim, Bo Yeon Kim, So Young Yi, Dong-Sook Kim, Do-Yeon Cho, Jina Yu, Suhyun Kim, Joong-Won Park
Gut and Liver.2024; 18(1): 116. CrossRef
A Lactic Acid Metabolism-Related Gene Signature for Predicting Clinical Outcome and Tumor Microenvironmental Status in Patients with Hepatocellular Carcinoma
Zhongcheng Zhou, Bin Wu, Jing Chen, Yiyu Shen, Jing Wang, Xujian Chen, Faming Fei, Mingyuan Zhu
Nutrition and Cancer.2024; 76(3): 279. CrossRef
Association between Unplanned Conversion and Patient Survival after Laparoscopic Liver Resection for Hepatocellular Carcinoma: A Propensity Score Matched Analysis
Boram Lee, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, MeeYoung Kang, Yeshong Park, Jinju Kim
Journal of Clinical Medicine.2024; 13(4): 1116. CrossRef
Indication of Liver Transplant for HCC: Current Status and Future Directions
Julian K. Horwitz, Vatche G. Agopian
Current Hepatology Reports.2024; 23(1): 185. CrossRef
Exploring the metastasis-related biomarker and carcinogenic mechanism in liver cancer based on single cell technology
Qiuxiang Zheng, Cuiping Lu, Lian Yu, Ying Zhan, Zhiyong Chen
Heliyon.2024; 10(6): e27473. CrossRef
Achieving Textbook Outcomes after Laparoscopic Resection in Posterosuperior Segments of the Liver: The Impact of the Learning Curve
Mizelle D’Silva, Jai-Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae-Won Lee, Bo-Ram Lee, Mee-Young Kang, Ye-Shong Park, Jin-Ju Kim
Cancers.2024; 16(5): 930. CrossRef
Rapamycin inhibits B16 melanoma cell viability in vitro and in vivo by inducing autophagy and inhibiting the mTOR/p70‑S6k pathway
Penghui Wang, Haifang Zhang, Kaikai Guo, Chun Liu, Shimin Chen, Baopeng Pu, Sirun Chen, Tong Feng, Hanyi Jiao, Chang Gao
Oncology Letters.2024;[Epub] CrossRef
Commentary: Case Report: Lenvatinib for the treatment of recurrent hepatocellular carcinoma in people living with HIV: a report of two cases
Cuiming Sun, Ying Wen, Jin Zhou
Frontiers in Oncology.2024;[Epub] CrossRef
Clinical Application of Different Liquid Biopsy Components in Hepatocellular Carcinoma
Jing Xu, Yuanyuan Zhao, Zhishui Chen, Lai Wei
Journal of Personalized Medicine.2024; 14(4): 420. CrossRef
Atypical case of hepatoma recurrence two years post-transplant
Syed Muhammad Sinaan Ali, Abdul Haseeb, Muhammad Ashir Shafique, Muhammad Saqlain Mustafa, Naeemullah Arbani, Syeda Zainab Fatima
Journal of Medicine, Surgery, and Public Health.2024; 3: 100101. CrossRef
FOXM1 Upregulates O-GlcNAcylation Level Via The Hexosamine Biosynthesis Pathway to Promote Angiogenesis in Hepatocellular Carcinoma
Xiaorong Zhang, Yifan Zhong, Qing Yang
Cell Biochemistry and Biophysics.2024; 82(3): 2767. CrossRef
Statin, aspirin and metformin use and risk of hepatocellular carcinoma related outcomes following liver transplantation: A retrospective study
William Chung, Kevin Wong, Noel Ravindranayagam, Lauren Tang, Josephine Grace, Darren Wong, Danny Con, Marie Sinclair, Avik Majumdar, Numan Kutaiba, Samuel Hui, Paul Gow, Vijayaragavan Muralidharan, Alexander Dobrovic, Adam Testro
World Journal of Transplantation.2024;[Epub] CrossRef
Challenges in Liver Transplantation for Hepatocellular Carcinoma: A Review of Current Controversies
Ezequiel Mauro, Marco Sanduzzi-Zamparelli, Gabrielle Jutras, Raquel Garcia, Alexandre Soler Perromat, Neus Llarch, Victor Holguin Arce, Pablo Ruiz, Jordi Rimola, Eva Lopez, Joana Ferrer-Fàbrega, Ángeles García-Criado, Jordi Colmenero, Jennifer C. Lai, Ale
Cancers.2024; 16(17): 3059. CrossRef
Small graft size and hepatocellular carcinoma outcomes in living donor liver transplantation: a retrospective multicentric cohort study
Deok-Gie Kim, Shin Hwang, Kwang-Woong Lee, Jong Man Kim, Young Kyoung You, Donglak Choi, Je Ho Ryu, Bong-Wan Kim, Dong-Sik Kim, Jai Young Cho, Yang Won Nah, Man ki Ju, Tae-Seok Kim, Jae Geun Lee, Myoung Soo Kim, Alessandro Parente, Ki-Hun Kim, Andrea Schl
International Journal of Surgery.2024; 110(8): 4859. CrossRef
Postoperative adjuvant immunotherapy and molecular targeted therapy for patients of hepatocellular carcinoma with portal vein tumor thrombus after hepatectomy: a propensity score matching study
Jiangmin Zhou, Huifang Xiong, Zhiwei Zhang, Dong Chen, Wei Wang, Cheng Zhou, Biao Wu
Frontiers in Surgery.2024;[Epub] CrossRef
The complex role of immune cells in antigen presentation and regulation of T-cell responses in hepatocellular carcinoma: progress, challenges, and future directions
Jianbo Ning, Yutao Wang, Zijia Tao
Frontiers in Immunology.2024;[Epub] CrossRef
Are Ki-67 and Procalcitonin Expression Levels Useful in Predicting the Biological Behavior of Hepatocellular Carcinoma After Liver Transplantation?
Ertugrul Karabulut, Sami Akbulut, Emine Turkmen Samdanci, Ayse Nur Akatli, Ahmed Elsarawy, Zeynep Kucukakcali, Zeki Ogut, Adem Tuncer, Volkan Ince, Sezai Yilmaz
Journal of Clinical Medicine.2024; 14(1): 144. CrossRef
A mixed blessing for liver transplantation patients — Rapamycin
Guang-Han Fan, Chen-Zhi Zhang, Feng-Qiang Gao, Xu-Yong Wei, Sun-Bin Ling, Kai Wang, Jian-Guo Wang, Shu-Sen Zheng, Mehrdad Nikfarjam, Xiao Xu
Hepatobiliary & Pancreatic Diseases International.2023; 22(1): 14. CrossRef
Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma
Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Myung Ji Goh, Wonseok Kang, Seung Up Kim
European Journal of Gastroenterology & Hepatology.2023; 35(2): 191. CrossRef
Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review
Zurabi Lominadze, Kareen Hill, Mohammed Rifat Shaik, Justin P. Canakis, Mohammad Bourmaf, Cyrus Adams-Mardi, Ameer Abutaleb, Lopa Mishra, Kirti Shetty
International Journal of Molecular Sciences.2023; 24(3): 2358. CrossRef
Main factors influencing long-term outcomes of liver transplantation in 2022
Elisa Fuochi, Lorenzo Anastasio, Erica Nicola Lynch, Claudia Campani, Gabriele Dragoni, Stefano Milani, Andrea Galli, Tommaso Innocenti
World Journal of Hepatology.2023; 15(3): 321. CrossRef
Plumbagin Exhibits Genotoxicity and Induces G2/M Cell Cycle Arrest via ROS-Mediated Oxidative Stress and Activation of ATM-p53 Signaling Pathway in Hepatocellular Cells
Huan Liu, Wenchao Zhang, Lijie Jin, Shasha Liu, Liying Liang, Yanfei Wei
International Journal of Molecular Sciences.2023; 24(7): 6279. CrossRef
Microwave Ablation of Recurrent Hepatocellular Carcinoma after Curative Surgical Resection
Hamzah Adwan, Lars Hammann, Thomas J. Vogl
Journal of Clinical Medicine.2023; 12(7): 2560. CrossRef
An Analysis Regarding the Association Between Proteasome (PSM) and Hepatocellular Carcinoma (HCC)
Wei Huang, Jia Mei, Yuan-Jie Liu, Jie-Pin Li, Xi Zou, Xiao-Ping Qian, Yu Zhang
Journal of Hepatocellular Carcinoma.2023; Volume 10: 497. CrossRef
LI-RADS Morphological Type Predicts Prognosis of Patients with Hepatocellular Carcinoma After Radical Resection
Chunhui Zhang, Rui Yang, Xinxin Wang, Yuqing Tao, Shuli Tang, Zhennan Tian, Yang Zhou
Annals of Surgical Oncology.2023; 30(8): 4876. CrossRef
The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma
Letizia Todeschini, Luca Cristin, Alessandro Martinino, Amelia Mattia, Salvatore Agnes, Francesco Giovinazzo
Current Oncology.2023; 30(6): 5574. CrossRef
High expression of GPR50 promotes the proliferation, migration and autophagy of hepatocellular carcinoma cells in vitro
Weiming Zhao, Lingling Xi, Guoying Yu, Gaiping Wang, Cuifang Chang
Journal of Cell Communication and Signaling.2023; 17(4): 1435. CrossRef
SEER-based risk stratification system for patients with primary non-cirrhotic liver cancer
Runmin Cao, Honghe Jiang, Guangpeng Liang, Weibin Zhang
Journal of Cancer Research and Clinical Oncology.2023; 149(13): 12033. CrossRef
Sequencing Systemic Therapy in Hepatocellular Carcinoma
Ben Ponvilawan, Marc T. Roth
Current Treatment Options in Oncology.2023; 24(11): 1580. CrossRef
The current role of radiofrequency ablation in the treatment of intrahepatic recurrent hepatocellular carcinoma
Rong Fu, Wenwu Ling
Journal of Surgical Oncology.2023; 128(8): 1340. CrossRef
Sequential regorafenib or nivolumab therapy in recurrent hepatocellular carcinoma with sorafenib failure in liver transplant patients does not improve prognosis
Jieun Kwon, Jongman Kim, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh
Annals of Liver Transplantation.2023; 3(2): 104. CrossRef
Postoperative adjuvant immunotherapy for high-risk hepatocellular carcinoma patients
Wei-Qiao Zhang, Qiao Zhang, Li Tan, Zhi-Feng Guan, Feng Tian, Hong-Tao Tang, Kun He, Wei-Qiang Chen
Frontiers in Oncology.2023;[Epub] CrossRef
Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review
Sang Jin Kim, Jong Man Kim
Clinical and Molecular Hepatology.2022; 28(4): 739. CrossRef
Delayed Hepatocellular Carcinoma Recurrence After Liver Transplantation: Comprehensive Clinical Characterization of Case Series
Ta-Hsiang Wong, Cheng-Maw Ho, Hsao-Hsun Hsu, Yao-Ming Wu, Ming-Chih Ho, Po-Huang Lee, Rey-Heng Hu
Journal of Hepatocellular Carcinoma.2022; Volume 9: 1081. CrossRef

15,581 View
382 Download
65 Web of Science
Crossref

Editorial

Hepatic neoplasm

Can hepatocellular carcinoma recurrence be prevented after liver transplantation?: Jong Man Kim; Clin Mol Hepatol 2021;27(4):562-563.
Published online September 23, 2021; DOI: https://doi.org/10.3350/cmh.2021.0276

Citations

Citations to this article as recorded by

Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Satohiro Masuda, Florian Lemaitre, Markus J. Barten, Stein Bergan, Maria Shipkova, Teun van Gelder, Sander Vinks, Eberhard Wieland, Kirsten Bornemann-Kolatzki, Mercè Brunet, Brenda de Winter, Maja-Theresa Dieterlen, Laure Elens, Taihei Ito, Kamisha Johnso
Therapeutic Drug Monitoring.2025; 47(1): 4. CrossRef
Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation
Ji Won Han, Jong Young Choi, Eun Sun Jung, Ji Hoon Kim, Hee Sun Cho, Jae-Sung Yoo, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You
World Journal of Gastrointestinal Surgery.2023; 15(12): 2727. CrossRef
Optimal imaging criteria and modality to determine Milan criteria for the prediction of post-transplant HCC recurrence after locoregional treatment
Nieun Seo, Dong Jin Joo, Mi-Suk Park, Seung-seob Kim, Hye Jung Shin, Yong Eun Chung, Jin-Young Choi, Myoung Soo Kim, Myeong-Jin Kim
European Radiology.2022; 33(1): 501. CrossRef

7,849 View
144 Download
4 Web of Science
Crossref

Original Articles

Liver Transplantation

Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea: Kyeong Deok Kim, Ji Eun Lee, Jong Man Kim, Okjoo Lee, Na Young Hwang, Jinsoo Rhu, Gyu-Seong Choi, Kyunga Kim, Jae-Won Joh; Clin Mol Hepatol 2021;27(4):603-615.
Published online September 8, 2021; DOI: https://doi.org/10.3350/cmh.2021.0137

Background/Aims
Hepatitis B core antibody (anti-HBc)-positive donors are used as an extended donor pool, and current guidelines recommend the usage of nucleos(t)ide analogues (NAs) as prophylaxis for preventing de novo hepatitis B virus infection (DNH). We analyzed the long-term outcomes of a large cohort of liver transplantation (LT) patients receiving anti-HBc-positive grafts and evaluated the risk of DNH when hepatitis B immunoglobulin (HBIG) monotherapy was used as prophylaxis. We also compared the cost-effectiveness of HBIG and NAs.
Methods
We retrospectively reviewed 457 patients with anti-HBc-positive grafts and 898 patients with anti-HBc-negative grafts who underwent LT between January 2001 and December 2018. We compared recipient characteristics according to the anti-HBc status of the donor, and compared the costs of using NAs for the rest of the patient’s life and using HBIG to maintain hepatitis B surface antibody titers above 200 IU/L.
Results
The 1-, 5-, and 10-year patient survival rates were 87.7%, 73.5%, and 67.7%, respectively, in patients with anti-HBc-positive grafts, and 88.5%, 77.4%, and 70.3%, respectively, in patients with anti-HBc-negative grafts (P=0.113). Among 457 recipients with anti-HBc-positive grafts, 117 (25.6%) were non-HBV recipients. The overall incidence of DNH was 0.9%. When using HBIG under insurance coverage, the cumulative cost was lower compared with using NA continuously without insurance coverage in Korea.
Conclusions
Anti-HBc-positive grafts alone do not affect patient survival or graft survival. HBIG monoprophylaxis has good outcomes for preventing DNH, and the patient’s long-term cost burden is low in Korea because of the national insurance system in this cohort.

Citations

Citations to this article as recorded by

Management of Hepatitis B virus infection in patients on treatment with immunosuppressants or immunomodulators: Position Paper of Associazione Italiana Studio del Fegato (AISF), Associazione Italiana di Oncologia Medica (AIOM), Gruppo Italiano per il Trap
Mauro Viganò, Roberta D’Ambrosio, Ciro Celsa, Agostino Colli, Nicola Coppola, Bruno Daniele, Elisabetta Degasperi, Gianpiero D’Offizi, Vito Di Marco, Stefano Fagiuoli, Martina Gambato, Corrado Girmenia, Paolo Grossi, Pietro Lampertico, Andrea Lauterio, Ma
Digestive and Liver Disease.2025; 57(12): 2257. CrossRef
Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen
Yoshihiko Yano, Itsuko Sato, Takamitsu Imanishi, Ryutaro Yoshida, Takanori Matsuura, Yoshihide Ueda, Yuzo Kodama
Diagnostics.2024; 14(7): 728. CrossRef
Survival after liver transplantation from hepatitis B-core positive donors at a quaternary care hospital in Brazil
Fabiana Siroma, Edson Abdala, Stefanie Lima do Nascimento Castro, Wellington Andraus, Luiz Augusto Carneiro D´Álbuquerque, Alice Tung Wan Song
The Brazilian Journal of Infectious Diseases.2024; 28(6): 104384. CrossRef
Long-term outcomes of active vaccination against de novo hepatitis B among pediatric recipients of living donor liver transplantations with anti-HBc (+) grafts: a retrospective case–control study
Chee-Chien Yong, Yu-Hung Lin, Wendell Z. Espinosa, I-Hsuan Chen, Shih-Ho Wang, Yi-Chia Chan, Chao-Long Chen, Chih-Che Lin
International Journal of Surgery.2024; 110(10): 6702. CrossRef
Cost-effectiveness of Kidney Transplantation From Donors at Increased Risk of Blood-borne Virus Infection Transmission
Karan K. Shah, Melanie Wyld, James A. Hedley, Karen M.J. Waller, Nicole De La Mata, Angela C. Webster, Rachael L. Morton
Transplantation.2023; 107(9): 2028. CrossRef

10,174 View
157 Download
6 Web of Science
Crossref

Liver Transplantation

Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma: Incheon Kang, Jae Geun Lee, Sung Hoon Choi, Hyun Jeong Kim, Dai Hoon Han, Gi Hong Choi, Myoung Soo Kim, Jin Sub Choi, Soon Il Kim, Dong Jin Joo; Clin Mol Hepatol 2021;27(4):589-602.
Published online July 23, 2021; DOI: https://doi.org/10.3350/cmh.2021.0038

Background/Aims
This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC).
Methods
The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were retrospectively reviewed. The patients were divided into two groups: 1) patients treated with EVR in combination with calcineurin inhibitors (CNIs) (EVR group; n=114) and 2) patients treated with CNI-based therapy without EVR (non-EVR group; n=189). Time to recurrence (TTR) and overall survival (OS) after propensity score (PS) matching were compared between the groups, and prognostic factors for TTR and OS were evaluated.
Results
The EVR group exhibited more aggressive tumor biology than the non-EVR group, such as a higher number of tumors (P=0.003), a higher prevalence of microscopic vascular invasion (P=0.017) and exceeding Milan criteria (P=0.029). Compared with the PS-matched non-EVR group, the PS-matched EVR group had significantly better TTR (P<0.001) and OS (P<0.001). In multivariable analysis, EVR was identified as an independent prognostic factor for TTR (hazard ratio [HR], 0.248; P=0.001) and OS (HR, 0.145; P<0.001).
Conclusions
Combined with CNIs, EVR has the potential to prolong long-term survival in patients undergoing LT for HCC. These findings warrant further investigation in a well-designed prospective study.

Citations

Citations to this article as recorded by

Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Satohiro Masuda, Florian Lemaitre, Markus J. Barten, Stein Bergan, Maria Shipkova, Teun van Gelder, Sander Vinks, Eberhard Wieland, Kirsten Bornemann-Kolatzki, Mercè Brunet, Brenda de Winter, Maja-Theresa Dieterlen, Laure Elens, Taihei Ito, Kamisha Johnso
Therapeutic Drug Monitoring.2025; 47(1): 4. CrossRef
Genetic alterations are related to clinicopathological features and risk of recurrence/metastasis of hepatocellular carcinoma
Lili Meng, Zhenjian Jiang, Guangyue Shen, Shulan Lin, Feng Gao, Xinxin Guo, Bin Lv, Shuying Hu, Zheng Ni, Shanghua Chen, Yuan Ji
European Journal of Cancer Prevention.2025; 34(5): 456. CrossRef
Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort study
Suk-Chan Jang, Gi-Ae Kim, Young-Suk Lim, Hye-Lin Kim, Eui-Kyung Lee
American Journal of Transplantation.2025; 25(6): 1285. CrossRef
Adjuvant chemotherapy improves post-transplant outcome in patients with hepatocellular carcinoma
Heng-Kai Zhu, Hai-Bo Mou, Zhuo-Yi Wang, Wu Zhang, Dan Zhu, Si-Yi Zhong, Shu-Sen Zheng, Li Zhuang
Hepatobiliary & Pancreatic Diseases International.2025; 24(5): 491. CrossRef
Optimizing patient selection and immunosuppression in improving long-term survival after living donor liver transplantation for hepatocellular carcinoma
JaRyung Han, Young Seok Han
Annals of Liver Transplantation.2025; 5(1): 1. CrossRef
Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade
Dongdong Yu, Shuchan Li, Hao Chen, Lidong Wang
Clinical Transplantation.2025;[Epub] CrossRef
Toward optimized immunosuppression balance in liver transplantation: Clinical insights from lower tacrolimus exposure
Sung-Min Kim
Annals of Liver Transplantation.2025; 5(2): 65. CrossRef
High Number of Plasma Exchanges Increases the Risk of Bacterial Infection in ABO-incompatible Living Donor Liver Transplantation
Mun Chae Choi, Eun-Ki Min, Seung Hyuk Yim, Deok-Gie Kim, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim
Transplantation.2024; 108(8): 1760. CrossRef
Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation
Dong-Sik Kim, Young-In Yoon, Beom Kyung Kim, Ashok Choudhury, Anand Kulkarni, Jun Yong Park, Jongman Kim, Dong Hyun Sinn, Dong Jin Joo, YoungRok Choi, Jeong-Hoon Lee, Ho Joong Choi, Ki Tae Yoon, Sun Young Yim, Cheon-Soo Park, Deok-Gie Kim, Hae Won Lee, Wo
Hepatology International.2024; 18(2): 299. CrossRef
Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation
Paolo De Simone, Arianna Precisi, Quirino Lai, Juri Ducci, Daniela Campani, Piero Marchetti, Stefano Gitto
Cancers.2024; 16(7): 1243. CrossRef
Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence
María Martínez Burgos, Rocío González Grande, Susana López Ortega, Inmaculada Santaella Leiva, Jesús de la Cruz Lombardo, Julio Santoyo Santoyo, Miguel Jiménez Pérez
Biomedicines.2024; 12(6): 1302. CrossRef
Hepatocellular carcinoma recurrence after liver transplantation: risk factors, targeted surveillance and management options
Filippo Pelizzaro, Alberto Ferrarese, Martina Gambato, Alberto Zanetto, Francesco Paolo Russo, Giacomo Germani, Marco Senzolo, Mario Domenico Rizzato, Caterina Soldà, Alessandro Vitale, Enrico Gringeri, Umberto Cillo, Patrizia Burra
Hepatoma Research.2024;[Epub] CrossRef
Sirolimus improves the prognosis of liver recipients with hepatocellular carcinoma: A single-center experience
Peng Liu, Xin Wang, Huan Liu, Shu-Xian Wang, Qing-Guo Xu, Lin Wang, Xiao Xu, Jin-Zhen Cai
Hepatobiliary & Pancreatic Diseases International.2023; 22(1): 34. CrossRef
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra
Clinical and Molecular Hepatology.2023; 29(Suppl): S286. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Journal of Liver Cancer.2023; 23(1): 1. CrossRef
Immunosuppressive Medication Adherence in Patients With Hepatocellular Cancer Who Have Undergo Liver Transplantation: A Case Control Study
Sami Akbulut, Murat Tamer, Serdar Saritas, Ozlem Unal, Musap Akyuz, Selver Unsal, Zeynep Kucukakcali, Ertugrul Karabulut, Sertac Usta, Sezai Yilmaz
Transplantation Proceedings.2023; 55(5): 1231. CrossRef
Risk factors for late-onset Pneumocystis jirovecii pneumonia in liver transplant recipients
Eun-Ki Min, Juhan Lee, Su Jin Jeong, Deok-Gie Kim, Seung Hyuk Yim, Mun Chae Choi, Dong Jin Joo, Myoung Soo Kim, Jae Geun Lee
International Journal of Infectious Diseases.2023; 131: 166. CrossRef
Metronomic capecitabine with rapamycin exerts an immunosuppressive effect by inducing ferroptosis of CD4+ T cells after liver transplantation in rat
Hao Wang, Ruining Yang, Zhenglu Wang, Lei Cao, Dejun Kong, Qian Sun, Sei Yoshida, Jiashu Ren, Tao Chen, Jinliang Duan, Jianing Lu, Zhongyang Shen, Hong Zheng
International Immunopharmacology.2023; 124: 110810. CrossRef
Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation
Ji Won Han, Jong Young Choi, Eun Sun Jung, Ji Hoon Kim, Hee Sun Cho, Jae-Sung Yoo, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You
World Journal of Gastrointestinal Surgery.2023; 15(12): 2727. CrossRef
Safety of Tacrolimus Monotherapy within 12 Months after Liver Transplantation in the Era of Reduced Tacrolimus and Mycophenolate Mofetil: National Registry Study
Deok Gie Kim, Sung Hwa Kim, Shin Hwang, Suk Kyun Hong, Je Ho Ryu, Bong-Wan Kim, Young Kyoung You, Donglak Choi, Dong-Sik Kim, Yang Won Nah, Jai Young Cho, Tae-Seok Kim, Geun Hong, Dong Jin Joo, Myoung Soo Kim, Jong Man Kim, Jae Geun Lee
Journal of Clinical Medicine.2022; 11(10): 2806. CrossRef
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Korean Journal of Radiology.2022; 23(12): 1126. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef
Clinical association between tacrolimus intra-patient variability and liver transplantation outcomes in patients with and without hepatocellular carcinoma
Hyun Jeong Kim, Juhan Lee, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim
Scientific Reports.2022;[Epub] CrossRef
The first successful report of liver transplantation from category III donation after circulatory death in South Korea: a case report
Incheon Kang, Jae-myeong Lee, Jae Geun Lee
Korean Journal of Transplantation.2022; 36(4): 294. CrossRef
Can hepatocellular carcinoma recurrence be prevented after liver transplantation?
Jong Man Kim
Clinical and Molecular Hepatology.2021; 27(4): 562. CrossRef
Human Cytomegalovirus Is Associated with Lower HCC Recurrence in Liver Transplant Patients
Po-Jung Hsu, Hao-Chien Hung, Jin-Chiao Lee, Yu-Chao Wang, Chih-Hsien Cheng, Tsung-Han Wu, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan, Wei-Chen Lee, Chen-Fang Lee
Current Oncology.2021; 28(6): 4281. CrossRef
Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma
Soon Kyu Lee, Sung Won Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
International Journal of Molecular Sciences.2021; 22(19): 10271. CrossRef
Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation
Filippo Pelizzaro, Martina Gambato, Enrico Gringeri, Alessandro Vitale, Umberto Cillo, Fabio Farinati, Patrizia Burra, Francesco Paolo Russo
Cancers.2021; 13(19): 4882. CrossRef

11,738 View
265 Download
27 Web of Science
Crossref

Liver Transplantation

Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry: Jong Man Kim, Deok Gie Kim, Jihyun Kim, Keunsung Lee, Kwang-Woong Lee, Je Ho Ryu, Bong-Wan Kim, Dong Lak Choi, Young Kyoung You, Dong-Sik Kim, Yang Won Nah, Koo Jeong Kang, Jai Young Cho, Geun Hong, Hee Chul Yu, Ju Ik Moon, Dongho Choi, Shin Hwang, Myoung Soo Kim; Clin Mol Hepatol 2021;27(3):451-462.
Published online February 2, 2021; DOI: https://doi.org/10.3350/cmh.2020.0292

Background/Aims
To analyze the incidence and risk factors of outcomes after liver transplantation (LT) in the Korean population.
Methods
This study analyzed data from the liver cohort of Korean Organ Transplantation Registry (KOTRY) who had LT between May 2014 and December 2017. Study measures included the incidence of post-LT outcomes in recipients of living donor LT (LDLT) and deceased donor LT (DDLT). Cox multivariate proportional hazards model was used to determine the potential risk factors predicting the outcomes.
Results
A total of 2,563 adult recipients with LT (LDLT, n=1,956; DDLT, n=607) were included, with mean±standard deviation age of 53.9±8.9 years, and 72.2% were male. The post-LT outcomes observed in each LDLT and DDLT recipients were death (4.0% and 14.7%), graft loss (5.0% and 16.1%), rejection (7.0% and 12.0%), renal failure (2.7% and 13.8%), new onset of diabetes (12.5% and 15.4%), and hepatocellular carcinoma (HCC) recurrence (both 6.7%). In both LDLT and DDLT recipients, the most common post-LT complications were renal dysfunction (33.6% and 51.4%), infection (26.7% and 48.4%), and surgical complication (22.5% and 23.9%). Incidence of these outcomes were generally higher among recipients of DDLT than LDLT. Multivariate analysis indicated recipient age and DDLT as significant risk factors associated with death and graft loss. DDLT and ABO incompatible transplant were prognostic factors for rejection, and HCC beyond Milan criteria at pre-transplant was a strong predictor of HCC recurrence.
Conclusions
This study is a good indicator of the post-LT prognosis in the Korean population and suggests a significant burden of post-LT complications.

Citations

Citations to this article as recorded by

Outcomes of living-donor liver transplantation in older patients over 65 and 70 years compared to the younger recipients
Deok-Gie Kim, Young Jin Yoo, Minyu Kang, Hwa-hee Koh, Eun-Ki Min, Jae Geun Lee, Myoung Soo Kim, Dong Jin Joo
Asian Journal of Surgery.2026; 49(1): 76. CrossRef
Temporal evolution of living donor liver transplantation survival—A United Network for Organ Sharing registry study
Christian T.J. Magyar, Zhihao Li, Laia Aceituno, Marco P.A.W. Claasen, Tommy Ivanics, Woo Jin Choi, Luckshi Rajendran, Blayne A. Sayed, Roxana Bucur, Nadia Rukavina, Nazia Selzner, Anand Ghanekar, Mark Cattral, Gonzalo Sapisochin
American Journal of Transplantation.2025; 25(2): 406. CrossRef
Impact of Chronic Hepatitis C Virus on Acute Kidney Injury After Living Donor Liver Transplantation
Jae Hwan Kim, Kyoung-Sun Kim, Hye-Mee Kwon, Sung-Hoon Kim, In-Gu Jun, Jun-Gol Song, Gyu-Sam Hwang
Anesthesia & Analgesia.2025; 141(3): 608. CrossRef
Preoperative Factors Affecting Graft Survival After ABO-incompatible Adult Liver Transplantation
Hyun-Jun Nam, Deok-Gie Kim, Eun-Ki Min, Jae Geun Lee, Dai Hoon Han, Sinyoung Kim, Kyung-A Lee, Gi Hong Choi, Dong Jin Joo, Hyun Ok Kim, Soon Sung Kwon, Myoung Soo Kim
Transplantation.2025; 109(3): e157. CrossRef
Association of primary hepatocellular carcinoma laterality with oncological outcomes for hepatic resection patients: A retrospective, multicenter, propensity score-matched study
Okjoo Lee, Jaehong Jeong, So Kyung Yoon, Jun Chul Chung, Jongman Kim, Kwang-Woong Lee, Hyung Chul Kim
Asian Journal of Surgery.2025; 48(4): 2241. CrossRef
Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development foll
Jongman Kim
Clinical and Molecular Hepatology.2025; 31(2): 589. CrossRef
Emergency living donor liver transplantation
Jongman Kim
Annals of Liver Transplantation.2025; 5(1): 27. CrossRef
Safety and Therapeutic Outcomes of Adjuvant Immunotherapy With Autologous Cytokine-induced Killer Cells for Patients With Hepatocellular Carcinoma Beyond Milan Criteria After Liver Transplantation
Geun Hong, Dong Kyu Han, Jinsoo Rhu, Suk Kyun Hong, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Jongman Kim, Jaeseok Yang, Kyung-Suk Suh
Transplantation.2025; 109(10): e596. CrossRef
Meta‐Analysis: Comparison of Living Versus Deceased Liver Transplantation for Primary Sclerosing Cholangitis
Ana Beatriz Afonso, Carolina Morais da Silva, Paulo Nogueira, Mariana Verdelho Machado
Alimentary Pharmacology & Therapeutics.2025; 62(8): 768. CrossRef
Integrating Alpha‐Fetoprotein and Protein Induced by Vitamin K Antagonist‐II as Surveillance Tools After Liver Transplantation for Hepatocellular Carcinoma: A Novel Protocol for Early Detection of Tumor Recurrence
Jiyoung Kim, Kwang‐Woong Lee, Jae‐Yoon Kim, Jaewon Lee, Hyun Hwa Choi, Su young Hong, Jeong‐Moo Lee, Suk Kyun Hong, YoungRok Choi, Nam‐Joon Yi, Kyung‐Suk Suh
Clinical Transplantation.2025;[Epub] CrossRef
The evaluation of inflammatory and immune composite markers for complications after deceased donor liver transplantation – a retrospective cohort study
Zhihong Zheng, Shuman Kuang, Zipei Wang, Jin Gu, Jichang Jiang, Zhou Yu, Lijin Zhao
Annals of Medicine.2025;[Epub] CrossRef
Machine Learning–Based Selection of Resection vs Transplant and Survival in Hepatocellular Carcinoma
Hyun Uk Kim, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You
JAMA Network Open.2025; 8(9): e2532353. CrossRef
Living versus deceased donor liver transplantation in highly urgent patients using Korean national data
Jongman Kim, Sang Jin Kim, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
Annals of Liver Transplantation.2025; 5(2): 115. CrossRef
Predicting risk factors for waiting mortality in adult emergent living donor liver transplantation based on Korean national data
Sang Jin Kim, Jongman Kim, Kyunga Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
Annals of Liver Transplantation.2025; 5(2): 107. CrossRef
Liver Transplantation for Hepatocellular Carcinoma: A Comprehensive Review
Seok-Hwan Kim
Convergence Hepatology.2025; 1(1): 24. CrossRef
Causes of death and associated factors with death after liver transplantation: a nationwide database study
Junghyun Yoon, Hanjoon Kim, Dongho Choi, Boyoung Park
HPB.2024; 26(1): 54. CrossRef
Clinical impact and risk factors for cytomegalovirus infection in deceased donor liver transplantation without prophylaxis: Single center experience
Deok-Gie Kim, Eun-Ki Min, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim
Annals of Liver Transplantation.2024; 4(1): 23. CrossRef
Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation
Xu Zhang, Chi Chen, Yan Wang, Jun Xu
Journal of Gastroenterology and Hepatology.2024; 39(11): 2272. CrossRef
Chitinase-3 like-protein-1, a prognostic biomarker in patients with hepatocellular carcinoma and concomitant myosteatosis
Chiyu He, Zhihang Hu, Zuyuan Lin, Hao Chen, Chenghao Cao, Jinyan Chen, Xudong Yang, Huigang Li, Wei Shen, Xuyong Wei, Li Zhuang, Shusen Zheng, Xiao Xu, Di Lu
BMC Cancer.2024;[Epub] CrossRef
Mortality and associated factors among patients who underwent liver transplantation in South Korea from 2017 to 2021: a retrospective observational study
Tak Kyu Oh, In-Ae Song
Annals of Surgical Treatment and Research.2024; 107(5): 245. CrossRef
Effects of combined immunosuppressant and hepatitis B virus antiviral use on COVID-19 vaccination in recipients of living donor liver transplantation
Ryunjin Lee, Jiwan Choi, Eunkyeong Lee, Jooyoung Lee, Jiye Kim, Seoon Kang, Hye-In An, Sung-Han Kim, Sung-Min Kim, Eun-Kyoung Jwa, Gil-Chun Park, Jung-Man Namgoong, Gi-Won Song, Young-In Yoon, Eunyoung Tak, Sung-Gyu Lee
PeerJ.2024; 12: e18651. CrossRef
Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study
Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
European Journal of Internal Medicine.2023; 107: 66. CrossRef
Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study
Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim
American Journal of Gastroenterology.2023; 118(6): 1001. CrossRef
Physical Performance Decline During the Early Posttransplantation Period Affects Survival After Living Donor Liver Transplantation
Deok-Gie Kim, Shin Hwang, Kwang-Woong Lee, Gyu-seong Choi, Young Kyoung You, Je Ho Ryu, Bong-Wan Kim, Yang Won Nah, Dong-Sik Kim, Jai Young Cho, Koo Jeong Kang, Geun Hong, Hee Chul Yu, Man ki Ju, Suk-Won Suh, Kwan Woo Kim, Dongho Choi, Jaehong Jeong, Soo
Transplantation.2023; 107(7): 1545. CrossRef
Validation of the Model for End-Stage Liver Disease 3.0 in Korean Patients on the Liver Transplant Waiting List
Jiwon Yang, Jung-Bin Park, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Jonggi Choi
Clinical Gastroenterology and Hepatology.2023; 21(13): 3437. CrossRef
Incidence, mortality, and risk factors associated with carbapenem‐resistant Acinetobacter baumannii bacteremia within 30 days after liver transplantation
Eun‐Ki Min, Seung Hyuk Yim, Mun Chae Choi, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim, Deok‐Gie Kim
Clinical Transplantation.2023;[Epub] CrossRef
Risk Factors for Cytomegalovirus Infection and Its Impact on Survival after Living Donor Liver Transplantation in South Korea: A Nested Case-Control Study
Seung Hyuk Yim, Mun Chae Choi, Deok-Gie Kim, Eun-Ki Min, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim
Pathogens.2023; 12(4): 521. CrossRef
Impact of institutional case volume of solid organ transplantation on patient outcomes and implications for healthcare policy in Korea
Christine Kang, Ho Geol Ryu
Korean Journal of Transplantation.2023; 37(1): 1. CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
Beom Kyung Kim, Sang Hoon Ahn
Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis
Fernanda Onofrio, Katina Zheng, Cherry Xu, Shiyi Chen, Wei Xu, Mary Vyas, Katie Bingham, Keyur Patel, Leslie Lilly, Mark Cattral, Nazia Selzner, Elmar Jaeckel, Cynthia Tsien, Aliya Gulamhusein, Gideon M. Hirschfield, Mamatha Bhat
Hepatology Communications.2023;[Epub] CrossRef
Cancer Incidence in Living Liver Donors After Donor Hepatectomy
Jongman Kim, Jae Heon Kim, Hyun Jung Kim
Journal of Korean Medical Science.2023;[Epub] CrossRef
The Effect of Model for End-Stage Liver Disease 3.0 on Disparities between Patients with and without Hepatocellular Carcinoma in Korea
Kunhee Kim, Deok-Gie Kim, Jae Geun Lee, Dong Jin Joo, Hye Won Lee
Yonsei Medical Journal.2023; 64(11): 647. CrossRef
Pretransplant Functional Status Predicts Postoperative Morbidity and Mortality after Liver Transplantation in Patients with Cirrhosis
Myung Ji Goh, Jihye Kim, Won Hyuk Chang, Dong Hyun Sinn, Geum-Yeon Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Jong Man Kim, Wonseok Kang
Gut and Liver.2023; 17(5): 786. CrossRef
Successful liver transplantation from a donor with occlusive portal vein thrombosis
M. S. Novruzbekov, O. D. Olisov, V. A. Gulyaev, K. N. Lutsyk, B. I. Yaremin, B. I. Kazymov, K. M. Magomedov, A. R. Akhmedov, K. F. Alekberov
Transplantologiya. The Russian Journal of Transplantation.2023; 15(3): 334. CrossRef
Evidence-based hyponatremia management in liver disease
Ji Young Ryu, Seon Ha Baek, Sejoong Kim
Clinical and Molecular Hepatology.2023; 29(4): 924. CrossRef
Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation
Ji Won Han, Jong Young Choi, Eun Sun Jung, Ji Hoon Kim, Hee Sun Cho, Jae-Sung Yoo, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You
World Journal of Gastrointestinal Surgery.2023; 15(12): 2727. CrossRef
Outcomes of living liver donors are worse than those of matched healthy controls
Jin Yong Choi, Jae Heon Kim, Jong Man Kim, Hyun Jung Kim, Hyeong Sik Ahn, Jae-Won Joh
Journal of Hepatology.2022; 76(3): 628. CrossRef
Changes in the Deceased-Donor Trend in Korea: Establishment of Regional Trauma Centers and KODA
Jeong-Moo Lee
Journal of Clinical Medicine.2022; 11(5): 1239. CrossRef
Healthy Spouses can be Considered as Living Liver Donors
Okjoo Lee, Jong Man Kim, Sang Jin Kim, Jinsoo Rhu, Gyu‐Seong Choi, Jae‐Won Joh
World Journal of Surgery.2022; 46(6): 1474. CrossRef
De Novo Intrahepatic Cholangiocarcinoma After Deceased Donor Liver Transplant in an Adult Patient
Hyung Hwan Moon, Dong Hoon Shin, Young Il Choi
Experimental and Clinical Transplantation.2022; 20(3): 316. CrossRef
Long-Term Outcomes of Laparoscopic Liver Resection for Centrally Located Hepatocellular Carcinoma
Hyo Jun Kim, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Yeongsoo Jo, Meeyouong Kang, Yeshong Park, Eunhye Lee
Medicina.2022; 58(6): 737. CrossRef
Long-term Clinical Outcomes and Predictive Factors for Living-donor Liver Transplant Recipients With Biliary Strictures
Ji Won Han, Jong Young Choi, Soon Kyu Lee, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Young Hoon Choi, In Seok Lee, Jung Suk Oh, Ho Jong Chun, Ho Joong Choi, Young Kyoung You
Transplantation.2022; 106(10): 1990. CrossRef
Non-Renal Risk Factors for Chronic Kidney Disease in Liver Recipients with Functionally Intact Kidneys at 1 Month
Deok-Gie Kim, Shin Hwang, Jong Man Kim, Je Ho Ryu, Young Kyoung You, Donglak Choi, Bong-Wan Kim, Dong-Sik Kim, Yang Won Nah, Tae-Seok Kim, Jai Young Cho, Geun Hong, Jae Do Yang, Jaryung Han, Suk-Won Suh, Kwan Woo Kim, Yun Kyung Jung, Ju Ik Moon, Jun Young
Journal of Clinical Medicine.2022; 11(14): 4203. CrossRef
Evidence of nonsurgical treatment for polycystic liver disease
Jeong-Ju Yoo, Hye In Jo, Eun-Ae Jung, Jae Seung Lee, Sang Gyune Kim, Young Seok Kim, Beom Kyung Kim
Therapeutic Advances in Chronic Disease.2022;[Epub] CrossRef
Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database
Hankil Lee, Beom Kyung Kim
Journal of Gastroenterology and Hepatology.2022; 37(11): 2154. CrossRef
Low-grade hepatocellular carcinoma characteristics, a practical nomogram and risk stratification system: a SEER population-based study
Dashuai Yang, Yang Su, Fangrui Zhao, Yong Hu, Kailiang Zhao, Xiangyun Xiong, Mingqiang Zhu, Junpeng Pei, Youming Ding
Expert Review of Gastroenterology & Hepatology.2022; 16(11-12): 1115. CrossRef
Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicenter analysis of the US, the UK, and Canada
Tommy Ivanics, David Wallace, Marco P.A.W. Claasen, Madhukar S. Patel, Rushin Brahmbhatt, Chaya Shwaartz, Andreas Prachalias, Parthi Srinivasan, Wayel Jassem, Nigel Heaton, Mark S. Cattral, Nazia Selzner, Anand Ghanekar, Gabriela Morgenshtern, Neil Mehta,
Journal of Hepatology.2022; 77(6): 1607. CrossRef
Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review
Sang Jin Kim, Jong Man Kim
Clinical and Molecular Hepatology.2022; 28(4): 739. CrossRef
Development and Validation of a Difficulty Scoring System for Laparoscopic Liver Resection to Treat Hepatolithiasis
Yeongsoo Jo, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Eunhye Lee, Yeshong Park, MeeYoung Kang, Junghyun Lee
Medicina.2022; 58(12): 1847. CrossRef
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim
Diagnostics.2022; 13(1): 3. CrossRef
New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease
Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim
Clinical and Translational Gastroenterology.2022; 13(12): e00542. CrossRef
Extubation in the operating room results in fewer composite mechanical ventilation-related adverse outcomes in patients after liver transplantation: a retrospective cohort study
Yan Xu, Yiding Zuo, Li Zhou, Xuechao Hao, Xiao Xiao, Mao Ye, Lulong Bo, Chunling Jiang, Jiayin Yang
BMC Anesthesiology.2021;[Epub] CrossRef
Can hepatocellular carcinoma recurrence be prevented after liver transplantation?
Jong Man Kim
Clinical and Molecular Hepatology.2021; 27(4): 562. CrossRef

13,023 View
353 Download
50 Web of Science
Crossref

Review

Liver fibrosis, cirrhosis, and portal hypertension

Changes in the epidemiology and management of bacterial infections in cirrhosis: Salvatore Piano, Marta Tonon, Paolo Angeli; Clin Mol Hepatol 2021;27(3):437-445.
Published online January 28, 2021; DOI: https://doi.org/10.3350/cmh.2020.0329

Abstract
PDF

Patients with cirrhosis are susceptible to develop infections because of immune dysfunction, changes in microbiome and increase in bacterial translocation from the gut to systemic circulation. Bacterial infections can worse the clinical course of the disease, triggering the development of complications such as acute kidney injury, hepatic encephalopathy, organ failures and acute on chronic liver failure. In recent years, the spread of multi drug resistant bacteria made more challenging the management of infections in patients with cirrhosis. Hence, the mortality rate associated to sepsis is increasing in these patients. Therefore, the optimization of the management of infections has a high priority in cirrhosis. Herein we reviewed the recent changes in the epidemiology and the management of bacterial infections in patients with liver cirrhosis.

Citations

Citations to this article as recorded by

Global Trends in Antimicrobial Resistance Among Cirrhosis Patients With Bacteremia: A Systematic Review and Meta-analysis
Ellis K. Paintsil, Cynthia K. Adu-Asiamah, Victoria T. Kronsten, Yevedzo Ntuli, Debbie L. Shawcross
Clinical Gastroenterology and Hepatology.2026; 24(1): 69. CrossRef
Prospective surveillance reveals high rates of antimicrobial resistance in urinary tract infections among patients with cirrhosis.
Carolina Vazquez, Gonzalo Gómez Perdiguero, Esteban González Ballerga, Ilse Pardo Ivirico, Camila M. Briz, Agustín Di Santo, Maria D. Murga, Ana Palazzo, Lorena Notari, Josefina Pages, Julia Brutti, Brenda Osso Sánchez, Manuel Mendizabal, Margarita Anders
Annals of Hepatology.2026; 31(1): 102135. CrossRef
Towards evidence-based empiric antibiotic recommendations for spontaneous infections in patients with cirrhosis
Melisa Dirchwolf, Gonzalo Gomez Perdiguero, Fernando Cairo, Carolina Vazquez, Lorena Notari, Maria Dolores Murga, Martin Elizondo, Fernando Bessone, Marina Agozino, Julia Brutti, Alina Raquel Zerega, Josefina Pages, Teodoro Eduardo Stieben, Pablo Calzetta
Digestive and Liver Disease.2025; 57(2): 394. CrossRef
Higher Rate of Spontaneous Bacterial Peritonitis Recurrence With Secondary Spontaneous Bacterial Peritonitis Prophylaxis Compared With No Prophylaxis in 2 National Cirrhosis Cohorts
Scott Silvey, Nilang R. Patel, Stephanie Y. Tsai, Mahum Nadeem, Richard K. Sterling, John D. Markley, Evan French, Jacqueline G. O'Leary, Jasmohan S. Bajaj
American Journal of Gastroenterology.2025; 120(5): 1066. CrossRef
Bacterial resistance profile and its association with poor outcome among cirrhosis patients attending a tertiary care referral center in northern India
Gerlin Varghese, Ashima Jamwal, Deepika Sarawat, Surender Singh, Nidhi Tejan, Sangram Singh Patel, Chinmoy Sahu
Indian Journal of Gastroenterology.2025; 44(2): 198. CrossRef
Lactate-to-albumin ratio as a potential prognostic predictor in patients with cirrhosis and sepsis: a retrospective cohort study
Jianjun Wang, Xi Chen, Chuan Qin, Ruizi Shi, Yu Huang, Jianping Gong, Xintao Zeng, Decai Wang
BMC Infectious Diseases.2025;[Epub] CrossRef
A Case of Complicated Bacteremia: When the Source Is in the Blood
Raquel Costeira, Elisa Macedo Brás, Ricardo Manuel Pereira, Inês Barbosa Leão, Catia Canelas
Cureus.2025;[Epub] CrossRef
Relationship between coagulopathy score and survival in critically ill patients with liver cirrhosis and sepsis: a retrospective study
Tao Wang, Decai Wang, Ruizi Shi, Xintao Zeng, Pei Yang, Xi Chen, Sirui Chen, Chuan Qin, Chidan Wan, Jianjun Wang
BMC Infectious Diseases.2025;[Epub] CrossRef
Infection risk and management in patients with cirrhosis: A critical overview
Miguel Suárez, Raquel Martínez, Raquel Gómez-Molina, Jorge Mateo
World Journal of Hepatology.2025;[Epub] CrossRef
A National Survey Shows a Dilemma Toward Spontaneous Bacterial Peritonitis Prophylaxis Among US-Based Hepatology Professionals
Deborah DiazGranados, Jacqueline G. O'Leary, Madhumita Yamuzala, Shari Rogal, Jasmohan S. Bajaj
Clinical and Translational Gastroenterology.2025; 16(7): e00858. CrossRef
A Serum DLL1 and CRP dual-marker model for bacterial infection detection in patients with decompensated cirrhosis: A dual-cohort diagnostic study
Juanjun Huang, Luhu Yu, Debin Zeng, Yulin Wang, Zhi Wang, Jian Chen, Wei Zhu
Science Progress.2025;[Epub] CrossRef
Predictive role of the Albumin-Bilirubin score in ICU patients with cirrhosis and sepsis: insights from a large retrospective cohort
Jianjun Wang, Pei Yang, Chuan Qin, Yongwei Huang, Zhaohui Hu, Ruizi Shi, Sirui Chen, Xi Chen, Hua Luo, Jianping Gong, Xintao Zeng, Decai Wang
BMC Gastroenterology.2025;[Epub] CrossRef
Impact of Serious Infection on Mortality of Patients With Chronic Liver Disease: A Nationwide Population-based Cohort Study
Jae Yoon Jeong, Ju-Yeon Cho, Danbee Kang, Jung Hee Kim, Soo Jin Park, Eun-Jeong Joo, Hyunwoo Oh, Yong Kyun Cho, Byung Ik Kim, Won Sohn
Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Associations of lactate-to-hematocrit ratio with short- and long-term prognoses in critically ill patients with cirrhosis and sepsis: a retrospective cohort study
Jianjun Wang, Xi Chen, Sirui Chen, Zhaohui Hu, Yancheng Liu, Ruizi Shi, Chuan Qin, Jianping Gong, Xintao Zeng, Decai Wang
BMC Infectious Diseases.2025;[Epub] CrossRef
Machine learning-based nomogram for mortality risk stratification in cirrhotic patients with sepsis: a single-center predictive model
Xing-Cheng Zhang, Bo-Wen Li, Xi-Qun Lei, Nan-Bing Shan, Jun-Ping Wei, Zhong-Hua Lu, Yun Sun
Frontiers in Medicine.2025;[Epub] CrossRef
Pre‐transplant multidrug‐resistant infections in liver transplant recipients‐epidemiology and impact on transplantation outcome
Gabriela T. Lemos, Debora R. B. Terrabuio, Nathalia N. Nunes, Alice T. W. Song, Isabel C. V. Oshiro, Luiz Augusto C. D'Albuquerque, Anna S. Levin, Edson Abdala, Maristela P. Freire
Clinical Transplantation.2024;[Epub] CrossRef
Identifying hub genes of sepsis-associated and hepatic encephalopathies based on bioinformatic analysis—focus on the two common encephalopathies of septic cirrhotic patients in ICU
Juan Li, Dong Yang, Shengmei Ge, Lixia Liu, Yan Huo, Zhenjie Hu
BMC Medical Genomics.2024;[Epub] CrossRef
Kidney pathology in liver cirrhosis
E. G. Malaeva
Health and Ecology Issues.2024; 20(4): 70. CrossRef
Navigating the Labyrinth: Intensive Care Challenges for Patients with Acute-on-Chronic Liver Failure
Fuat H. Saner, Dimitri A. Raptis, Saad A. Alghamdi, Massimo M. Malagó, Dieter C. Broering, Dmitri Bezinover
Journal of Clinical Medicine.2024; 13(2): 506. CrossRef
High‐dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study
Jun Sik Yoon, Ji Hoon Hong, Soo Young Park, Seung Up Kim, Hwi Young Kim, Ju Yeon Kim, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Han Ah Lee, Gi‐Ae Kim, Dong Hyun Sinn, Sung Jae Park, Youn Jae Lee, Yoon Jun Kim, Jung‐Hwan Yoon, Jeong‐Hoon Lee
Alimentary Pharmacology & Therapeutics.2024; 59(8): 973. CrossRef
Pulmonary Bacterial Infection and Liver Cirrhosis: Current Status and Treatment
Yingying Zhao, Song Yang, Huichun Xing
Infectious Microbes and Diseases.2024; 6(1): 5. CrossRef
Retrospective study of the incidence, risk factors, treatment outcomes of bacterial infections at uncommon sites in cirrhotic patients
Sophie Schneitler, Christina Schneider, Markus Casper, Frank Lammert, Marcin Krawczyk, Sören L Becker, Matthias Christian Reichert
World Journal of Hepatology.2024; 16(3): 418. CrossRef
Infectious Complications of Portal Hypertension
Simone Incicco, Paolo Angeli, Salvatore Piano
Clinics in Liver Disease.2024; 28(3): 525. CrossRef
Development of a nomogram for predicting in-hospital mortality in patients with liver cirrhosis and sepsis
Hai-rong Lin, Qiu-xia Liao, Xin-xin Lin, Ye Zhou, Jian-dong Lin, Xiong-jian Xiao
Scientific Reports.2024;[Epub] CrossRef
Review article: Evaluation and care of the critically ill patient with cirrhosis
Iva Kosuta, Madhumita Premkumar, K. Rajender Reddy
Alimentary Pharmacology & Therapeutics.2024; 59(12): 1489. CrossRef
Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real‐world U.S. patients, 2003–2021
Sally Tran, Biyao Zou, KeeSeok Lee, Leslie Kam, YeeHui Yeo, Linda Henry, Ramsey Cheung, Mindie H. Nguyen
Alimentary Pharmacology & Therapeutics.2024; 60(2): 212. CrossRef
Prevalence and predictors of multidrug-resistant bacteremia in liver cirrhosis
Aryoung Kim, Byeong Geun Song, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Myung Ji Goh
The Korean Journal of Internal Medicine.2024; 39(3): 448. CrossRef
Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy
Francisco Idalsoaga, Camila Robles, Andrea Ortiz, Oscar Corsi, Eduardo Fuentes-López, Luis Antonio Díaz, Gustavo Ayares, Marco Arrese, Juan Pablo Arab
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef
Protocolo terapéutico de las infecciones bacterianas en la cirrosis
C. Meruéndano Padrón, J. Donate Ortega, C. García Huerta, M.Á. Rodríguez Gandía
Medicine - Programa de Formación Médica Continuada Acreditado.2024; 14(10): 581. CrossRef
Prognostic value of the neutrophil to lymphocyte ratio in the clinical course of liver cirrhosis
M. R. Sarkarova, M. V. Maevskaya
Meditsinskiy sovet = Medical Council.2024; (8): 66. CrossRef
Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine
Shihao Zheng, Chengyuan Xue, Size Li, Xiaobin Zao, Xiaoke Li, Qiyao Liu, Xu Cao, Wei Wang, Wenying Qi, Hongbo Du, Peng Zhang, Yongan Ye
Frontiers in Pharmacology.2024;[Epub] CrossRef
Increased serum albumin corrected anion gap levels are associated with poor prognosis in septic patients with liver cirrhosis
Zetao Pan, Jiancheng Lin, Cunyang Huo, Di Yin, Qiang Guo
Scientific Reports.2024;[Epub] CrossRef
Incidence, risk factors and clinical outcomes of multidrug-resistant microorganism infections among patients admitted for decompensated cirrhosis: A prospective study
Helena Masnou, Ariadna Aguilar, Ignacio Iborra, Margarita Sala, Maria Torner, Ariadna Clos-Parals, Alba Ardèvol, Montserrat Giménez, Marta Fortuny, Maria Rosa Sarrias, Rosa M. Morillas, Eugeni Domènech
Gastroenterología y Hepatología.2023; 46(4): 288. CrossRef
Impact of multidrug resistance on the management of bacterial infections in cirrhosis
Carlos Terra, Ângelo Zambam de Mattos, Marcelo Souza Chagas, Andre Torres, Denusa Wiltgen, Barbara Muniz Souza, Renata Mello Perez
World Journal of Clinical Cases.2023; 11(3): 534. CrossRef
Old and New Precipitants in Hepatic Encephalopathy: A New Look at a Field in Continuous Evolution
Daniele Bellafante, Stefania Gioia, Jessica Faccioli, Oliviero Riggio, Lorenzo Ridola, Silvia Nardelli
Journal of Clinical Medicine.2023; 12(3): 1187. CrossRef
Infection prevention and control programme and COVID-19 measures: Effects on hospital-acquired infections in patients with cirrhosis
Simone Di Cola, Jakub Gazda, Lucia Lapenna, Giancarlo Ceccarelli, Manuela Merli
JHEP Reports.2023; 5(5): 100703. CrossRef
The Role of Microbiota in Liver Transplantation and Liver Transplantation-Related Biliary Complications
Ulrich Wirth, Tianxiao Jiang, Josefine Schardey, Katharina Kratz, Mingming Li, Malte Schirren, Florian Kühn, Alexandr Bazhin, Jens Werner, Markus Guba, Christian Schulz, Joachim Andrassy
International Journal of Molecular Sciences.2023; 24(5): 4841. CrossRef
Challenges and recommendations when selecting empirical antibiotics in patients with cirrhosis
Melisa Dirchwolf, Gonzalo Gomez Perdiguero, Ingrid Mc Grech, Sebastian Marciano
World Journal of Hepatology.2023; 15(3): 377. CrossRef
Clinical and microbiological characteristics of bacterial infections in patients with cirrhosis. A prospective cohort study from Argentina and Uruguay
Carolina Vazquez, María Nelly Gutierrez-Acevedo, Sabrina Barbero, Lorena del Carmen Notari, Marina Agozino, José Luis Fernandez, María Margarita Anders, Nadia Lorena Grigera, Florencia Antinucci, Orlando Nicolas Federico Orozco-Ganem, María Dolores Murga,
Annals of Hepatology.2023; 28(4): 101097. CrossRef
Gut Microbiota and Infectious Complications in Advanced Chronic Liver Disease: Focus on Spontaneous Bacterial Peritonitis
Valeria Maccauro, Carlo Airola, Francesco Santopaolo, Antonio Gasbarrini, Francesca Romana Ponziani, Maurizio Pompili
Life.2023; 13(4): 991. CrossRef
Bacterial Infections in Acute on Chronic Liver Failure
Simone Incicco, Paolo Angeli, Salvatore Piano
Clinics in Liver Disease.2023; 27(3): 703. CrossRef
Real-world efficacy of antibiotic prophylaxis for upper gastrointestinal bleeding in cirrhotic patients in Japan
Masayuki Ueno, Takashi Fujiwara, Hironobu Tokumasu, Toshifumi Mano, Takahisa Kayahara, Hiroyuki Takabatake, Youichi Morimoto, Kazuhiro Matsueda, Toshio Fukuoka, Motowo Mizuno
Journal of Gastroenterology.2023; 58(8): 766. CrossRef
Incidence, risk factors and clinical outcomes of multidrug-resistant microorganism infections among patients admitted for decompensated cirrhosis: A prospective study
Helena Masnou, Ariadna Aguilar, Ignacio Iborra, Margarita Sala, Maria Torner, Ariadna Clos-Parals, Alba Ardèvol, Montserrat Giménez, Marta Fortuny, Maria Rosa Sarrias, Rosa M. Morillas, Eugeni Domènech
Gastroenterología y Hepatología (English Edition).2023; 46(4): 288. CrossRef
Management of sepsis in a cirrhotic patient admitted to the intensive care unit: A systematic literature review
Nkola Ndomba, Jonathan Soldera
World Journal of Hepatology.2023; 15(6): 850. CrossRef
Antibiotic resistance in patients with liver cirrhosis: Prevalence and current approach to tackle
Valentina Liakina
World Journal of Clinical Cases.2023; 11(31): 7530. CrossRef
Characteristics of bacterial infections and prevalence of multidrug-resistant bacteria in hospitalized patients with liver cirrhosis in Germany
Wolfgang Maximilian Kremer, Simon Johannes Gairing, Leonard Kaps, Esmeralda Ismail, Vasiliki Kalampoka, Max Hilscher, Maurice Michel, Ekkehard Siegel, Jörn M. Schattenberg, Peter R. Galle, Martin F. Sprinzl, Marcus-Alexander Wörns, Michael Nagel, Christia
Annals of Hepatology.2022; 27(5): 100719. CrossRef
Management of Multidrug-Resistant Infections in Cirrhosis
Charles E. Gallaher, Debbie L. Shawcross
Seminars in Liver Disease.2022; 42(02): 173. CrossRef
Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study
Ji Hyun Kim, Baek Gyu Jun, Minjong Lee, Hye Ah Lee, Tae Suk Kim, Jeong Won Heo, Da Hye Moon, Seong Hee Kang, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim, Dae Hee Choi
Clinical and Molecular Hepatology.2022; 28(3): 540. CrossRef
Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database
Hankil Lee, Beom Kyung Kim
Journal of Gastroenterology and Hepatology.2022; 37(11): 2154. CrossRef
Early Diagnosis and Prevention of Infections in Cirrhosis
Anand V. Kulkarni, Madhumita Premkumar, Juan P. Arab, Karan Kumar, Mithun Sharma, Nageshwar D. Reddy, Nagaraja R. Padaki, Rajender K. Reddy
Seminars in Liver Disease.2022; 42(03): 293. CrossRef
Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis
Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim, Joo Won Baik, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
Clinical and Molecular Hepatology.2022; 28(4): 876. CrossRef
New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease
Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim
Clinical and Translational Gastroenterology.2022; 13(12): e00542. CrossRef
Antibiotics and Liver Cirrhosis: What the Physicians Need to Know
Caterina Zoratti, Rita Moretti, Lisa Rebuzzi, Irma Valeria Albergati, Antonietta Di Somma, Giuliana Decorti, Stefano Di Bella, Lory Saveria Crocè, Mauro Giuffrè
Antibiotics.2021; 11(1): 31. CrossRef
Bacterial Infections in Cirrhosis
Marta Tonon, Paolo Angeli, Salvatore Piano
Infectious Microbes and Diseases.2021; 3(3): 117. CrossRef

13,810 View
454 Download
50 Web of Science
Crossref

Editorial

Liver fibrosis, cirrhosis, and portal hypertension

Alcohol-related cirrhosis: The most challenging etiology of cirrhosis is more burdensome than ever: Marta Tonon, Salvatore Piano; Clin Mol Hepatol 2021;27(1):94-96.
Published online December 3, 2020; DOI: https://doi.org/10.3350/cmh.2020.0305

Citations

Citations to this article as recorded by

Hepatic encephalopathy and spontaneous bacterial peritonitis are associated with increased liver-related readmissions in cirrhosis
Shan Wang, Lin Zhang, Jin Li, Jiajun Feng, Jie Gao, Rui Huang
Frontiers in Medicine.2025;[Epub] CrossRef
UHRF1 ameliorates liver cirrhosis through suppressing macrophage M1 polarization by catalyzing HMGA2 promoter methylation
Ruixi Li, Qiang Tao, Jiandong Zha, Shikai Wang, Xiaozhun Huang, Jicai Wang, Hang Zhai, Shengjie Hong, Guangquan Zhang
Biochemical Pharmacology.2025; 242: 117357. CrossRef
Global burden of cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2021
Ying Zhang, Ming Luo, Yingzi Ming
BMC Gastroenterology.2025;[Epub] CrossRef
Role of MicroRNAs in Alcohol-Related Liver Disease
Prabhudas Nelaturi, Sangeetha P Kademani, Krishna Sumanth Nallagangula, Sambandam Ravikumar
Alcoholism Treatment Quarterly.2024; 42(1): 115. CrossRef
Burden of caregiving of alcohol related liver disease patients: a possible role of training and caregiver groups frequency. Proposal of a method, preliminary results
Patrizia BALBINOT, Rinaldo PELLICANO, Gianni TESTINO
Minerva Gastroenterology.2024;[Epub] CrossRef
Metabolomics in cirrhosis: Recent advances and opportunities
Yan-qun Luo, Cai-yun Zhang, Xia-zhen Nong, Ying Gao, Lei Wang, Guang Ji, Tao Wu
Clinica Chimica Acta.2024; 557: 117886. CrossRef
Deletion of Mixed Lineage Kinase Domain Like Pseudokinase Aggravates Chronic Alcohol-Induced Liver Injury via Increasing Apoptosis
Keon Hwi Im, Waqar Khalid Saeed, Eun Bin Kim, A. Hyeon Lee, Ji Eun Kim, Seung Min Lee, Xuanyuan hanning, Hyun Sung Kim, Dae Won Jun, Eileen L. Yoon
Digestive Diseases and Sciences.2024; 69(5): 1701. CrossRef
Hepatoprotective Effect of Kaempferol: A Review of the Dietary Sources, Bioavailability, Mechanisms of Action, and Safety
Maulana Yusuf Alkandahri, Barolym Tri Pamungkas, Zulpakor Oktoba, Mareetha Zahra Shafirany, Lela Sulastri, Maya Arfania, Ebta Narasukma Anggraeny, Ade Pratiwi, Fitri Dwi Astuti, Indriyani, Siti Yuliani Dewi, Salsa Zulfa Hamidah, Srinivas Mutalik
Advances in Pharmacological and Pharmaceutical Sciences.2023; 2023: 1. CrossRef
Continued alcohol consumption and hepatic encephalopathy determine quality of life and psychosocial burden of caregivers in patients with liver cirrhosis
Michael Nagel, Vanessa Weidner, Sina Schulz, Jens U. Marquardt, Peter R. Galle, Jörn M. Schattenberg, Marc Nguyen-Tat, Marcus-Alexander Wörns, Christian Labenz
Health and Quality of Life Outcomes.2022;[Epub] CrossRef
Scoping review of managed alcohol programs
Shannon M. Smith-Bernardin, Leslie W. Suen, Jill Barr-Walker, Isabel Arrellano Cuervo, Margaret A. Handley
Harm Reduction Journal.2022;[Epub] CrossRef

8,239 View
159 Download
10 Web of Science
Crossref

Reviews

Liver Transplantation

Liver graft from donation after circulatory death donor: Real practice to improve graft viability: Koji Hashimoto; Clin Mol Hepatol 2020;26(4):401-410.
Published online July 10, 2020; DOI: https://doi.org/10.3350/cmh.2020.0072

Abstract
PDF

Donation after circulatory death (DCD) is an increasing source of liver grafts for transplantation, yet outcomes have been inferior compared to donation after brain death liver transplantation. These worse outcomes are mainly due to the severe graft injury resulting from mandatory warm ischemia during DCD organ recovery. New evidence, however, indicates that improved donor selection and surgical techniques can decrease the risk of graft failure and ischemic cholangiopathy (IC). Under current best practices, DCD organs are retrieved with the super-rapid technique, optimizing timing and protecting the liver graft from detrimental warm ischemia. Graft viability is influenced by both the quantity and quality of warm ischemia, which is unique to each donor and causes various degrees of pathophysiologic consequences. Evidence also shows that the choice of preservation solution and premortem heparin administration influences graft viability. Additionally, although the precise mechanism of IC remains unknown, stasis of blood during donor warm ischemia may cause the formation of microthrombi in the peribiliary vascular plexus and ischemia of the bile duct. Importantly, thrombolytic protocols show a possible preventive modality for IC. Finally, while ex vivo machine perfusion technology has gained an interest in DCD liver transplantation, further studies are necessary to evaluate the effectiveness of this evolving field to improve graft quality and transplant outcomes.

Citations

Citations to this article as recorded by

Current Understanding of Marginal Grafts in Liver Transplantation
Ze Xiang, Jiarui Li, Huixuan Zeng, Xiaonan Xiang, Fengqiang Gao, Kai Wang, Xuyong Wei, Shusen Zheng, Xiao Xu
Aging and disease.2025; 16(2): 1036. CrossRef
Outcomes of Multiorgan Heart Transplant Between Donation After Circulatory Death and Brain Death
Toyokazu Endo, Jaimin R. Trivedi, Stephanie Moore, Sheng Fu, Rohan Samson, Michele Gallo, Siddharth Pahwa, Mark S. Slaughter, Erin M. Schumer
ASAIO Journal.2025; 71(4): 316. CrossRef
Letter in reference to “Association of Procurement Technique with Organ Yield and Cost Following Donation After Circulatory Death”
Lambros Tsonis, Malcolm MacConmara, Magdy Attia, Farhan Zafar
American Journal of Transplantation.2025; 25(6): 1372. CrossRef
Advances and Challenges of Thrombolytic Therapy for Donation After Circulatory Death Organs
Peng Zhang, Han Liang, Yanfeng Wang
Clinical Transplantation.2025;[Epub] CrossRef
Rutaecarpine alleviates hepatic ischemia‒reperfusion injury in liver transplantation by inhibiting inflammatory response and oxidative stress
Yan Liu, Feng Qi, Lun-Jian Xiang, Zhu-Jun Yi, Sheng-Wei Li
Frontiers in Pharmacology.2025;[Epub] CrossRef
MELD Score Before and After Plasmapheresis in Recipients of ABO-Incompatible Living Donor Liver Transplantation
Ja Eun Lee, Sooyeon Lee, Justin Sangwook Ko, Mi Sook Gwak, Gaab Soo Kim
Transplantation Proceedings.2025; 57(5): 799. CrossRef
The Impact of Normothermic Machine Perfusion on Biliary Complications in Donation After Circulatory Death Donor Liver Transplantation
Rikako Oki, Emily Kerby, Ingrid Rocha, Saleh Al-Juburi, Katsunori Miyake, Guillermo Polanco, Jennifer Orellana, David Ephraim, Adhnan Mohamed, Abbas Al-Kurd, Ahmed Nassar, Atsushi Yoshida, Marwan Abouljoud, Shunji Nagai
Transplantation Direct.2025; 11(7): e1821. CrossRef
Intraoperative blood loss as a predictor of outcomes in liver transplantation: determining optimal cutoff values for improved graft survival
Ayato Obana, Miho Akabane, Khalid Mumtaz, Kejal Shah, Matthew Hamilton, Rithin Punjala, Austin Schenk, Navdeep Singh, Sylvester Black, Kenneth Washburn, Musab Alebrahim
Langenbeck's Archives of Surgery.2025;[Epub] CrossRef
From pixels to prognosis: A comprehensive evidence synthesis on pre-retrieval imaging in deceased and living liver donors
Andrea Peloso, Daniel Pietrasz, Charles-Henry Wassmer, Edoardo Maria Muttillo, Beat Moeckli, Rohan Kumar, François Cauchy, Alexis Ricoeur, Philippe Compagnon, Christian Toso
Hepatobiliary & Pancreatic Diseases International.2025;[Epub] CrossRef
Better liver transplant outcomes by donor interventions?
Amelia J. Hessheimer, Eva Flores, Jordi Vengohechea, Constantino Fondevila
Current Opinion in Organ Transplantation.2024; 29(4): 219. CrossRef
Optimizing DCD Liver Grafts With Prolonged Warm Ischemic Time Using Stabilized Plasmin in a Static Cold Storage Orthotopic Rat Liver Transplant Model
Riley Kahan, Nader Abraham, Min Zhang, Valery Novokhatny, Isaac Alderete, Paul Cray, Fengming Chen, Qimeng Gao, Greta Cywinska, Ryan Neill, Kentaro Nakata, Ahmed Hassan, Caroline Rush, Jude Penaflor, Justin J. Pollara, Matthew G. Hartwig, Benjamin Hughes,
Transplantation Direct.2024; 10(8): e1665. CrossRef
An extensive evaluation of hepatic markers of damage and regeneration in controlled and uncontrolled donation after circulatory death
Giuseppina Basta, Fabio Melandro, Serena Babboni, Serena Del Turco, Rudina Ndreu, Francesco Torri, Caterina Martinelli, Beatrice Silvestrini, Adriano Peris, Chiara Lazzeri, Fabio Guarracino, Riccardo Morganti, Paolo Maremmani, Pietro Bertini, Paolo De Sim
Liver Transplantation.2023; 29(8): 813. CrossRef
Anesthetic Considerations of Organ Procurement After Brain and Cardiac Death: A Narrative Review
Michael B Brown, Apolonia E Abramowicz, Peter J Panzica, Garret Weber
Cureus.2023;[Epub] CrossRef
DCD liver transplant in patients with a MELD over 35
Raphael P. H. Meier, Miguel Nunez, Shareef M. Syed, Sandy Feng, Mehdi Tavakol, Chris E. Freise, John P. Roberts, Nancy L. Ascher, Ryutaro Hirose, Garrett R. Roll
Frontiers in Immunology.2023;[Epub] CrossRef
Comparison of Biliary Complications Rates After Brain Death, Donation After Circulatory Death, and Living-Donor Liver Transplantation: A Single-Center Cohort Study
Raphael Pascal Henri Meier, Yvonne Kelly, Hillary Braun, Daniel Maluf, Chris Freise, Nancy Ascher, John Roberts, Garrett Roll
Transplant International.2022;[Epub] CrossRef
The first successful report of liver transplantation from category III donation after circulatory death in South Korea: a case report
Incheon Kang, Jae-myeong Lee, Jae Geun Lee
Korean Journal of Transplantation.2022; 36(4): 294. CrossRef
Extended criteria grafts and emerging therapeutics strategy in liver transplantation. The unstable balance between damage and repair
Davide Ghinolfi, Fabio Melandro, Francesco Torri, Caterina Martinelli, Valentina Cappello, Serena Babboni, Beatrice Silvestrini, Paolo De Simone, Giuseppina Basta, Serena Del Turco
Transplantation Reviews.2021; 35(4): 100639. CrossRef
The Immunological Basis of Liver Allograft Rejection
Vincenzo Ronca, Grace Wootton, Chiara Milani, Owen Cain
Frontiers in Immunology.2020;[Epub] CrossRef

11,695 View
184 Download
17 Web of Science
Crossref

Hepatic neoplasm

Appropriate treatment modality for solitary small hepatocellular carcinoma: Radiofrequency ablation vs. resection vs. transplantation?: Keun Soo Ahn, Koo Jeong Kang; Clin Mol Hepatol 2019;25(4):354-359.
Published online April 22, 2019; DOI: https://doi.org/10.3350/cmh.2018.0096

Abstract
PDF

There has been controversy regarding the first-line treatment modality for the patients who have small solitary hepatocellular carcinoma (HCC); radiofrequency ablation (RFA) or percutaneous ethanol injection (PEI), surgical hepatic resection (HR) and liver transplantation (LT). For selection of treatment modality of HCC, it should be considered of hepatic reservoir function as well as the tumor stage. If the liver function is good enough, HR may be the first choice regardless of the tumor size. However, recent studies comparing RFA with resection showed comparable outcome and similar survival rates. RFA, HR and LT provide good outcome for patients who have small HCCs. RFA would be desired in patients who have below 3.0 cm in size and low alpha-fetoprotein (<200 ng/mL). However, in small HCC with high tumor marker, HR should be considered. Better patient selection for the ‘resection first’ approach and early detection of recurrence can achieve better outcomes of the salvage LT strategy. Another benefit of resection first strategy is that it make possible to do enlist of LT for patients before recurrence at high risk of HCC recurrence after resection on the basis of pathologic aggressiveness, microvascular invasion and/or satellites nodule. They should be applied appropriately according to the tumor size, location, tumor markers and underlying liver parenchymal disease.

Citations

Citations to this article as recorded by

Association of primary hepatocellular carcinoma laterality with oncological outcomes for hepatic resection patients: A retrospective, multicenter, propensity score-matched study
Okjoo Lee, Jaehong Jeong, So Kyung Yoon, Jun Chul Chung, Jongman Kim, Kwang-Woong Lee, Hyung Chul Kim
Asian Journal of Surgery.2025; 48(4): 2241. CrossRef
Preoperative Transarterial Chemoembolization for Resectable Single Hepatocellular Carcinoma: A Single-Center Cohort Study
Sang-Hoon Kim, Ki-Hun Kim, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, Woo-Hyoung Kang, Eun-Kyoung Jwa, Byeong-Gon Na, Sung Min Kim, Sung-Gyu Lee
Annals of Surgical Oncology.2025; 32(7): 5008. CrossRef
A nomogram based on PNI and preoperative TACE can predict overall survival in patients with larger than 2 cm HCC after hepatectomy
Huizhi Zhang, Chunyu Zhang, Run Hu, Kai Lei, Xingxing Wang, Zuojin Liu
Updates in Surgery.2025; 77(4): 1113. CrossRef
From conventional therapy to treatment with lipid-polymer hybrid nanoparticles for hepatocellular carcinoma
Dina Farinha, Ana Bela Sarmento-Ribeiro, Henrique Faneca
Materials Today Chemistry.2025; 47: 102870. CrossRef
The Cost-Effectiveness Analysis of Radiofrequency Ablation Compared to Hepatic Resection for Resectable Small Hepatocellular Carcinoma in Thailand
Nutcha Pinjaroen, Wantanee Kulpeng, Pisit Tangkijvanich, Taya Kitiyakara
Clinical Therapeutics.2025; 47(8): 602. CrossRef
Melanin@PLGA/Nuciferine Nanoparticles for Enhanced Photothermal Therapy of Hepatocellular Carcinoma by Promoting Autophagy
Yingxuan Mao, Xinling Du, Weidong Wang, Tianxiu Dong, Mingwei Zhu, Jiamei Niu, Mingming Li, Jian Jiang, Linlin Han, Xiuhua Yang
International Journal of Nanomedicine.2025; Volume 20: 11081. CrossRef
Long-term outcomes of thermal ablation vs surgical resection for single small hepatocellular carcinoma
Ying-Ming Gao, Sai-Kang Tang, Zhi-Wen Luo, Wei-Hua Zhi, Xue Yan, Xin Yin, Xin-Yu Bi, Yue Han
World Journal of Clinical Oncology.2025;[Epub] CrossRef
Mechanisms of rapid tumor progression after insufficient radiofrequency ablation of hepatocellular carcinoma
Wenming Hou, Ge Ge, Xu Chen, Xinhua Xu
Frontiers in Cell and Developmental Biology.2025;[Epub] CrossRef
Impact of Hepatocellular Carcinoma Tumor Size on Sonazoid Contrast-Enhanced Ultrasound Enhancement Features
Sheng Chen, Yi-Jie Qiu, Qi Zhang, Xiu-Yun Lu, Yun-Lin Huang, Yi Dong, Wen-Ping Wang
Ultrasound in Medicine & Biology.2024; 50(1): 39. CrossRef
Perfluorobutane application value in microwave ablation of small hepatocellular carcinoma (<3 cm)
Yanghong Pan, Delin Liu, Fei Liang, Zixiang Kong, Xu Zhang, Qinqin Ai
Clinical Hemorheology and Microcirculation.2024; 87(3): 323. CrossRef
Impact of preoperative transcatheter arterial chemoembolization (TACE) on postoperative long-term survival in patients with nonsmall hepatocellular carcinoma: a propensity score matching analysis
Run Hu, Jie Xu, Hongxiang Wang, Jiaguo Wang, Kai Lei, Xiaoping Zhao, Huizhi Zhang, Ke You, Zuojin Liu
BMC Cancer.2024;[Epub] CrossRef
Partial Hepatectomy and Ablation for Survival of Early-Stage Hepatocellular Carcinoma Patients: A Bayesian Emulation Analysis
Jiping Wang, Yunju Im, Rong Wang, Shuangge Ma
Life.2024; 14(6): 661. CrossRef
Meta analysis of radiofrequency ablation versus surgical resection in small and large nodule of hepatocellular carcinoma
Rino A. Gani, Maria Teressa, Refael A. Budiman, Kemal F. Kalista, Cosmas Rinaldi A. Lesmana
HPB.2024; 26(10): 1216. CrossRef
Nomograms established for predicting microvascular invasion and early recurrence in patients with small hepatocellular carcinoma
Xi Wang, Xinqun Chai, Ji Zhang, Ruiya Tang, Qinjunjie Chen
BMC Cancer.2024;[Epub] CrossRef
Retrospective Analysis of Radiofrequency Ablation in Patients with Small Solitary Hepatocellular Carcinoma: Survival Outcomes and Development of a Machine Learning Prognostic Model
Qi-fan He, Yue Xiong, Yi-hui Yu, Xiang-chao Meng, Tian-xu Ma, Zhong-hua Chen
Current Medical Science.2024; 44(5): 1006. CrossRef
Comparison of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma patients: a SEER population-based propensity score matching study
Xi Wang, Xinqun Chai, Ruiya Tang, Yunjie Xu, Qinjunjie Chen
Updates in Surgery.2024; 76(8): 2755. CrossRef
Comparison of the long‐term outcomes of patients with hepatocellular carcinoma within the Milan criteria treated by ablation, resection, or transplantation
Ning‐Ning Zhang, Jian Zheng, Ying Wu, Jia‐Yu Lv, Shu‐Wen Zhang, Ya‐Min Zhang, Wen‐Tao Jiang, Tian‐Qiang Song, Victoria Kim, Samer Tohme, Tian Liu, Wei Zhang, Jie Gu, Ze‐Yu Wang, Yu‐Hong Suo, Shuai Wang, Wang Li, Li Zhang, Yan Xie, Yong‐He Zhou, Jian‐Yong
Cancer Medicine.2023; 12(3): 2312. CrossRef
Short and long-term outcomes after minimally invasive liver resection for single small hepatocellular carcinoma: An analysis of 714 patients from the IGoMILS (Italian group of minimally invasive liver surgery) registry
Felice Giuliante, Francesca Ratti, Elena Panettieri, Vincenzo Mazzaferro, Alfredo Guglielmi, Giuseppe M. Ettorre, Salvatore Gruttadauria, Fabrizio Di Benedetto, Umberto Cillo, Luciano De Carlis, Raffaele Dalla Valle, Alessandro Ferrero, Roberto Santambrog
HPB.2023; 25(6): 674. CrossRef
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression
Aleena Malik, Meghan P Jairam, Ronald Chow, Seyed A Mirshahvalad, Patrick Veit-Haibach, Charles B Simone
Future Oncology.2023; 19(4): 279. CrossRef
Fibrosis-4 index, a predictor for prognosis of hepatocellular carcinoma patients after curative hepatectomy even in hepatitis B virus dominant populations
Sang Oh Yun, Jong Man Kim, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh
Annals of Surgical Treatment and Research.2023; 104(4): 195. CrossRef
Real world for management of hepatocellular carcinoma: a large population-based study
Supatsri Sethasine, Nitipon Simasingha, Sarita Ratana-Amornpin, Varocha Mahachai
Scandinavian Journal of Gastroenterology.2023; 58(10): 1153. CrossRef
Treatment of hepatocellular carcinoma with macroscopic vascular invasion: A systematic review and network meta-analysis
Francisco Tustumi, Fabricio Ferreira Coelho, Daniel de Paiva Magalhães, Sérgio Silveira Júnior, Vagner Birk Jeismann, Gilton Marques Fonseca, Jaime Arthur Pirola Kruger, Luiz Augusto Carneiro D'Albuquerque, Paulo Herman
Transplantation Reviews.2023; 37(3): 100763. CrossRef
Development and validation of a model to predict the risk of distant metastases from hepatocellular carcinoma: a real-world retrospective study
Guangzhao Shao, Zhongqi Fan, Wei Qiu, Guoyue Lv
Journal of Cancer Research and Clinical Oncology.2023; 149(18): 16489. CrossRef
Nonvitamin K oral anticoagulants with proton pump inhibitor cotherapy ameliorated the risk of upper gastrointestinal bleeding
Parata Chaiyana, Karjpong Techathuvanan, Supatsri Sethasine
Scientific Reports.2023;[Epub] CrossRef
Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial
Zhenyu Wen, Junxiao Wang, Bo Tu, Yane Liu, Yuqing Yang, Li Hou, Xiang Yang, Xiaoyan Liu, Hui Xie
Cancer Medicine.2023; 12(20): 20311. CrossRef
Comparative long‐term outcomes of laparoscopic hepatectomy and radiofrequency ablation for hepatocellular carcinoma located in the anterolateral segments of the liver
Sungho Kim, Chang Jin Yoon, Jai Young Cho, Ho‐Seong Han, Yoo‐Seok Yoon, Hae Won Lee, Jun Suh Lee, Moonhwan Kim, Boram Lee, Soyeon Ahn
Journal of Hepato-Biliary-Pancreatic Sciences.2022; 29(3): 349. CrossRef
Hepatectomy outcomes in patients with hepatitis C virus-related hepatocellular carcinoma with or without cirrhosis
Jong Man Kim, Jinsoo Rhu, Sang Yun Ha, Gyu-Seong Choi, Choon Hyuck David Kwon, Jae-Won Joh
Annals of Surgical Treatment and Research.2022; 102(1): 1. CrossRef
Achievement of textbook outcomes and comparisons with benchmark values after laparoscopic left lateral sectionectomy
Mizelle D’Silva, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Moonhwan Kim
Updates in Surgery.2022; 74(4): 1299. CrossRef
Association between achieving textbook outcomes and better survival after laparoscopic liver resection in the anterolateral segments in patients with hepatocellular carcinoma
Mizelle D'Silva, Jai Young Cho, Ho‐Seong Han, Yoo‐Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Moonhwan Kim, Yeongsoo Jo
Journal of Hepato-Biliary-Pancreatic Sciences.2022; 29(8): 855. CrossRef
A Case-Matched Analysis of Laparoscopic Liver Resection for Hepatocellular Carcinoma Located in Posterosuperior Segments of the Liver According to Adaption of Developed Techniques
Yujin Kwon, Boram Lee, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Munwhan Kim, Youngsoo Jo
Medicina.2022; 58(4): 543. CrossRef
A scoring system to predict the risk of major complications after laparoscopic liver resection in elderly patients with hepatocellular carcinoma
Boram Lee, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Moonhwan Kim, Yeongsoo Jo
Surgical Endoscopy.2022; 36(10): 7756. CrossRef
Role of the pre- to postoperative alpha-fetoprotein ratio in the prognostic evaluation of liver cancer after radiofrequency ablation
Biwei Luo, Linsen Liu, Jian’gang Bi, Shiyun Bao, Yusen Zhang
The International Journal of Biological Markers.2022; 37(3): 306. CrossRef
A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma
Shu-Wen Zhang, Ning-Ning Zhang, Wen-Wen Zhu, Tian Liu, Jia-Yu Lv, Wen-Tao Jiang, Ya-Min Zhang, Tian-Qiang Song, Li Zhang, Yan Xie, Yong-He Zhou, Wei Lu
Frontiers in Oncology.2022;[Epub] CrossRef
Minor hepatectomy for hepatocellular carcinoma in a patient with portal hypertension: A case report and review of the literature
Ting-Chun Tseng, Wen-Yao Yin
Medicine.2022; 101(48): e32176. CrossRef
Improved Outcomes of Laparoscopic Liver Resection for Hepatocellular Carcinoma Located in Posterosuperior Segments of the Liver
Yujin Kwon, Jai Young Cho, Ho‐Seong Han, Yoo‐Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Moonwhan Kim
World Journal of Surgery.2021; 45(4): 1178. CrossRef
The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus–related hepatocellular carcinoma
Ji Hyun Lee, Beom Kyung Kim, Soo Young Park, Won Young Tak, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Dong Hyun Sinn, Seung Up Kim
European Journal of Internal Medicine.2021; 89: 48. CrossRef
External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Journal of Viral Hepatitis.2021; 28(6): 951. CrossRef
Fast calculation of 3D radiofrequency ablation zone based on a closed-form solution of heat conduction equation fitted by ex vivo measurements
Rendong Chen, Jianfeng Zhang, Dexing Kong, Qiong Lou, Fang Lu
Physics in Medicine & Biology.2021; 66(5): 055022. CrossRef
Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Cancers.2021; 13(23): 5892. CrossRef
Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study
Riad Salem, Guy E. Johnson, Edward Kim, Ahsun Riaz, Vivian Bishay, Eveline Boucher, Kirk Fowers, Robert Lewandowski, Siddharth A. Padia
Hepatology.2021; 74(5): 2342. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
A Survivorship-Period-Cohort Model for Cancer Survival: Application to Liver Cancer in Taiwan, 1997–2016
Yan-Teng Peng, Fan-Tsui Meng, Shih-Yung Su, Chun-Ju Chiang, Ya-Wen Yang, Wen-Chung Lee
American Journal of Epidemiology.2021; 190(9): 1961. CrossRef
Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma
Han Ah Lee, Young-Sun Lee, Beom Kyung Kim, Young Kul Jung, Seung Up Kim, Jun Yong Park, Ji Hoon Kim, Hyunggin An, Do Young Kim, Hyung Joon Yim, Sang Hoon Ahn, Jong Eun Yeon, Kwan Soo Byun, Kwang-Hyub Han, Soon Ho Um, Yeon Seok Seo
Gut and Liver.2021; 15(3): 420. CrossRef
New Developments in the Treatment of Hepatocellular Carcinoma: The Concept of Adjuvant and Neoadjuvant Chemotherapy
Anil C. Anand, Subrat K. Acharya
Journal of Clinical and Experimental Hepatology.2021; 11(3): 284. CrossRef
New next-generation microwave thermosphere ablation for small hepatocellular carcinoma
Hideyuki Tamai, Jumpei Okamura
Clinical and Molecular Hepatology.2021; 27(4): 564. CrossRef
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
Journal of Viral Hepatitis.2021; 28(11): 1570. CrossRef
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123. CrossRef
The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Journal of Hepatocellular Carcinoma.2021; Volume 8: 467. CrossRef
Prognostic effect of preoperative neutrophil-lymphocyte ratio is related with tumor necrosis and tumor-infiltrating lymphocytes in hepatocellular carcinoma
Sang Yun Ha, Sangjoon Choi, Sujin Park, Jong Man Kim, Gyu-Seong Choi, Jae-Won Joh, Cheol-Keun Park
Virchows Archiv.2020; 477(6): 807. CrossRef
Tumor Diameter for Hepatocellular Carcinoma: Why Should Size Matter?
Sertac Usta, Cuneyt Kayaalp
Journal of Gastrointestinal Cancer.2020; 51(4): 1114. CrossRef
Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation
Byung-Yoon Yun, Hye Won Lee, In Kyung Min, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Cancers.2020; 12(9): 2527. CrossRef
Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion

Sojung Han, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Dai Hoon Han, Beom Kyung Kim
Journal of Hepatocellular Carcinoma.2020; Volume 7: 403. CrossRef

11,272 View
373 Download
56 Web of Science
Crossref

Original Article

Liver Transplantation

Evaluation of bioenergetic and mitochondrial function in liver transplantation: Rui Miguel Martins, João Soeiro Teodoro, Emanuel Furtado, Anabela Pinto Rolo, Carlos Marques Palmeira, José Guilherme Tralhão; Clin Mol Hepatol 2019;25(2):190-198.
Published online March 22, 2019; DOI: https://doi.org/10.3350/cmh.2018.0087

Abstract
PDF

Background/Aims
We measured changes in mitochondrial function and bioenergetics that occur during ischemia/ reperfusion in fresh liver samples of patients undergoing liver transplantation. These variations correlated with markers of liver function and clinical outcome. Ischemia/reperfusion injury related to liver transplantation affects mitochondrial function and bioenergetics. Experimental studies were conducted to identify the role of bioenergetics and mitochondrial dysfunction. To the best of our knowledge, no investigation of these two factors’ impacts on liver transplantation has been performed.
Methods
This was a prospective study of 28 patients who underwent liver transplantation. We measured parameters of mitochondrial function and bioenergetics in biopsies performed during the procedure.
Results
We observed a statistically significant reduction in mitochondrial membrane potential, an increase in lag phase, and decreases in mitochondrial respiration and adenosine triphosphate content (P<0.010). Higher postoperative aminotransferase peaks correlated with worse mitochondrial function; mitochondrial respiration correlated with arterial lactate (P<0.010).
Conclusions
There is a relationship between mitochondrial function and ischemia/reperfusion injury. The future use of these clinical markers as prognostic factors may allow early identification of post-transplant liver failure and may indicate the need to perform a new transplant.

Citations

Citations to this article as recorded by

Ischaemia–Reperfusion Injury in Organ Transplantation: Role of Coenzyme Q10
David Mantle, Neve Cufflin, Tyler T. Purcell, Iain P. Hargreaves
Journal of Clinical Medicine.2025; 14(18): 6486. CrossRef
The Predictive Value of Graft Viability and Bioenergetics Testing Towards the Outcome in Liver Transplantation
Andras T. Meszaros, Annemarie Weissenbacher, Melanie Schartner, Tim Egelseer-Bruendl, Martin Hermann, Jasmin Unterweger, Christa Mittelberger, Beatrix A. Reyer, Julia Hofmann, Bettina G. Zelger, Theresa Hautz, Thomas Resch, Christian Margreiter, Manuel Ma
Transplant International.2024;[Epub] CrossRef
ZLN005, a PGC-1α Activator, Protects the Liver against Ischemia–Reperfusion Injury and the Progression of Hepatic Metastases
Celine Tohme, Tony Haykal, Ruiqi Yang, Taylor J. Austin, Patricia Loughran, David A. Geller, Richard L. Simmons, Samer Tohme, Hamza O. Yazdani
Cells.2024; 13(17): 1448. CrossRef
Preservation of Mitochondrial Health in Liver Ischemia/Reperfusion Injury
Ivo F. Machado, Carlos M. Palmeira, Anabela P. Rolo
Biomedicines.2023; 11(3): 948. CrossRef
Shaping of Hepatic Ischemia/Reperfusion Events: The Crucial Role of Mitochondria
João S. Teodoro, Rui T. Da Silva, Ivo F. Machado, Arnau Panisello-Roselló, Joan Roselló-Catafau, Anabela P. Rolo, Carlos M. Palmeira
Cells.2022; 11(4): 688. CrossRef
Development of a Multivariable Prediction Model for Citrate Accumulation in Liver Transplant Patients Undergoing Continuous Renal Replacement Therapy with Regional Citrate Anticoagulation
Xin Xin, Jing Tang, Hui-Miao Jia, Tian-En Zhang, Yue Zheng, Li-Feng Huang, Qi Ding, Jun-Cong Li, Shu-Yan Guo, Wen-Xiong Li
Blood Purification.2022; 51(2): 111. CrossRef
Mitochondrial respiration during normothermic liver machine perfusion predicts clinical outcome
Andras T. Meszaros, Julia Hofmann, Madita L. Buch, Benno Cardini, Theresia Dunzendorfer-Matt, Florian Nardin, Michael J. Blumer, Margot Fodor, Martin Hermann, Bettina Zelger, Giorgi Otarashvili, Melanie Schartner, Annemarie Weissenbacher, Rupert Oberhuber
eBioMedicine.2022; 85: 104311. CrossRef
Hepatic31P‐magnetic resonance spectroscopy identified the impact of melatonin‐pretreated mitochondria in acute liver ischaemia‐reperfusion injury
Sheung‐Fat Ko, Yi‐Ling Chen, Pei‐Hsun Sung, John Y. Chiang, Yi‐Ching Chu, Chung‐Cheng Huang, Chi‐Ruei Huang, Hon‐Kan Yip
Journal of Cellular and Molecular Medicine.2020; 24(17): 10088. CrossRef

11,599 View
175 Download
10 Web of Science
Crossref

Review

Alcohol-related liver disease

Severe acute alcoholic hepatitis and liver transplant: A never-ending mournful story: Aiman Obed, Abdalla Bashir, Steffen Stern, Anwar Jarrad; Clin Mol Hepatol 2018;24(4):358-366.
Published online October 24, 2018; DOI: https://doi.org/10.3350/cmh.2018.0044

Abstract
PDF

Severe acute alcoholic liver disease (SAAH) unresponsive to medical therapy shows one-year-mortality rates of up to 90%. Most transplant centers request six months of alcohol abstinence prior to transplantation, the so-called “6-month rule.” This regulation is not based on strong evidence, repeatedly making it a topic of controversial debates. The majority of patients with SAAH will die before fulfilling the 6-month rule. Therefore, liver transplantation (LT) protocols are becoming more flexible towards the rigid abstinence regulation, especially concerning SAAH patients. We conducted a literature review regarding LT in SAAH and its outcomes, including post-transplant mortality and recidivism. We studied available data on PubMed from 2011 and onwards whilst including articles dealing with genetic components, medical therapy and historic snapshots of alcoholism. Emerging studies recommend LT in SAAH not responding to medical therapies even without realizing the required abstinence period, since the majority of these patients would die within 6 months. SAAH without response to medical therapy has one-year-mortality rates of up to 90%. The 6-month rule is not based on strong evidence and is repeatedly a topic of controversial debates. There is genetic linkage to alcoholism and medical therapy is not as effective as estimated, yet. The 6-months-regulation has not shown to evidently decrease the risk of recidivism post-LT, which is a lifesaving treatment in SAAH patients. Insisting on rigid sobriety rules results in excluding patients with a low risk of recidivism from being transplanted. Moreover, the genetic linkage of alcoholism must be recognized.

Citations

Citations to this article as recorded by

Early liver transplantation for severe alcohol-associated hepatitis: A single-center experience
A Asgharpour, RK Sterling, E Smirnova, N Duong, K Houston, H Khan, Keller Nicole, S Matherly, J Wedd, H Lee, MS Siddiqui, V Patel, S Bullock, S Weinland, V Kumaran, S Lee, A Sharma, D Imai, A Kahn, M Levy, D Bruno
Journal of Liver Transplantation.2023; 12: 100184. CrossRef
Trasplante en la enfermedad hepática por alcohol
Jessica Paola Neira-Moreno
Hepatología.2021; : 199. CrossRef
Outcome of patients with severe alcoholic hepatitis after Model for End-Stage Liver Disease-based allocation system implementation in Korea
Tae Jin Kwon, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Dong Hyun Sinn, Seung Woon Paik
Korean Journal of Transplantation.2021; 35(1): 24. CrossRef
Early Liver Transplantation for Severe Alcoholic Hepatitis
Jessica L. Mellinger, Jonathan G. Stine
Digestive Diseases and Sciences.2020; 65(6): 1608. CrossRef
Emerging Noninvasive Biomarkers, and Medical Management Strategies for Alcoholic Hepatitis: Present Understanding and Scope
Khushboo S. Gala, Vatsalya Vatsalya
Cells.2020; 9(3): 524. CrossRef
Das „framing“ der sechsmonatigen Karenzregel in der Lebertransplantation. Ein Beispiel für sprachlich vermittelte Deutungsmuster zur Eingrenzung des Indikationsgebietes
Nadia Primc
Ethik in der Medizin.2020; 32(3): 239. CrossRef

14,450 View
209 Download
4 Web of Science
Crossref

Original Article

Liver Transplantation

Fatigue and weakness hinder patient social reintegration after liver transplantation: So Hyun Kang, YoungRok Choi, Ho-Seong Han, Yoo-Seok Yoon, Jai Young Cho, Sungho Kim, Kil Hwan Kim, In Gun Hyun, Ahmed Shehta; Clin Mol Hepatol 2018;24(4):402-408.
Published online October 8, 2018; DOI: https://doi.org/10.3350/cmh.2018.0028

Background/Aims
With improvements in the survival of liver transplantation (LT) recipients, the focus is shifting to patient quality of life (QOL), and employment is an important factor in aiding the social reintegration of LT patients. This study aims to evaluate the current employment status of liver graft recipients and various factors that may hinder reemployment.
Methods
Fifty patients above age 18 who underwent either living or deceased donor LT at a single center from March 2009 to July 2016 were interviewed during their visit to the outpatient clinic. The internally developed questionnaire consisted of 10 items. The Karnofsky Performance Scale and EQ-5D were used to evaluate patient function and QOL.
Results
A total of 25 (50%) patients returned to work after transplantation (the working group), and 21 (84%) patients in the working group returned to work within the first year after transplantation. In the non-working group (n=25), 17 (68%) answered that their health was the reason for unemployment. Fatigue and weakness were the most frequent symptoms.
Conclusions
The data shows that as many as 50% of total patients returned to work after receiving LT. Fatigue and weakness were the most common complaints of the unemployed group, and resolving the causes of these symptoms may help to increase the employment rate.

Citations

Citations to this article as recorded by

Does Weekend Discharge Affect Readmission and Survival in Liver Transplant Patients? Insights From a Cohort Study
Ayato Obana, Miho Akabane, Hannah Chi, Nolan Ladd, Matthew Yoder, Lily Kaufman, Rithin Punjala, Kejal Shah, Matthew Hamilton, Ashley Limkemann, Austin Schenk, Navdeep Singh, Black Slyvester, Khalid Mumtaz, Kenneth Washburn, Musab Alebrahim
Clinical Transplantation.2025;[Epub] CrossRef
Burden, stress and depression in caregivers of cirrhosis patients before and after liver transplantation
Adriano Virches, Mariana B Claudino, Maria C Miyazaki, Eliane T Miyazaki, Renato F Silva, Rita C Silva, Heitor B Farias, Neide A Domingos, Randolfo Santos Jr, Patricia S Fucuta
World Journal of Transplantation.2025;[Epub] CrossRef
Factors Associated with Returning to Work in Liver Transplantation Survivors: A Cross-sectional Study
Yuxin Rao, Saxiao Tang, Feicui Lv, Li Dong, Li Ji, Zhiru Li, Ruijie Bao, Jingyun Wu, Fangyan Lu
Asian Nursing Research.2025; 19(2): 193. CrossRef
Predictors of return to work status among patients with autoimmune encephalitis at one year post-discharge: a prospective observational study
Yejie Peng, Linxue Hu, Yuhui Wang, Yan Liang, Dezhi Chen
BMC Neurology.2025;[Epub] CrossRef
Acute Inpatient Rehabilitation Functional Outcomes and Disposition After Liver Transplant
Meghan E. Willoughby, Jacob L. Ramsey-Morrow, Kyle A. Littell, Flora M. Hammond
Archives of Rehabilitation Research and Clinical Translation.2024; 6(2): 100332. CrossRef
Determination of Hopelessness and Fatigue Levels in Kidney Transplant Patients
Kübra Arslan, Ezgi Seyhan Ak
SN Comprehensive Clinical Medicine.2024;[Epub] CrossRef
Physical Activity Behaviour in Solid Organ Transplant Recipients: Proposal of Theory-Driven Physical Activity Interventions
Sofie Leunis, Marieke Vandecruys, Véronique Cornelissen, Amaryllis H. Van Craenenbroeck, Sabina De Geest, Diethard Monbaliu, Stefan De Smet
Kidney and Dialysis.2022; 2(2): 298. CrossRef
The mediating effect of social functioning on the relationship between social support and fatigue in middle-aged and young recipients with liver transplant in China
Dan Zhang, Junling Wei, Xiaofei Li
Frontiers in Psychology.2022;[Epub] CrossRef
Fatigue after heart transplantation – a possible barrier to self‐efficacy
Matilda Almgren, Pia Lundqvist, Annette Lennerling, Anna Forsberg
Scandinavian Journal of Caring Sciences.2021; 35(4): 1301. CrossRef
Impact of biliary complications on quality of life in live-donor liver transplant recipients
Reginia Nabil Guirguis, Ehab Hasan Nashaat, Azza Emam Yassin, Wesam Ahmed Ibrahim, Shereen A Saleh, Mohamed Bahaa, Mahmoud El-Meteini, Mohamed Fathy, Hany Mansour Dabbous, Iman Fawzy Montasser, Manar Salah, Ghada Abdelrahman Mohamed
World Journal of Hepatology.2021; 13(10): 1405. CrossRef
Real-Life Experience of mTOR Inhibitors in Liver Transplant Recipients in a Region Where Living Donation Is Predominant
Pil Soo Sung, Ji Won Han, Changho Seo, Joseph Ahn, Soon Kyu Lee, Hee Chul Nam, Ho Joong Choi, Young Kyoung You, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Frontiers in Pharmacology.2021;[Epub] CrossRef
Effect of Music on Fatigue, Comfort, and Vital Signs in Patients After Liver Transplant Surgery
Bilsev Demir, Gürkan Kapιkιran, Meral Özkan
Holistic Nursing Practice.2021; 35(3): 150. CrossRef
Health-related quality of life, workability, and return to work of patients after liver transplantation
Christian Fazekas, Daniela Kniepeiss, Nora Arold, Franziska Matzer, Jolana Wagner-Skacel, Peter Schemmer
Langenbeck's Archives of Surgery.2021; 406(6): 1951. CrossRef
Effects of acupoint massage combined with relaxation therapy on patients with postoperative fatigue syndrome after lumbar surgery
Qiuhui Zheng, Rongyun Wang, Yanan Shi, Qiuhua Sun
Medicine.2021; 100(19): e25849. CrossRef
Rehabilitation for social reintegration in liver transplant patients
Jong Man Kim
Clinical and Molecular Hepatology.2018; 24(4): 370. CrossRef

14,643 View
125 Download
14 Web of Science
Crossref

Editorial

Liver Transplantation

Clinical implication of hepatic volumetry for living donor liver transplantation: Woo Kyoung Jeong; Clin Mol Hepatol 2018;24(1):51-53.
Published online March 22, 2018; DOI: https://doi.org/10.3350/cmh.2018.1003

Citations

Citations to this article as recorded by

The Effect of Portal Vein Variants on the Margin of Error in Graft Volume Calculation in Living Donor Right Lobe Liver Transplantation
Feyza Sönmez Topcu, Veysel Ersan, Emrah Şahin, Adem Tunçer, Hasret Ayyıldız Civan, Abuzer Dirican, Bülent Ünal
Transplantation Proceedings.2025; 57(9): 1773. CrossRef
Multivariable linear model for predicting graft weight based on 3-dimensional volumetry in regards to body weight change of living liver donor: an observational cohort study
Seungwook Han, Jinsoo Rhu, Soyoung Lim, Gyu-seong Choi, Jong Man Kim, Jae-Won Joh
Annals of Surgical Treatment and Research.2024; 107(2): 91. CrossRef
Accuracy and Efficiency of Right-Lobe Graft Weight Estimation Using Deep-Learning-Assisted CT Volumetry for Living-Donor Liver Transplantation
Rohee Park, Seungsoo Lee, Yusub Sung, Jeeseok Yoon, Heung-Il Suk, Hyoungjung Kim, Sanghyun Choi
Diagnostics.2022; 12(3): 590. CrossRef

11,087 View
96 Download
3 Web of Science
Crossref

Reviews

Alcohol-related liver disease

Role of liver transplantation in severe alcoholic hepatitis: Ravi Daswani, Ashish Kumar, Praveen Sharma, Vikas Singla, Naresh Bansal, Anil Arora; Clin Mol Hepatol 2018;24(1):43-50.
Published online January 10, 2018; DOI: https://doi.org/10.3350/cmh.2017.0027

Abstract
PDF

Severe alcoholic hepatitis has very high short term mortality and corticosteroids have been the mainstay of treatment for decades. Patients with Lille score >0.45 are considered non-responders to steroids and have poor outcome. Recently Orthotopic Liver Transplantation (OLT) is being increasingly used as rescue treatment for these patients, without waiting for 6 months of abstinence. Liver transplant is the only rescue treatment which can potentially provide long term benefit for patients who are steroid non-responders. However, with scarcity of organs being a concern, all patients of severe alcoholic hepatitis cannot be chosen for transplantation in an arbitrary way. There is a need for development of predictive tools and
objective
protocols to select patients who can justify the use of precious liver grafts. With a stringent criteria for selection of patients receiving the graft, liver transplantation in severe alcoholic hepatitis can become a viable rescue therapeutic option conferring significant survival advantage of both short- and long-term basis. The optimal criteria for selection will also prevent misuse of the liver donor pool as well as to prevent mortality in salvageable patients. Further research needs to be done to identify subset of patients which are at low risk of recidivism and also cannot be managed with pharmacotherapy alone. We reviewed the current knowledge on role of OLT in patient with acute severe alcoholic hepatitis in the present review.

Citations

Citations to this article as recorded by

Outcomes and risk factors for de novo major depressive disorder after liver transplantation: Nested case-control study
Young Jin Yoo, Jinhee Lee, Deok-Gie Kim, Minyu Kang, Hwa-hee Koh, Eun-Ki Min, Jae Geun Lee, Myoung Soo Kim, Dong Jin Joo
Annals of Hepatology.2025; 30(1): 101779. CrossRef
Role of inflammation in alcoholic liver diseases and its management
Uday Sanglodkar
International Journal of Research in Medical Sciences.2025; 13(11): 5047. CrossRef
S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)
Thomas Berg, Niklas F. Aehling, Tony Bruns, Martin-Walter Welker, Tobias Weismüller, Jonel Trebicka, Frank Tacke, Pavel Strnad, Martina Sterneck, Utz Settmacher, Daniel Seehofer, Eckart Schott, Andreas Anton Schnitzbauer, Hartmut H. Schmidt, Hans J. Schli
Zeitschrift für Gastroenterologie.2024; 62(09): 1397. CrossRef
Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency
Thomas G. Cotter, Burhaneddin Sandıkçı, Sonali Paul, Anuhya Gampa, Jennifer Wang, Helen Te, Anjana Pillai, Kapuluru G. Reddy, Diego di Sabato, Ester C. Little, Vinay Sundaram, John Fung, Michael R. Lucey, Michael Charlton
American Journal of Transplantation.2021; 21(3): 1039. CrossRef
The Utility of a Pre-Transplant Psychosocial Evaluation in Predicting Post-Liver Transplant Outcomes
Jacqueline H. Becker, Eyal Shemesh, Akhil Shenoy, Ailie Posillico, Christopher S. Knight, Se-Kang Kim, Sander S. Florman, Thomas Schiano, Rachel A. Annunziato
Progress in Transplantation.2021; 31(1): 4. CrossRef
Outcome of patients with severe alcoholic hepatitis after Model for End-Stage Liver Disease-based allocation system implementation in Korea
Tae Jin Kwon, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Dong Hyun Sinn, Seung Woon Paik
Korean Journal of Transplantation.2021; 35(1): 24. CrossRef
Know When to Hold ‘em, Know When to Treat ‘em, Know When to Cut ‘em: Why Severe Alcoholic Hepatitis Is Becoming a Surgical Disease
William Carey
Digestive Diseases and Sciences.2020; 65(12): 3431. CrossRef
Liver Transplantation
Erin Maynard
Surgical Clinics of North America.2019; 99(1): 65. CrossRef
Integration of an Addiction Team in a Liver Transplantation Center
Hélène Donnadieu‐Rigole, Laura Jaubert, José Ursic‐Bedoya, Bertrand Hanslik, Thibault Mura, Lucie Gamon, Stéphanie Faure, Francis Navarro, Pascal Perney, Astrid Herrero, Georges‐Philippe Pageaux
Liver Transplantation.2019; 25(11): 1611. CrossRef
Predictors of 90-day mortality in patients with severe alcoholic hepatitis: Experience with 183 patients at a tertiary care center from India
Ravi Daswani, Ashish Kumar, Shrihari Anil Anikhindi, Praveen Sharma, Vikas Singla, Naresh Bansal, Anil Arora
Indian Journal of Gastroenterology.2018;[Epub] CrossRef
Severe acute alcoholic hepatitis and liver transplant: A never-ending mournful story
Aiman Obed, Abdalla Bashir, Steffen Stern, Anwar Jarrad
Clinical and Molecular Hepatology.2018; 24(4): 358. CrossRef

14,102 View
189 Download
10 Web of Science
Crossref

Autoimmune liver disease

Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea: Sook-Hyang Jeong; Clin Mol Hepatol 2018;24(1):10-19.
Published online January 5, 2018; DOI: https://doi.org/10.3350/cmh.2017.0066

Abstract
PDF

Autoimmune liver diseases including autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) are rare diseases. The aim of this review is to examine the epidemiology and clinical characteristics of AIH and PBC in South Korea. There were 4,085 patients registered as AIH in the Rare Intractable Disease Registry of Korea between 2009-2013, with a median age of 56 years and female-to male ratio of 6.4. The age-adjusted incidence and prevalence of AIH were 1.07/100,000/year and 4.82/100,000 persons, respectively. Among the patients, 1.1% underwent liver transplantation, and case fatality was 2.18%. Liver cirrhosis at diagnosis was accompanied in 23%; liver biopsy was performed in 75.2%, and prednisolone therapy or prednisolone and azathioprine combination therapy was done in 73% with a remission rate of 86%. There were 2,824 patients with PBC (≥20 years) registered in Korea between 2009-2013 with a median age of 57 years and female-to male ratio of 6.2. The age-adjusted incidence and prevalence of PBC were 0.86/100,000/year and 4.75/100,000 persons, respectively. Among the patients, 2.5% underwent liver transplantation, and case fatality was 2.2% with a 5-year transplantation-free survival of 95.4%. Ursodeoxycholic acid (UDCA) was prescribed in 90% of the patients with a UDCA inadequate response rate of 30%. In conclusion, AIH and PBC are rare but mostly treatable diseases if diagnosed in the early stages. However, scarce data, low awareness, delayed diagnosis and non-availability of 2nd line therapeutics are important issues to be solved. Therefore, governmental support for research and drug development and nationwide cooperative studies are warranted.

Citations

Citations to this article as recorded by

Concurrent nonalcoholic fatty liver disease may decrease liver fibrosis severity in patients with primary biliary cholangitis
Wenhui Ren, Zilong Wang, Xinyue Liu, Xin Liu, Danli Ma, Qian Jin, Jian Wang, Jiajun Feng, Huiying Rao, Xiaoxiao Wang, Rui Huang
BMC Gastroenterology.2025;[Epub] CrossRef
Clinical Characterization of Autoimmune Hepatic Involvement in Sjogren’s Disease: A Retrospective Cohort Study in Korea
Youngjae Park, Jennifer Jooha Lee, Ji Hyeon Ju, Wan-Uk Kim, Sung-Hwan Park, Seung-Ki Kwok
International Journal of Molecular Sciences.2025; 26(12): 5734. CrossRef
Autoimmune hepatitis: current concepts in epidemiology, diagnosis, and management
Brian J. Wentworth, Kwang Il Seo
Kosin Medical Journal.2025; 40(4): 249. CrossRef
Epidemiology of autoimmune liver disease in Korea: evidence from a nationwide real-world database
Jihye Lim, Hwa Jung Kim
Orphanet Journal of Rare Diseases.2024;[Epub] CrossRef
Registry of patients with autoimmune liver diseases in St. Petersburg: clinical and epidemiological data
Igor G. Bakulin, Svetlana A. Burlakova, Ekaterina V. Skazyvaeva, Maria I. Skalinskaya
HERALD of North-Western State Medical University named after I.I. Mechnikov.2024; 16(2): 61. CrossRef
Ionic Liquid 1-Octyl-3-Methylimidazolium (M8OI) Is Mono-Oxygenated by CYP3A4 and CYP3A5 in Adult Human Liver
Alistair C. Leitch, Tarek M. Abdelghany, Alex Charlton, Martin Cooke, Matthew C. Wright
Journal of Xenobiotics.2024; 14(3): 907. CrossRef
Treatment of Autoimmune Hepatitis
Ja Kyung Kim
The Korean Journal of Gastroenterology.2023; 81(2): 72. CrossRef
Diagnosis of Autoimmune Hepatitis
Jeong Han Kim
The Korean Journal of Gastroenterology.2023; 81(2): 66. CrossRef
Association of the etiology and peak level of markedly elevated aminotransferases with mortality: a multicenter study
Ji Yoon Kwak, Hyun-gyu Kim, Ji Hee Han, Hankyu Jeon, Ra Ri Cha, Sang Soo Lee
Hepatology Communications.2023;[Epub] CrossRef
KASL clinical practice guidelines for management of autoimmune hepatitis 2022

Clinical and Molecular Hepatology.2023; 29(3): 542. CrossRef
Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis
Hyejung Jang, Nayoung Han, Christine E. Staatz, Jae-Hwan Kwak, In-hwan Baek
Clinics and Research in Hepatology and Gastroenterology.2023; 47(10): 102227. CrossRef
Diagnostic Approach to Autoimmune Hepatitis
Kiyoung Lim, Jung Gil Park
The Korean Journal of Medicine.2022; 97(1): 33. CrossRef
Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in China
Zi-Xuan Shen, Dan-Dan Wu, Jie Xia, Xian-Bo Wang, Xin Zheng, Yan Huang, Bei-Ling Li, Zhong-Ji Meng, Yan-Hang Gao, Zhi-Ping Qian, Feng Liu, Xiao-Bo Lu, Jia Shang, Hua-Dong Yan, Yu-Bao Zheng, Wen-Yi Gu, Yan Zhang, Jian-Yi Wei, Wen-Ting Tan, Yi-Xin Hou, Qun Z
World Journal of Gastroenterology.2022; 28(31): 4417. CrossRef
Contemporary Epidemiology of Primary Biliary Cholangitis
Francesca Colapietro, Arianna Bertazzoni, Ana Lleo
Clinics in Liver Disease.2022; 26(4): 555. CrossRef
Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events
Joo Hyun Oh, Myung Ji Goh, Yewan Park, Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Yong-Han Paik
Digestive Diseases and Sciences.2021; 66(8): 2816. CrossRef
Current understanding of primary biliary cholangitis
Atsushi Tanaka
Clinical and Molecular Hepatology.2021; 27(1): 1. CrossRef
Changing Trends in Liver Cirrhosis Etiology and Severity in Korea: the Increasing Impact of Alcohol
Jae Hyun Yoon, Chung Hwan Jun, Jeong Han Kim, Eileen L. Yoon, Byung Seok Kim, Jeong Eun Song, Ki Tae Suk, Moon Young Kim, Seong Hee Kang
Journal of Korean Medical Science.2021;[Epub] CrossRef
A Case of Autoimmune Hepatitis after Occupational Exposure to N,N-Dimethylformamide
Boo-ok Jang, Gwang Hyeon Choi, Hee Yoon Jang, Soomin Ahn, Jae Kyun Choi, Siho Kim, Kyunghan Lee, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeong
Journal of Korean Medical Science.2020;[Epub] CrossRef
Long‐term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country
Jonggi Choi, Gwang Hyeon Choi, Danbi Lee, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Young‐Hwa Chung, Yung‐Sang Lee, Kang Mo Kim
Liver International.2019; 39(5): 985. CrossRef
Additional fibrate treatment in UDCA‐refractory PBC patients
Sung Won Chung, Jeong‐Hoon Lee, Minseok Albert Kim, Galam Leem, Sun Woong Kim, Young Chang, Hyo Young Lee, Jun Sik Yoon, Jun Yong Park, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung‐Hwan Yoon
Liver International.2019; 39(9): 1776. CrossRef
Etiopathogenesis of autoimmune hepatitis
Annarosa Floreani, Paula Restrepo-Jiménez, Maria Francesca Secchi, Sara De Martin, Patrick S.C. Leung, Edward Krawitt, Christopher L. Bowlus, M. Eric Gershwin, Juan-Manuel Anaya
Journal of Autoimmunity.2018; 95: 133. CrossRef

17,040 View
300 Download
21 Web of Science
Crossref

Original Article

Liver Transplantation

Resection plane-dependent error in computed tomography volumetry of the right hepatic lobe in living liver donors: Heon-Ju Kwon, Kyoung Won Kim, Bohyun Kim, So Yeon Kim, Chul Seung Lee, Jeongjin Lee, Gi Won Song, Sung Gyu Lee; Clin Mol Hepatol 2018;24(1):54-60.
Published online August 1, 2017; DOI: https://doi.org/10.3350/cmh.2017.0023

Abstract
PDF

Background/Aims
Computed tomography (CT) hepatic volumetry is currently accepted as the most reliable method for preoperative estimation of graft weight in living donor liver transplantation (LDLT). However, several factors can cause inaccuracies in CT volumetry compared to real graft weight. The purpose of this study was to determine the frequency and degree of resection plane-dependent error in CT volumetry of the right hepatic lobe in LDLT.
Methods
Forty-six living liver donors underwent CT before donor surgery and on postoperative day 7. Prospective CT volumetry (V_P) was measured via the assumptive hepatectomy plane. Retrospective liver volume (V_R) was measured using the actual plane by comparing preoperative and postoperative CT. Compared with intraoperatively measured weight (W), errors in percentage (%) V_P and V_R were evaluated. Plane-dependent error in V_P was defined as the absolute difference between V_P and V_R. % plane-dependent error was defined as follows: |V_P–V_R|/W∙100.
Results
Mean V_P, V_R, and W were 761.9 mL, 755.0 mL, and 696.9 g. Mean and % errors in V_P were 73.3 mL and 10.7%. Mean error and % error in V_R were 64.4 mL and 9.3%. Mean plane-dependent error in V_P was 32.4 mL. Mean % plane-dependent error was 4.7%. Plane-dependent error in V_P exceeded 10% of W in approximately 10% of the subjects in our study.
Conclusions
There was approximately 5% plane-dependent error in liver V_P on CT volumetry. Plane-dependent error in V_P exceeded 10% of W in approximately 10% of LDLT donors in our study. This error should be considered, especially when CT volumetry is performed by a less experienced operator who is not well acquainted with the donor hepatectomy plane.

Citations

Citations to this article as recorded by

Radiomics Beyond Radiology: Literature Review on Prediction of Future Liver Remnant Volume and Function Before Hepatic Surgery
Fabrizio Urraro, Giulia Pacella, Nicoletta Giordano, Salvatore Spiezia, Giovanni Balestrucci, Corrado Caiazzo, Claudio Russo, Salvatore Cappabianca, Gianluca Costa
Journal of Clinical Medicine.2025; 14(15): 5326. CrossRef
The Effect of Portal Vein Variants on the Margin of Error in Graft Volume Calculation in Living Donor Right Lobe Liver Transplantation
Feyza Sönmez Topcu, Veysel Ersan, Emrah Şahin, Adem Tunçer, Hasret Ayyıldız Civan, Abuzer Dirican, Bülent Ünal
Transplantation Proceedings.2025; 57(9): 1773. CrossRef
Optimizing accuracy: a comparative analysis of preoperative liver volumetry in living donor liver transplantation from a surgeon’s perspective – a retrospective cohort study
EunJin Choi, Seok-Hwan Kim
International Journal of Surgery.2025; 111(11): 8149. CrossRef
3-D reconstruction in liver surgery: a systematic review
Filippo Banchini, Patrizio Capelli, Anis Hasnaoui, Gerardo Palmieri, Andrea Romboli, Mario Giuffrida
HPB.2024; 26(10): 1205. CrossRef
Fully automated assessment of the future liver remnant in a blood-free setting via CT before major hepatectomy via deep learning
Tingting Xie, Jingyu Zhou, Xiaodong Zhang, Yaofeng Zhang, Xiaoying Wang, Yongbin Li, Guanxun Cheng
Insights into Imaging.2024;[Epub] CrossRef
Accuracy of preoperative liver volumetry in living donor liver transplantation—A systematic review and meta-analysis
Mika S. Buijk, Marcel Dijkshoorn, Roy S. Dwarkasing, Alicia C. Chorley, Robert C. Minnee, Markus U. Boehnert
Journal of Liver Transplantation.2023; 10: 100150. CrossRef
Prediction of Posthepatectomy Liver Failure with a Combination of Albumin-Bilirubin Score and Liver Resection Percentage
Kazuhiro Takahashi, Masahiko Gosho, Jaejeong Kim, Osamu Shimomura, Yoshihiro Miyazaki, Kinji Furuya, Yoshimasa Akashi, Tsuyoshi Enomoto, Shinji Hashimoto, Tatsuya Oda
Journal of the American College of Surgeons.2022; 234(2): 155. CrossRef
CT and MR imaging evaluation of living liver donors
Federica Vernuccio, Susan A. Whitney, Kadiyala Ravindra, Daniele Marin
Abdominal Radiology.2021; 46(1): 17. CrossRef
Estimation of the Right Posterior Section Volume in Live Liver Donors: Semiautomated CT Volumetry Using Portal Vein Segmentation
So Yeong Jeong, Jeongjin Lee, Kyoung Won Kim, Jin Kyoo Jang, Heon-Ju Kwon, Gi Won Song, Sung Gyu Lee
Academic Radiology.2020; 27(2): 210. CrossRef
Reproducibility and reliability of computed tomography volumetry in estimation of the right‐lobe graft weight in adult‐to‐adult living donor liver transplantation: Cantlie’s line vs portal vein territorialization
Heon‐Ju Kwon, Kyoung Won Kim, Jin Kyoo Jang, Jeongjin Lee, Gi‐Won Song, Sung‐Gyu Lee
Journal of Hepato-Biliary-Pancreatic Sciences.2020; 27(8): 541. CrossRef
Liver Graft Volume Estimation by Manual Volumetry and Software-Aided Interactive Volumetry: Which is Better?
Birkan Bozkurt, Ertan Emek, Turkmen Arikan, Ozgur Ceyhan, Pinar Yazici, Tolga Sahin, Elmar Mammadov, Ayfer Serin, Nagihan Inan Gurcan, Yildiray Yuzer, Yaman Tokat
Transplantation Proceedings.2019; 51(7): 2387. CrossRef
Clinical implication of hepatic volumetry for living donor liver transplantation
Woo Kyoung Jeong
Clinical and Molecular Hepatology.2018; 24(1): 51. CrossRef
MRI in donor candidates for living donor liver transplant: Technical and practical considerations
Bohyun Kim, So Yeon Kim, Kyoung Won Kim, Hye Young Jang, Jong Keon Jang, Gi Won Song, Sung Gyu Lee
Journal of Magnetic Resonance Imaging.2018; 48(6): 1453. CrossRef

12,833 View
184 Download
15 Web of Science
Crossref

Case Report

Benign liver tumors and cystic disease of liver

Living-donor liver transplantation for giant hepatic hemangioma with diffuse hemangiomatosis in an adult: a case report: Ju Hyun Lee, Chang Jin Yoon, Young Hoon Kim, Ho-Seong Han, Jai Young Cho, Haeryoung Kim, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeong; Clin Mol Hepatol 2018;24(2):163-168.
Published online July 19, 2017; DOI: https://doi.org/10.3350/cmh.2017.0002

Abstract
PDF

Hepatic hemangioma represents the most common benign primary hepatic neoplasm. Although most such tumors are small and asymptomatic, giant hepatic hemangioma is frequently symptomatic, and requires intervention. Moreover, diffuse multiple hepatic hemangiomatosis occupying almost the entire liver is extremely rare in adults, and the optimal management for this condition is unclear. We report a case of a rapidly growing, symptomatic giant hepatic hemangioma with diffuse hepatic hemangiomatosis in a 50-year-old female patient who was treated by living-donor liver transplantation. This case shows malignant behavior of a benign hemangioma that required liver transplantation. Although this case could not meet the criteria for transplantation according to the MELD (model for end-stage liver disease) score system, it should be considered as an exceptional indication for deceased-donor liver allocation. Further studies of the mechanism underlying hemangioma growth are warranted.

Citations

Citations to this article as recorded by

Manejo quirúrgico de hemangiomas hepáticos gigantes
Luis Manuel Barrera-Lozano, Jaime Alberto Ramírez Ramírez, Cristian Leonardo Muñoz, Sebastián Cerquera-Cajamarca, Jorge Iván Gutiérrez-Montoya
Revista Colombiana de Cirugía.2025; 40(2): 245. CrossRef
Laparoscopic microwave ablation for giant cavernous hemangioma coexistent with diffuse hepatic hemangiomatosis: Two case reports
Fei Xu, Jian Kong, Shu-Ying Dong, Li Xu, Shao-Hong Wang, Wen-Bing Sun, Jun Gao
World Journal of Gastrointestinal Surgery.2025;[Epub] CrossRef
A case of portal hypertension due to an invasive hepatic hemangioma following a long-term disease course
Naruhiro Kimura, Koutarou Yoshida, Yuuichi Kojima, Yuto Tanaka, Nao Nakajima, Hiroyuki Abe, Satoshi Ikarashi, Akira Sakamaki, Kenichi Mizuno, Shuji Terai
Clinical Journal of Gastroenterology.2025;[Epub] CrossRef
Endovascular treatment of giant hepatic hemangiomas: a systematic review and meta-analysis
Sofia Malosso Tronconi, João Felipe Federici de Almeida, Ana Terezinha Guillaumon
Jornal Vascular Brasileiro.2025;[Epub] CrossRef
Tratamento endovascular de hemangiomas hepáticos gigantes: uma revisão sistemática com metanálise
Sofia Malosso Tronconi, João Felipe Federici de Almeida, Ana Terezinha Guillaumon
Jornal Vascular Brasileiro.2025;[Epub] CrossRef
Exceptional Liver Transplant Indications: Unveiling the Uncommon Landscape
Teodor Cabel, Cristina Madalina Pascu, Catalin Stefan Ghenea, Bogdan Florin Dumbrava, Deniz Gunsahin, Andreea Andrunache, Livia-Marieta Negoita, Afrodita Panaitescu, Ecaterina Mihaela Rinja, Christopher Pavel, Oana-Mihaela Plotogea, Madalina Stan-Ilie, Va
Diagnostics.2024; 14(2): 226. CrossRef
Liver transplantation for liver hemangioma: The Paul Brousse Hospital experience and a systematic review of the literature
Ainhoa Andres Imaz, Maria Conticchio, Chady Salloum, Daniel Cherqui, René Adam, Daniel Azoulay
Journal of Liver Transplantation.2024; 13: 100193. CrossRef
Surgery for a symptomatic massive liver haemangioma
Sowmiya Velusamy, Souradeep Dutta, Debasis Naik, Vishnu Prasad Nelamangala Ramakrishnaiah
BMJ Case Reports.2024; 17(3): e257370. CrossRef
Adult diffuse hepatic hemangiomatosis lesion occupying the entire abdominal and pelvic cavities: a case report
Ya-Nan Ge, Yan Shao, Shu-Chen Dong, Xing-Bin Ma, Wei Wang
Frontiers in Medicine.2024;[Epub] CrossRef
Hepatic hemangioma: proportion and predictor of surgical treatment with emphasis on its growth rate
Young Cheol Shin, Eun Ju Cho, Hee Young Na, Jai Young Cho, Ho-Seong Han, Yoon Jin Lee, Haeryoung Kim, Sangmi Jang, Gwang Hyeon Choi, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeong
The Korean Journal of Internal Medicine.2023; 38(6): 818. CrossRef
Liver transplantation for giant hepatic hemangioma: A collective review
Cheon-Soo Park, Yong-Kyu Chung
Annals of Liver Transplantation.2023; 3(2): 69. CrossRef
Adult diffuse hepatic hemangiomatosis: A case report and review of the literature
Shihua He, Wenjing Chen, Ying Yang, Xiaoli Tang, Guangde Zhou, Jianhui Zhou, Chuanghong Wu
Clinics and Research in Hepatology and Gastroenterology.2022; 46(2): 101789. CrossRef
A Comprehensive Review of Hepatic Hemangioma Management
Hassan Aziz, Zachary J. Brown, Azarakhsh Baghdadi, Ihab R. Kamel, Timothy M. Pawlik
Journal of Gastrointestinal Surgery.2022; 26(9): 1998. CrossRef
Liver transplantation for giant hemangioma of the liver: A case report and review of the literature
Yun Zhao, Xiu-Ping Li, Yuan-Yuan Hu, Ji-Chang Jiang, Li-Jin Zhao
Frontiers in Medicine.2022;[Epub] CrossRef
Autologous Partial Liver Transplantation for a Symptomatic Giant Hepatic Hemangioma. A Case Report
Ayato Obana, Yoshinobu Sato
Transplantation Proceedings.2022; 54(10): 2787. CrossRef
Liver Transplantation for Rapidly Progressive Giant Hepatic Hemangioma With Diffuse Hemangiomatosis
Sadhana Shankar, Ashwin Rammohan, Venugopal H. Kulaseharan, Rathnavel Kanagavelu, Mettu S. Reddy, Mohamed Rela
Experimental and Clinical Transplantation.2021; 19(10): 1106. CrossRef
A case of diffuse hepatic hemangiomatosis coexistent with giant hemangioma: case report and literature review
M. Isabel González-Nieto, Luz Adriana Escobar Hoyos
Radiology Case Reports.2021; 16(6): 1518. CrossRef
Liver transplantation for benign liver tumors
Ana Ostojic, Anna Mrzljak, Danko Mikulic
World Journal of Hepatology.2021; 13(9): 1098. CrossRef
Orthotopic liver transplantation for Management of a Giant Liver Hemangioma: a case report and review of literature
Hesameddin Eghlimi, Peyman Arasteh, Nazanin Azade
BMC Surgery.2020;[Epub] CrossRef
Invasive management of symptomatic hepatic hemangioma
Wenfang Dong, Bin Qiu, Haifeng Xu, Leren He
European Journal of Gastroenterology & Hepatology.2019; 31(9): 1079. CrossRef

23,729 View
245 Download
18 Web of Science
Crossref

Original Article

Liver Transplantation

Influence of ultrasound contrast agents on spectral Doppler analysis in recipients of liver transplantation: Young Seo Cho, Kyoung Won Kim, Hye Young Jang, Bo Hyun Kim, Jeongjin Lee, Gi Won Song, Sung Gyu Lee, Dagvasumberel Munkhbaatar; Clin Mol Hepatol 2017;23(3):224-229.
Published online July 4, 2017; DOI: https://doi.org/10.3350/cmh.2016.0064

Abstract
PDF

Background/Aims
Clinical validation is required to determine whether Doppler measurements are comparable before and after administering ultrasound contrast agent (USCA). The purpose of this study is to explore whether the use of USCA affects spectral Doppler analysis in recipients of liver transplantation (LT).
Methods
For this study, 36 patients were examined using Doppler ultrasonography (US) along with a contrast-enhanced US for surveillance of vascular complications after LT. The following spectral Doppler US parameters were measured before and after administration of USCA: peak systolic velocity, end-diastolic velocity, resistive index, and systolic acceleration time of the graft hepatic artery; peak flow velocity of the graft portal vein; and peak flow velocity and venous pulsatility index of the graft hepatic vein.
Results
The mean peak systolic and end-diastolic velocities of the hepatic artery and the peak flow velocity of the portal and hepatic veins were increased after intravenously administration of the USCA, ranging from 10% to 13%. However, the changes were not statistically significant (P=0.097, 0.103, 0.128, and 0.190, respectively). There were no significant differences in other measured parameters, including the resistive index (P=0.205) and systolic acceleration time (P=0.489) of the hepatic artery and venous pulsatility index (P=0.494) of the hepatic vein.
Conclusions
The measured velocities of graft hepatic vessels tended to increase after administration of USCA, but without statistical significance. The comparison of serial Doppler parameters with or without injection of USCA is valid during Doppler surveillance in recipients of LT.

Citations

Citations to this article as recorded by

Effect of contrast-enhanced ultrasound (CEUS) on liver stiffness measurements obtained by transient and shear-wave elastography
Stefano KAYALI, Andrea PASTA, Rinaldo PELLICANO, Sharmila FAGOONEE, Elisabetta GIULIANA, Chiara FACCHINI, Simona PILI, Silvia BUCCILLI, Sara LABANCA, Paolo BORRO
Panminerva Medica.2022;[Epub] CrossRef

11,323 View
128 Download
1 Web of Science
Crossref

Liver Imaging

Liver fibrosis, cirrhosis, and portal hypertension

Portal flow steal after liver transplantation: Bohyun Kim, Kyoung Won Kim, Gi-Won Song, Sung-Gyu Lee; Clin Mol Hepatol 2015;21(3):314-317.
Published online September 30, 2015; DOI: https://doi.org/10.3350/cmh.2015.21.3.314

Abstract
PDF

Portal flow steal occasionally persists even after the liver transplantation, which may reduce the portal flow and thus threaten the patients' outcome. Therefore, pre- and peri-operative detection of portal steal phenomenon requiring radiological or surgical interruption is essential for the liver transplantation candidates as well as for the recipients.

Citations

Citations to this article as recorded by

Late Onset Hepatic Encephalopathy after Living Donor Liver Transplant: Successful Reversal by Plug Embolization of Shunt—A Report of Two Cases
Shahnawaz Bashir, Dibyalochan Praharaj, Adnan Khan, Subhash Gupta, Pragati Gakher
Journal of Clinical Interventional Radiology ISVIR.2025; 09(03): 189. CrossRef
Portal Steal During Liver Transplantation in a 31-Year-Old: When Absent Varices Signal Extensive Splenorenal Shunting
Noor Abu Zar, Chia Chey
Cureus.2025;[Epub] CrossRef
Clinical Impact of Spontaneous Portosystemic Shunts in Liver Transplantation: A Comprehensive Assessment Through Total Shunt Area Measurement
Leonardo Centonze, Giovanna Gorga, Riccardo De Carlis, Davide Bernasconi, Andrea Lauterio, Luca Carbonaro, Ivan Vella, Cristiano Sgrazzutti, Niccolò Incarbone, Francesco Rizzetto, Maria Grazia Valsecchi, Angelo Vanzulli, Luciano De Carlis
Transplantation.2023; 107(4): 913. CrossRef
Short-Term Results of Plug-Assisted Retrograde Transvenous Obliteration for Portal Steal from Complicated Portosystemic Shunts in Living-Donor Liver Transplantation
Gun Ha Kim, Dong Il Gwon, Gi-Young Ko, Hee Ho Chu, Deok-Bog Moon, Dong-Hwan Jung, Sung-Gyu Lee
Journal of Vascular and Interventional Radiology.2023; 34(4): 645. CrossRef
Imaging and Intervention in the Management of Vascular Complications Following Liver Transplantation
Vijay Kubihal, Shridhar Sasturkar, Amar Mukund
Journal of Clinical and Experimental Hepatology.2023; 13(5): 854. CrossRef
Role of portocaval shunts in development of complications after liver transplantation
D. L. Tsoy, M. I. Prudkov, O. G. Orlov, E. N. Bessonova, I. G. Leshchenko, L. V. Kardopoltsev, A. N. Ageev, S. I. Solodushkin
Transplantologiya. The Russian Journal of Transplantation.2022; 14(2): 159. CrossRef
Understanding Local Hemodynamic Changes After Liver Transplant: Different Entities or Simply Different Sides to the Same Coin?
Francisco Calderon Novoa, Juan Mattera, Martín de Santibañes, Victoria Ardiles, Adrian Gadano, Daniel E D’Agostino, Eugenia Fratantoni, Eduardo De Santibañes, Juan Pekolj
Transplantation Direct.2022; 8(9): e1369. CrossRef
Life-Threatening Portal Flow Steal Reappearing Under Increased Intrahepatic Vascular Resistance After Living Donor Liver Transplantation
Jae-Hyun Kwon, Young-In Yoon, Deok-Bog Moon, Gil-Chun Park, Gi-Won Song, Dong-Hwan Jung, Kyu-Bo Sung, Gi-Young Ko, Dong-Il Gwon, Yong-Kyu Jung, I-Ji Jeong, Jin-Uk Choi, Min-Jae Kim, Sang-Hoon Kim, Sung-Gyu Lee
Transplantation Proceedings.2021; 53(1): 166. CrossRef
Endovascular management of portal steal syndrome due to portosystemic shunts after living donor liver transplantation
Surabhi Jajodia, Anubhav H Khandelwal, Rohit Khandelwal, Abhay K Kapoor, Sanjay S Baijal
JGH Open.2021; 5(5): 599. CrossRef
Post-transplant inflow modulation for early allograft dysfunction after living donor liver transplantation
Mohamed Elshawy, Takeo Toshima, Yoshiki Asayama, Yuichiro Kubo, Shinichiro Ikeda, Toru Ikegami, Shingo Arakaki, Tomoharu Yoshizumi, Masaki Mori
Surgical Case Reports.2020;[Epub] CrossRef
N-butyl-2 cyanoacrylate (NBCA) embolus in the graft portal vein after portosystemic collateral embolization in liver transplantation recipient: what is the clinical significance?
Hye Young Jang, Kyoung Won Kim, Jae Hyun Kwon, Heon-Ju Kwon, Bohyun Kim, Nieun Seo, Jeongjin Lee, Gi-Won Song, Sung-Gyu Lee
Acta Radiologica.2017; 58(11): 1326. CrossRef

10,768 View
104 Download
8 Web of Science
Crossref

Original Article

Viral hepatitis

Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure: Jung Min Ha, Won Sohn, Ju Yeon Cho, Jeung Hui Pyo, Kyu Choi, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Chul Koh, Seung Woon Paik, Byung Chul Yoo, Yong-Han Paik; Clin Mol Hepatol 2015;21(3):232-241.
Published online September 30, 2015; DOI: https://doi.org/10.3350/cmh.2015.21.3.232

Abstract
PDF

Background/Aims

Hepatitis-B-related acute-on-chronic liver failure has a poor prognosis. However, the advent of potent oral antiviral agents means that some patients can now recover with medical treatment. We aimed to identify the prognostic factors for hepatitis-B-related acute-on-chronic liver failure including the initial as well as the dynamically changing clinical parameters during admission.

Methods

Sixty-seven patients were retrospectively enrolled from 2003 to 2012 at Samsung Medical Center. The patients were classified into three categories: Recovery group (n=23), Liver transplantation group (n=28), and Death group (n=16). The Liver transplantation and Death groups were combined into an Unfavorable prognosis group. We analyzed the prognostic factors including the Model for End-Stage Liver Disease (MELD) scores determined at 3-day intervals.

Results

A multivariable analysis showed that the unfavorable prognostic factors were a high initial MELD score (≥28) (odds ratio [OR] =6.64, p=0.015), moderate-to-severe ascites at admission (OR=6.71, P=0.012), and the aggravation of hepatic encephalopathy during hospitalization (≥grade III) (OR=15.41, P=0.013). Compared with the baseline level, significant reductions in the MELD scores were observed on the 7th day after admission in the Recovery group (P=0.016).

Conclusions

Dynamic changes in clinical parameters during admission are useful prognostic factors for hepatitis-B-related acute-on-chronic liver failure.

Citations

Citations to this article as recorded by

Plasma galectin-3 can be considered as a non-invasive marker to predict the prognosis of ACLF patients with new typing
Li Bai, Wang Lu, Qi Yang, Xiaoxuan Liu, Yu Chen, Zhongping Duan
Scientific Reports.2025;[Epub] CrossRef
Construction of a novel prognostic scoring model for HBV-ACLF liver failure based on dynamic data
Qun Cai, Hao Wang, Mingyan Zhu, Yixin Xiao, Tingting Zhuo
Scientific Reports.2024;[Epub] CrossRef
PLT Counts as a Predictive Marker after Plasma Exchange in Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure
Xue Li, Hao Li, Yucui Zhu, Huaqian Xu, Shanhong Tang
Journal of Clinical Medicine.2023; 12(3): 851. CrossRef
Falla hepática aguda sobre crónica: análisis de una serie de casos y revisión de la literatura
Jhon Edwar García-Rueda, Ricardo Londoño-García, Tomás Marín-Cuartas, Juan Esteban Hernández-Abaunza, Sebastián Osorio-Rico, Angélica María Bermúdez-Flórez, Juan Carlos Restrepo-Gutiérrez
Hepatología.2022; : 72. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef
A dynamic prediction model for prognosis of acute-on-chronic liver failure based on the trend of clinical indicators
Zhenjun Yu, Yu Zhang, Yingying Cao, Manman Xu, Shaoli You, Yu Chen, Bing Zhu, Ming Kong, Fangjiao Song, Shaojie Xin, Zhongping Duan, Tao Han
Scientific Reports.2021;[Epub] CrossRef
Clinical Course and Outcome Patterns of Acute-on-chronic Liver Failure: A Multicenter Retrospective Cohort Study
Man-Man Xu, Ming Kong, Peng-Fei Yu, Ying-Ying Cao, Fang Liu, Bing Zhu, Yi-Zhi Zhang, Wang Lu, Huai-Bin Zou, Bin-Wei Duan, Shao-Li You, Shao-Jie Xin, Tao Han, Zhong-Ping Duan, Yu Chen
Journal of Clinical and Translational Hepatology.2021; 000(000): 000. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology.2019; 25(2): 93. CrossRef
A Dynamic Model for Predicting Outcome in Patients with HBV Related Acute-On-Chronic Liver Failure
Wei Lin, Jing Zhang, Xiaohui Liu, Hongqun Liu, Jinqiu He, Ming Li, Shuqin Zhang, Hong Chen, Changqing Zhang, Wenfang Wu, Chenggang Jin, Samuel S. Lee, Zhongping Duan, Yuexin Zhang
Annals of Hepatology.2018; 17(3): 392. CrossRef

11,557 View
96 Download
9 Web of Science
Crossref

Reviews

Alcohol-related liver disease

Managing alcoholic liver disease: Vijay H. Shah; Clin Mol Hepatol 2015;21(3):212-219.
Published online September 30, 2015; DOI: https://doi.org/10.3350/cmh.2015.21.3.212

Abstract
PDF

Alcoholic liver disease continues to be a significant cause of liver-related morbidity and mortality throughout the world. A number of diagnostic and prognostic models have been developed in the management of this condition, although specific roles for liver biopsy still remain particularly in the setting of alcoholic hepatitis. Despite a large number of recent treatment trials, the ideal pharmacotherapy approach remains undefined. Most essential is the supportive care and focus on abstinence and nutrition. Owing in part to a great deal of attention from governmental funding sources, a number of new treatment approaches are undergoing rigorous evaluation, hopefully providing future treatment options in this very severe condition.

Citations

Citations to this article as recorded by

New perspective on fecal microbiota transplantation in liver diseases
Ki Tae Suk, Hong Koh
Journal of Gastroenterology and Hepatology.2022; 37(1): 24. CrossRef
Incidence and management patterns of alcohol-related liver disease in Korea: a nationwide standard cohort study
Ha Il Kim, Seo Young Park, Hyun Phil Shin
Scientific Reports.2021;[Epub] CrossRef
Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
Meegun Hong, Dae Hee Han, Jitaek Hong, Dong Joon Kim, Ki Tae Suk
Probiotics and Antimicrobial Proteins.2019; 11(2): 335. CrossRef
Development of colorectal cancer predicts increased risk of subsequent hepatocellular carcinoma in patients with alcoholic liver disease: case-control and cohort study
Won Kim, Dongjae Jeong, Jungwha Chung, Donghyeon Lee, Saekyoung Joo, Eun Sun Jang, Yoon Jin Choi, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Sook-Hyang Jeong, Nayoung Kim, Dong Ho Lee, Jin-Wook Kim
Scientific Reports.2019;[Epub] CrossRef
Growing burden of alcoholic liver disease in China: A review
Wen-Jun Wang, Peng Xiao, Hong-Qin Xu, Jun-Qi Niu, Yan-Hang Gao
World Journal of Gastroenterology.2019; 25(12): 1445. CrossRef
Effect of Taurine on Ethanol-Induced Oxidative Stress in Mouse Liver and Kidney
Zofia Goc, Edyta Kapusta, Grzegorz Formicki, Monika Martiniaková, Radoslav Omelka
Chinese Journal of Physiology.2019; 62(4): 148. CrossRef
Liver Fibrosis: A Clinical Update
Lindsey C. Shipley, Page D. Axley, Ashwani K. Singal
EMJ Hepatology.2019; : 105. CrossRef
Role of liver transplantation in severe alcoholic hepatitis
Ravi Daswani, Ashish Kumar, Praveen Sharma, Vikas Singla, Naresh Bansal, Anil Arora
Clinical and Molecular Hepatology.2018; 24(1): 43. CrossRef
Epidemiology of alcoholic liver disease in Korea
Jae Young Jang, Dong Joon Kim
Clinical and Molecular Hepatology.2018; 24(2): 93. CrossRef
CX3CR1 differentiates F4/80low monocytes into pro-inflammatory F4/80high macrophages in the liver
Young-Sun Lee, Myung-Ho Kim, Hyon-Seung Yi, So Yeon Kim, Hee-Hoon Kim, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun, Jin-Seok Byun, Won-Il Jeong
Scientific Reports.2018;[Epub] CrossRef
Local care and treatment of liver disease (LOCATE) – A cluster-randomized feasibility study to discover, assess and manage early liver disease in primary care
Magdy El-Gohary, Mike Moore, Paul Roderick, Emily Watkins, Joanne Dash, Tina Reinson, Colin Newell, Miranda Kim, Beth Stuart, Taeko Becque, Nick Sheron, Isabelle Chemin
PLOS ONE.2018; 13(12): e0208798. CrossRef
Bilateral optic neuropathy related to severe anemia in a patient with alcoholic cirrhosis: a case report and review of the literature
Lisa Humbertjean-Selton, Jérôme Selton, Nolwenn Riou-Comte, Jean-Christophe Lacour, Gioia Mione, Sébastien Richard
Clinical and Molecular Hepatology.2018; 24(4): 417. CrossRef
Treatment of Severe Alcoholic Hepatitis With Corticosteroid, Pentoxifylline, or Dual Therapy
Young-Sun Lee, Hyun Jung Kim, Ji Hoon Kim, Yang Jae Yoo, Tae Suk Kim, Seong Hee Kang, Sang Jun Suh, Moon Kyung Joo, Young Kul Jung, Beom Jae Lee, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Jae Seon Kim, Jong-Jae Park, Soon Ho Um, Young-Tae Bak, Kwan So
Journal of Clinical Gastroenterology.2017; 51(4): 364. CrossRef
Korean Patients Undergoing Deceased Donor Liver Transplantation for Alcoholic Liver Disease Have Non-Inferior Survival Outcomes than for Hepatitis B Virus: a Real-World Experience without Minimum Abstinence before Transplantation
Suk Kyun Hong, Nam-Joon Yi, Hyo-Sin Kim, Sung Woo Ahn, Kyung Chul Yoon, Hyeyoung Kim, Kwang-Woong Lee, Kyung-Suk Suh
Journal of Korean Medical Science.2017; 32(6): 919. CrossRef

13,862 View
261 Download
14 Web of Science
Crossref

Liver development and regeneration

Clinical implications of advances in liver regeneration: Yong Jin Kwon, Kyeong Geun Lee, Dongho Choi; Clin Mol Hepatol 2015;21(1):7-13.
Published online March 25, 2015; DOI: https://doi.org/10.3350/cmh.2015.21.1.7

Abstract
PDF

Remarkable advances have been made recently in the area of liver regeneration. Even though liver regeneration after liver resection has been widely researched, new clinical applications have provided a better understanding of the process. Hepatic damage induces a process of regeneration that rarely occurs in normal undamaged liver. Many studies have concentrated on the mechanism of hepatocyte regeneration following liver damage. High mortality is usual in patients with terminal liver failure. Patients die when the regenerative process is unable to balance loss due to liver damage. During disease progression, cellular adaptations take place and the organ microenvironment changes. Portal vein embolization and the associating liver partition and portal vein ligation for staged hepatectomy are relatively recent techniques exploiting the remarkable progress in understanding liver regeneration. Living donor liver transplantation is one of the most significant clinical outcomes of research on liver regeneration. Another major clinical field involving liver regeneration is cell therapy using adult stem cells. The aim of this article is to provide an outline of the clinical approaches being undertaken to examine regeneration in liver diseases.

Citations

Citations to this article as recorded by

Human umbilical cord mesenchymal stem cells enhance liver regeneration and decrease collagen content in fibrosis mice after partial hepatectomy by activating Wnt/β-catenin signaling
Xuewei Li, Jinghui Feng, Haiqin Cheng, Ning Jin, Shanshan Jin, Zhizhen Liu, Jun Xu, Jun Xie
Acta Biochimica et Biophysica Sinica.2025; 57(4): 604. CrossRef
From Cells to Exosomes: a Review of Non-Surgical Biotherapeutic-Based Strategies for Liver Regeneration in the Face of End-Stage Diseases
Fatemeh Askari Yazdian, Matin Mojaveri Samak, Amirhossein Larijani, Mohammad Taghi Ashoobi, Mohadese Kharaqani, Mohammad Amin Ghezel, Zahra Barabadi, Elham Vojoudi
Stem Cell Reviews and Reports.2025; 21(6): 1669. CrossRef
Liver regeneration after injury: Mechanisms, cellular interactions and therapeutic innovations
Qi Liu, Senyan Wang, Jing Fu, Yao Chen, Jing Xu, Wenjuan Wei, Hao Song, Xiaofang Zhao, Hongyang Wang
Clinical and Translational Medicine.2024;[Epub] CrossRef
Interleukin‐33 facilitates liver regeneration through serotonin‐involved gut‐liver axis
Yankai Wen, Christoph Emontzpohl, Long Xu, Constance L. Atkins, Jong‐Min Jeong, Yang Yang, Kangho Kim, Chuan Wu, Shizuo Akira, Cynthia Ju
Hepatology.2023; 77(5): 1580. CrossRef
Liver Regeneration-Related Genes of Nontumor Liver Tissues Predict the Prognosis of Patients with Hepatocellular Carcinoma
Yanchao Xu, Yunzheng Li, Yanjun Lu, Weihong Wang, Zhaowu Lian, Zijie Wu, Binghua Li, Decai Yu
Journal of Hepatocellular Carcinoma.2023; Volume 10: 2197. CrossRef
Clinical Application of Regenerative Medicine in the Treatment of End-Stage Liver Diseases
洪刘
Advances in Clinical Medicine.2022; 12(08): 7256. CrossRef
Predicting liver regeneration following major resection
Karolin Dehlke, Linda Krause, Silvana Tyufekchieva, Anastasia Murtha-Lemekhova, Philipp Mayer, Artyom Vlasov, Ursula Klingmüller, Nikola S. Mueller, Katrin Hoffmann
Scientific Reports.2022;[Epub] CrossRef
Comparing various scoring systems in the treatment of hepatocellular carcinoma with ALPPS
Yan Xu, Xiaoling Hu, Jiangbin Li, Rui Dong
International Journal of Surgery: Global Health.2021; 4(2): e44. CrossRef
Establishing a 3D In Vitro Hepatic Model Mimicking Physiologically Relevant to In Vivo State
Hyun Kyoung Kang, Madina Sarsenova, Da-Hyun Kim, Min Soo Kim, Jin Young Lee, Eun-Ah Sung, Myung Geun Kook, Nam Gyo Kim, Soon Won Choi, Vyacheslav Ogay, Kyung-Sun Kang
Cells.2021; 10(5): 1268. CrossRef
Astragaloside IV Suppresses Hepatic Proliferation in Regenerating Rat Liver after 70% Partial Hepatectomy via Down-Regulation of Cell Cycle Pathway and DNA Replication
Gyeong-Seok Lee, Hee-Yeon Jeong, Hyeon-Gung Yang, Young-Ran Seo, Eui-Gil Jung, Yong-Seok Lee, Kung-Woo Nam, Wan-Jong Kim
Molecules.2021; 26(10): 2895. CrossRef
Geometrical model of lobular structure and its importance for the liver perfusion analysis
Eduard Rohan, Jana Camprová Turjanicová, Václav Liška, Adélia Sequeira
PLOS ONE.2021; 16(12): e0260068. CrossRef
Small-molecule-mediated reprogramming: a silver lining for regenerative medicine
Yohan Kim, Jaemin Jeong, Dongho Choi
Experimental & Molecular Medicine.2020; 52(2): 213. CrossRef
Extent of liver resection is associated with incomplete liver restoration and splenomegaly a long period after liver resection
Nguyen Hai Nam, Kojiro Taura, Yusuke Kimura, Yusuke Uemoto, Kenji Yoshino, Ken Fukumitsu, Takamichi Ishii, Satoru Seo, Keiko Iwaisako, Shinji Uemoto
Surgery.2020; 168(1): 40. CrossRef
Directly induced hepatogenic cells derived from human fibroblast ameliorate liver fibrosis
Ja Sung Choi, Seongho Han, Hyun Aae Ryu, Sung‐Whan Kim
Journal of Tissue Engineering and Regenerative Medicine.2020; 14(8): 1028. CrossRef
CDK5RAP3 Deficiency Restrains Liver Regeneration after Partial Hepatectomy Triggering Endoplasmic Reticulum Stress
Shuchun Yang, Rui Yang, Huanmin Wang, Yue Huang, Yuyan Jia
The American Journal of Pathology.2020; 190(12): 2403. CrossRef
Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells
Yohan Kim, Kyojin Kang, Seung Bum Lee, Daekwan Seo, Sangtae Yoon, Sung Joo Kim, Kiseok Jang, Yun Kyung Jung, Kyeong Geun Lee, Valentina M. Factor, Jaemin Jeong, Dongho Choi
Journal of Hepatology.2019; 70(1): 97. CrossRef
The role of extracellular matrix on liver stem cell fate: A dynamic relationship in health and disease
Natalia Sánchez-Romero, Pilar Sainz-Arnal, Iris Pla-Palacín, Pablo Royo Dachary, Helen Almeida, Cristina Pastor, Daniela Rubio Soto, Milagros Chico Rodriguez, Emma Olmedo Arbizu, Lourdes Bengochea Martinez, Trinidad Serrano-Aulló, Pedro M. Baptista
Differentiation.2019; 106: 49. CrossRef
CD11b+Ly6G+ myeloid‐derived suppressor cells promote liver regeneration in a murine model of major hepatectomy
Ido Nachmany, Yoel Bogoch, Ayelet Sivan, Omer Amar, Ekaterina Bondar, Nitzan Zohar, Oran Yakubovsky, Ofer Fainaru, Joseph M. Klausner, Niv Pencovich
The FASEB Journal.2019; 33(5): 5967. CrossRef
Roles of hepatic stellate cells in acute liver failure: From the perspective of inflammation and fibrosis
Juan Li, Ying-Ren Zhao, Zhen Tian
World Journal of Hepatology.2019; 11(5): 412. CrossRef
Mesenchymal Stem Cells for Liver Regeneration in Liver Failure: From Experimental Models to Clinical Trials
Maria P. de Miguel, I. Prieto, A. Moratilla, J. Arias, M. A. Aller
Stem Cells International.2019; 2019: 1. CrossRef
Generation of functional human hepatocytes in vitro: current status and future prospects
Tomoko Yamaguchi, Juntaro Matsuzaki, Takeshi Katsuda, Yoshimasa Saito, Hidetsugu Saito, Takahiro Ochiya
Inflammation and Regeneration.2019;[Epub] CrossRef
Beneficial and Deleterious Effects of Female Sex Hormones, Oral Contraceptives, and Phytoestrogens by Immunomodulation on the Liver
Luis E. Soria-Jasso, Raquel Cariño-Cortés, Víctor Manuel Muñoz-Pérez, Elizabeth Pérez-Hernández, Nury Pérez-Hernández, Eduardo Fernández-Martínez
International Journal of Molecular Sciences.2019; 20(19): 4694. CrossRef
Severe polycystic liver diseases: hepatectomy or waiting for liver transplantation?
Zeyu Zhang, Kuan Hu, Jiajin Yang, Yufan Zhou, Zhiming Wang, Yun Huang
Medicine.2019; 98(49): e18176. CrossRef
Progress and prospects of circular RNAs in Hepatocellular carcinoma: Novel insights into their function
Ji Hu, Peng Li, Yang Song, Yun‐xuan Ge, Xiao‐ming Meng, Cheng Huang, Jun Li, Tao Xu
Journal of Cellular Physiology.2018; 233(6): 4408. CrossRef
Three-Dimensional Bioprinting of Hepatic Structures with Directly Converted Hepatocyte-Like Cells
Kyojin Kang, Yohan Kim, Hyeryeon Jeon, Seung Bum Lee, Ji Sook Kim, Su A Park, Wan Doo Kim, Heung Mo Yang, Sung Joo Kim, Jaemin Jeong, Dongho Choi
Tissue Engineering Part A.2018; 24(7-8): 576. CrossRef
Shaping the future of liver surgery
D. Pereyra, P. Starlinger
European Surgery.2018; 50(3): 132. CrossRef
The multiple functions of melatonin in regenerative medicine
Maryam Majidinia, Russel J. Reiter, Seyed Kazem Shakouri, Iraj Mohebbi, Mojgan Rastegar, Mojtaba Kaviani, Saber Ghazizadeh Darband, Rana Jahanban-Esfahlan, Seyed Mohammad Nabavi, Bahman Yousefi
Ageing Research Reviews.2018; 45: 33. CrossRef
Associating liver partition and portal vein ligation versus 2-stage hepatectomy
Yi-Nan Shen, Cheng-Xiang Guo, Lin-Yan Wang, Yao Pan, Yi-Wen Chen, Xue-Li Bai, Ting-Bo Liang
Medicine.2018; 97(35): e12082. CrossRef
Portal venous velocity affects liver regeneration after right lobe living donor hepatectomy
Chen-Tai Hou, Yao-Li Chen, Chia-Cheng Lin, Chen-Te Chou, Kuo-Hua Lin, Ping-Yi Lin, Ya-Lan Hsu, Chia-Bang Chen, Hui-Chuan Lin, Chih-Jan Ko, Su-Han Wang, Li-Chueh Weng, Chia-En Hsieh, Gianfranco D. Alpini
PLOS ONE.2018; 13(9): e0204163. CrossRef
Nonintegrating Direct Conversion Using mRNA into Hepatocyte-Like Cells
Sangtae Yoon, Kyojin Kang, Young-duck Cho, Yohan Kim, Elina Maria Buisson, Ji-Hye Yim, Seung Bum Lee, Ki-Young Ryu, Jaemin Jeong, Dongho Choi
BioMed Research International.2018; 2018: 1. CrossRef
Deficiency of apoptosis-stimulating protein two of p53 promotes liver regeneration in mice by activating mammalian target of rapamycin
Hongbo Shi, Yizhi Zhang, Jing Ji, Ping Xu, Honglin Shi, Xiujuan Yue, Feng Ren, Yu Chen, Zhongping Duan, Dexi Chen
Scientific Reports.2018;[Epub] CrossRef
Low-Power Laser Irradiation (LPLI): A Clinical Point of View on a Promising Strategy to Improve Liver Regeneration
Tiago Gomes Araújo, Alexandre Gabarra Oliveira, Antonio R. Franchi Teixeira
Journal of Lasers in Medical Sciences.2018; 9(4): 223. CrossRef
Stereological analysis of size and density of hepatocytes in the porcine liver
Khan L. Junatas, Zbyněk Tonar, Tereza Kubíková, Václav Liška, Richard Pálek, Patrik Mik, Milena Králíčková, Kirsti Witter
Journal of Anatomy.2017; 230(4): 575. CrossRef
Cellular Mechanisms of Liver Regeneration and Cell-Based Therapies of Liver Diseases
Irina V. Kholodenko, Konstantin N. Yarygin
BioMed Research International.2017; 2017: 1. CrossRef
Administration of multipotent mesenchymal stromal cells restores liver regeneration and improves liver function in obese mice with hepatic steatosis after partial hepatectomy
Fernando Ezquer, Javiera Bahamonde, Ya-Lin Huang, Marcelo Ezquer
Stem Cell Research & Therapy.2017;[Epub] CrossRef
Generation of Multilayered 3D Structures of HepG2 Cells Using a Bio-printing Technique
Hyeryeon Jeon, Kyojin Kang, Su A Park, Wan Doo Kim, Seung Sam Paik, Sang-Hun Lee, Jaemin Jeong, Dongho Choi
Gut and Liver.2017; 11(1): 121. CrossRef
Three-dimensional (3D) printing of mouse primary hepatocytes to generate 3D hepatic structure
Yohan Kim, Kyojin Kang, Jaemin Jeong, Seung Sam Paik, Ji Sook Kim, Su A Park, Wan Doo Kim, Jisun Park, Dongho Choi
Annals of Surgical Treatment and Research.2017; 92(2): 67. CrossRef
Fabrication and evaluation of SDF-1 loaded galactosylated chitosan nanoparticles for liver targeting
Chu Xue-Hui, Feng Zhang-Qi, Xu Qian, Xiao Jiang-Qiang, Yuan Xian-Wen, Sun Xi-Tai
Materials Research Express.2017; 4(3): 035028. CrossRef
Establishment of Hepatocellular Cancer Induced Pluripotent Stem Cells Using a Reprogramming Technique
Han Joon Kim, Jaemin Jeong, Sunhoo Park, Young-Woo Jin, Seung-Sook Lee, Seung Bum Lee, Dongho Choi
Gut and Liver.2017; 11(2): 261. CrossRef
A phase I study on stereotactic body radiotherapy of liver metastases based on functional treatment planning using positron emission tomography with 2-[18F]fluoro-2-deoxy-d-galactose
Mette Marie Fode, Kirstine Bak-Fredslund, Jørgen Baltzer Petersen, Esben Worm, Michael Sørensen, Morten Høyer
Acta Oncologica.2017; 56(11): 1614. CrossRef
Expression of hypoxia inducible factor-1α and its correlation with phosphoenolpyruvate carboxykinase after portal vein ligation in rats
Changjun Jia, Hua Yang, Chaoliu Dai, Feng Xu, Songlin Peng, Yang Zhao, Chuang Zhao, Liang Zhao
Life Sciences.2017; 190: 97. CrossRef
MicroRNA-21 Contributes to Liver Regeneration by Targeting PTEN
Xiaoyu Chen, Meiyi Song, Wei Chen, Jasmina Dimitrova-Shumkovska, Yingying Zhao, Yan Cao, Yang Song, Wenzhuo Yang, Fei Wang, Yang Xiang, Changqing Yang
Medical Science Monitor.2016; 22: 83. CrossRef
The Role of IL-1 Family Members and Kupffer Cells in Liver Regeneration
Quanhui Tan, Jianjun Hu, Xiaolan Yu, Wen Guan, Huili Lu, Yan Yu, Yongsheng Yu, Guoqiang Zang, Zhenghao Tang
BioMed Research International.2016; 2016: 1. CrossRef
An updated systematic review of the evolution of ALPPS and evaluation of its advantages and disadvantages in accordance with current evidence
Yu-Long Cai, Pei-Pei Song, Wei Tang, Nan-Sheng Cheng
Medicine.2016; 95(24): e3941. CrossRef
Prediction of postoperative liver regeneration from clinical information using a data-led mathematical model
Kimiyo N. Yamamoto, Masatsugu Ishii, Yoshihiro Inoue, Fumitoshi Hirokawa, Ben D. MacArthur, Akira Nakamura, Hiroshi Haeno, Kazuhisa Uchiyama
Scientific Reports.2016;[Epub] CrossRef
Functional comparison of human embryonic stem cells and induced pluripotent stem cells as sources of hepatocyte-like cells
Jaemin Jeong, Kyu Nam Kim, Min Sung Chung, Han Joon Kim
Tissue Engineering and Regenerative Medicine.2016; 13(6): 740. CrossRef

16,469 View
229 Download
52 Web of Science
Crossref

Viral hepatitis

Management of viral hepatitis in liver transplant recipients: Soung Won Jeong, YoungRok Choi, Jin-Wook Kim; Clin Mol Hepatol 2014;20(4):338-344.
Published online December 24, 2014; DOI: https://doi.org/10.3350/cmh.2014.20.4.338

Abstract
PDF

Recurrence of viral hepatitis after liver transplantation (LT) can progress to graft failure and lead to a decrease in long-term survival. Recently, there have been remarkable improvement in the treatment of chronic hepatitis B (CHB) using potent antiviral agents. Combination of hepatitis B immunoglobulin and potent antiviral therapy has brought marked advances in the management of CHB for liver transplant recipients. Post-transplant antiviral therapy for hepatitis C virus infection is generally reserved for patients showing progressive disease. Acheiving a sustained virological response in patients with LT greatly ameliorates graft and overall survival, however this only occurs in 30% of transplant recipient using pegylated interferon and ribavirin (RBV). Direct acting antivirals such as protease inhibitors, polymerase or other non-structural proteins inhibitors are anticipated to establish the new standard of care for transplant recipients. In liver transplant recipients, hepatitis E virus infection is an uncommon disease. However, it can lead to chronic hepatitis and cirrhosis and may require retransplantation. Recently, 3-month course of RBV monotherapy has been reported as an effective treatment. This review focuses on the recent management and therapeutic approaches of viral hepatitis in liver transplant recipient.

Citations

Citations to this article as recorded by

Hepatitis E in post‐liver transplantation: is it time to routinely consider it?
Brian B. Borg, Zongdi Feng, Truman M. Earl, Christopher D. Anderson
Clinical Transplantation.2016; 30(9): 975. CrossRef
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus
Neal Patel, Kian Bichoupan, Lawrence Ku, Rachana Yalamanchili, Alyson Harty, Donald Gardenier, Michel Ng, David Motamed, Viktoriya Khaitova, Nancy Bach, Charissa Chang, Priya Grewal, Meena Bansal, Ritu Agarwal, Lawrence Liu, Gene Im, Jennifer Leong, Leona
World Journal of Gastroenterology.2016; 22(9): 2844. CrossRef
Antigenic composition and immunoreactivity differences between HEV recombinant capsid proteins generated from different genotypes
Nouredine Behloul, Jiyue Wen, Xing Dai, Chen Dong, Jihong Meng
Infection, Genetics and Evolution.2015; 34: 211. CrossRef

11,900 View
82 Download
3 Web of Science
Crossref

Original Article

Liver Transplantation

Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation: Hyeyoung Kim, Nam-Joon Yi, Juyeun Lee, Joohyun Kim, Mi-Ra Moon, Jaehong Jeong, Jeong-Moo Lee, Tae Suk You, Suk-Won Suh, Min-Su Park, YoungRok Choi, Geun Hong, Hae Won Lee, Kwang-Woong Lee, Kyung-Suk Suh; Clin Mol Hepatol 2014;20(3):291-299.
Published online September 25, 2014; DOI: https://doi.org/10.3350/cmh.2014.20.3.291

Abstract
PDF

Background/Aims

The dose of mycophenolate mofetil (MMF) has been reduced in Asia due to side effects associated with the conventional fixed dose of 2-3 g/day. We aimed to determine the pharmacokinetics of a reduced dose of MMF and to validate its feasibility in combination with tacrolimus in living-donor liver transplantation (LDLT).

Methods

Two sequential studies were performed in adult LDLT between October 2009 and 2011. First, we performed a prospective pharmacokinetic study in 15 recipients. We measured the area under the curve from 0 to 12 hours (AUC_0-12) for mycophenolic acid at postoperative days 7 and 14, and we performed a protocol biopsy before discharge. Second, among 215 recipients, we reviewed 74 patients who were initially administered a reduced dose of MMF (1.0 g/day) with tacrolimus (trough, 8-12 ng/mL during the first month, and 5-8 ng/mL thereafter), with a 1-year follow-up. We performed protocol biopsies at 2 weeks and 1 year post-LDLT.

Results

In the first part of study, AUC_0-12 was less than 30 mgh/L in 93.3% of cases. In the second, validating study, 41.9% of the recipients needed dose reduction or cessation due to side effects within the first year after LDLT. At 12 months post-LDLT, 17.6% of the recipients were administered a lower dose of MMF (0.5 g/day), and 16.2% needed permanent cessation due to side effects. The 1- and 12-month rejection-free survival rates were 98.6% and 97.3%, respectively.

Conclusions

A reduced dose of MMF was associated with low blood levels compared to the existing recommended therapeutic range. However, reducing the dose of MMF combined with a low level of tacrolimus was feasible clinically, with an excellent short-term outcome in LDLT.

Citations

Citations to this article as recorded by

Large-Scale Real-World Monitoring of Mycophenolic Acid Exposure in Liver Transplantation: Impact of Bayesian Dose Adjustment
Marc Labriffe, Hamza Sayadi, Jean-Baptiste Woillard, Ludovic Micallef, Franck Saint-Marcoux, Alexandre Destere, Pierre Marquet, Caroline Monchaud
Therapeutic Drug Monitoring.2025;[Epub] CrossRef
A Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Tacrolimus and Corticosteroids in Combination With or Without Mycophenolate Mofetil in Liver Transplantation Recipients Infected With Hepatitis B Virus
Jeong-Ik Park, Gi-Won Song, Je Ho Ryu, Sang-Tae Choi, Nam-Gyu Choi, Bo-Hyun Jung, Chong Woo Chu, Keon-Kuk Kim, Dong-Hwan Jung, Tae-Yong Ha, Deok-Bog Moon, Kwangho Yang, Min-Ho Shin, Yong-Kyu Chung, Shin Hwang, Young-In Yoon, Sung-Gyu Lee
Transplantation Proceedings.2023; 55(2): 387. CrossRef
Evaluation of a Weight-Based Mycophenolate Mofetil Dosing Protocol for Kidney Transplant Maintenance Immunosuppression
Melanie Tess Mahoney, Elisabeth Lapp Kincaide, Joelle Nelson, Kelsey Anne Klein, Reed Charles Hall, Suverta Bhayana
Journal of Clinical Nephrology.2023; 7(2): 047. CrossRef
Evaluation of the efficacy and safety of conversion from the tacrolimus capsule to tablet in stable liver transplant recipients with maintenance therapy: a 24-week, open-label, single-center, phase IV exploratory clinical study
Jae-Yoon Kim, Sukyoung Chang, Jiyoung Kim, Hyun Hwa Choi, Jaewon Lee, Su young Hong, Jeong-Moo Lee, Suk Kyun Hong, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh
Annals of Surgical Treatment and Research.2023; 105(4): 228. CrossRef
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Stein Bergan, Mercè Brunet, Dennis A. Hesselink, Kamisha L. Johnson-Davis, Paweł K. Kunicki, Florian Lemaitre, Pierre Marquet, Mariadelfina Molinaro, Ofelia Noceti, Smita Pattanaik, Tomasz Pawinski, Christoph Seger, Maria Shipkova, Jesse J. Swen, Teun van
Therapeutic Drug Monitoring.2021; 43(2): 150. CrossRef
Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation
Poh Seng Tan, Mark D. Muthiah, Tsingyi Koh, Yee Leong Teoh, Albert Chan, Alfred Kow, Qishi Zheng, Choon Hyuck David Kwon, Guan Huei Lee, Cosmas Rinaldi A. Lesmana, Vanessa de Villa, James Fung, Kieron Lim
Transplantation.2019; 103(3): 470. CrossRef
Early Onset Polymorphic Post-transplant Lymphoproliferative Disease Mimicking a Solitary Necrotizing Abscess in a Graft Liver
Pil Soo Sung, Jaejun Lee, Joon Lee, Hee Chul Nam, Si Hyun Bae, Seung Kew Yoon
Journal of Liver Cancer.2019; 19(2): 165. CrossRef
Efficacy and Safety of Generic Mycophenolate Mofetil (My-rept) 500-Milligram Tablets in Primary Liver Transplant Recipients
S.K. Hong, K.-W. Lee, K.C. Yoon, H.-S. Kim, H. Kim, N.-J. Yi, K.-S. Suh
Transplantation Proceedings.2017; 49(6): 1402. CrossRef
Types and Structure of Complications, and Causes of Mortality with Different Combinations of Immunosuppressants in Patients of Undergoing Organ Transplantation
Zhamalbek Ashimov, Zhanybek Gaibyldaev
Heart, Vessels and Transplantation.2017; 1(Issue 2): 61. CrossRef
Risk Factors for the Adverse Events after Conversion from Twice-Daily to Once-Daily Tacrolimus in Stable Liver Transplantation Patients
Suk-Won Suh, Kwang-Woong Lee, Jaehong Jeong, Hyeyoung Kim, Nam-Joon Yi, Kyung-Suk Suh
Journal of Korean Medical Science.2016; 31(11): 1711. CrossRef
Mycophenolate-mofetil

Reactions Weekly.2015; 1566(1): 164. CrossRef

14,736 View
105 Download
6 Web of Science
Crossref

Case Reports

Improved severe hepatopulmonary syndrome after liver transplantation in an adolescent with end-stage liver disease secondary to biliary atresia: Tae Jun Park, Keun Soo Ahn, Yong Hoon Kim, Hyungseop Kim, Ui Jun Park, Hyoung Tae Kim, Won Hyun Cho, Woo-Hyun Park, Koo Jeong Kang; Clin Mol Hepatol 2014;20(1):76-80.
Published online March 26, 2014; DOI: https://doi.org/10.3350/cmh.2014.20.1.76

Abstract
PDF

Hepatopulmonary syndrome (HPS) is a serious complication of end-stage liver disease, which is characterized by hypoxia, intrapulmonary vascular dilatation, and liver cirrhosis. Liver transplantation (LT) is the only curative treatment modality for patients with HPS. However, morbidity and mortality after LT, especially in cases of severe HPS, remain high. This case report describes a patient with typical findings of an extracardiac pulmonary arteriovenous shunt on contrast-enhanced transesophageal echocardiography (TEE), and clubbing fingers, who had complete correction of HPS by deceased donor LT. The patient was a 16-year-old female who was born with biliary atresia and underwent porto-enterostomy on the 55th day after birth. She had been suffered from progressive liver failure with dyspnea, clubbing fingers, and cyanosis. Preoperative arterial blood gas analysis revealed severe hypoxia (arterial O₂ tension of 54.5 mmHg and O₂ saturation of 84.2%). Contrast-enhanced TEE revealed an extracardiac right-to-left shunt, which suggested an intrapulmonary arteriovenous shunt. The patient recovered successfully after LT, not only with respect to physical parameters but also for pychosocial activity, including school performance, during the 30-month follow-up period.

Citations

Citations to this article as recorded by

Outcomes of liver transplantation in patients with hepatopulmonary syndrome in the pre and post-MELD eras: A systematic review
Catarina Aragon Pinto, Vivek N. Iyer, Hasan Ahmad Hasan Albitar, Alexandra Anderson, Hector Cajigas, Douglas A. Simonetto, Michael J. Krowka, Hilary M. DuBrock, Alice Gallo de Moraes
Respiratory Medicine and Research.2021; 80: 100852. CrossRef
Hepatopulmonary syndrome is related to the development of acute-on-chronic liver failure and poor prognosis in cirrhotic patients
Seul Ki Han, Moon Young Kim, Seong Hee Kang, Ki Tae Suk, Soon Koo Baik
Hepatology International.2021; 15(5): 1207. CrossRef
Impact of Bacterial Translocation on Hepatopulmonary Syndrome: A Prospective Observational Study
Ki Tae Suk, Moon Young Kim, Soung Won Jeong, Jae Young Jang, Yoon Ok Jang, Soon Koo Baik
Digestive Diseases and Sciences.2018; 63(1): 248. CrossRef

11,670 View
76 Download
3 Web of Science
Crossref

Liver Transplantation

Liver transplantation for acute-on-chronic liver failure from erythropoietic protoporphyria: Pyoung-Jae Park, Shin Hwang, Young-Il Choi, Young-Dong Yu, Gil-Chun Park, Sung-Won Jung, Sam-Youl Yoon, Gi-Won Song, Tae-Yong Ha, Sung-Gyu Lee; Korean J Hepatol 2012;18(4):411-415.
Published online December 21, 2012; DOI: https://doi.org/10.3350/cmh.2012.18.4.411

Abstract
PDF

Erythropoietic protoporphyria (EPP) is an inherited disorder of the heme metabolic pathway that is characterized by accumulation of protoporphyrin in the blood, erythrocytes, and tissues, and cutaneous manifestations of photosensitivity, all resulting from abnormalities in ferrochelatase (FECH) activity due to mutations in the FECH gene. Protoporphyrin is excreted by the liver, and excess protoporphyrin leads to cholelithiasis with obstructive episodes and chronic liver disease, finally progressing to liver cirrhosis. Patients with end-stage EPP-associated liver disease require liver transplantation. We describe here a 31-year-old male patient with EPP who experienced acute-on-chronic liver failure and underwent deceased-donor liver transplantation. Surgical and postoperative care included specific shielding from exposure to ultraviolet radiation to prevent photosensitivity-associated adverse effects. The patient recovered uneventfully and was doing well 24 months after transplantation. Future prevention and treatment of liver disease are discussed in detail.

Citations

Citations to this article as recorded by

Machine learning-based plasma metabolomics for improved cirrhosis risk stratification
Jingru Song, Ziwei Gao, Liqun Lai, Jie Zhang, Binbin Liu, Yi Sang, Siqi Chen, Jiachen Qi, Yujun Zhang, Huang Kai, Wei Ye
BMC Gastroenterology.2025;[Epub] CrossRef
Treatment strategy for erythropoietic protoporphyria accompanied by severe abdominal pain and liver injury
Xiaoxin Wu, Xiumei Zhou, Shuai Zhao, Keting He, Wenxin Zhoudi, Shangci Chen, Xiaowei Xu
Portal Hypertension & Cirrhosis.2024; 3(1): 36. CrossRef
Liver involvement in patients with erythropoietic protoporphyria: retrospective analysis of clinicopathological features of 5 cases
Chang Zhao, Jie-Xia Guan, Da-Yang Hui, Na-Na Zhang, Li-Rong Lu, Lu-Ying Tang, Chun-Kui Shao, Jian-Ning Chen
Annals of Diagnostic Pathology.2022; 56: 151859. CrossRef
Reappraisal of liver transplantation for erythropoietic protoporphyria: A deadly combination of disease recurrence and biliary complication
Yutaka Endo, Taizo Hibi, Masahiro Shinoda, Hideaki Obara, Minoru Kitago, Hiroshi Yagi, Yuta Abe, Yasushi Hasegawa, Kentaro Matsubara, Shutaro Hori, Masayuki Tanaka, Satomi Makiuchi, Yutaka Nakano, Osamu Itano, Tatsuo Kuroda, Yuko Kitagawa
Pediatric Transplantation.2022;[Epub] CrossRef
Surgical treatment for breast cancer in a patient with erythropoietic protoporphyria and photosensitivity: a case report
Akiko Shimazaki, Takuma Hashimoto, Masaya Kai, Tetsuzo Nakayama, Mai Yamada, Karen Zaguirre, Kentaro Tokuda, Makoto Kubo, Ken Yamaura, Masafumi Nakamura
Surgical Case Reports.2021;[Epub] CrossRef
Perioperative management of a bleeding jejunal tumor in a patient with erythropoietic protoporphyria
Yuki Takemoto, Shoichiro Mukai, Tetsuya Mochizuki, Masatoshi Kochi, Hiroyuki Egi, Hideki Ohdan
International Journal of Surgery Case Reports.2019; 60(C): 191. CrossRef
Current and innovative emerging therapies for porphyrias with hepatic involvement
Antonio Fontanellas, Matías A. Ávila, Karl E. Anderson, Jean-Charles Deybach
Journal of Hepatology.2019; 71(2): 422. CrossRef
Liver metabolomics in a mouse model of erythropoietic protoporphyria
Pengcheng Wang, Madhav Sachar, Grace L. Guo, Amina I. Shehu, Jie Lu, Xiao-bo Zhong, Xiaochao Ma
Biochemical Pharmacology.2018; 154: 474. CrossRef
Cimetidine/lactulose therapy ameliorates erythropoietic protoporphyria-related liver injury
Naoyuki Fujimori, Michiharu Komatsu, Naoki Tanaka, Mai Iwaya, Hajime Nakano, Ayumi Sugiura, Tomoo Yamazaki, Soichiro Shibata, Yugo Iwaya, Takashi Muraki, Yuki Ichikawa, Takefumi Kimura, Satoru Joshita, Takeji Umemura, Akihiro Matsumoto, Eiji Tanaka
Clinical Journal of Gastroenterology.2017; 10(5): 452. CrossRef
Les porphyries héréditaires : anomalies du métabolisme de l’hème
K. Peoc’h, C. Martin-Schmitt, N. Talbi, J.-C. Deybach, L. Gouya, H. Puy
La Revue de Médecine Interne.2016; 37(3): 173. CrossRef
Porphyrias: A 2015 update
Zoubida Karim, Said Lyoumi, Gael Nicolas, Jean-Charles Deybach, Laurent Gouya, Hervé Puy
Clinics and Research in Hepatology and Gastroenterology.2015; 39(4): 412. CrossRef

12,149 View
90 Download
Crossref

Review

Acute Liver failure in Korea: etiology, prognosis and treatment: Young Suk Lim; Korean J Hepatol 2010;16(1):5-18.
Published online March 26, 2010; DOI: https://doi.org/10.3350/kjhep.2010.16.1.5

Abstract
PDF

Acute liver failure (ALF) is a rare condition in which rapid deterioration of liver function results in altered mentation and coagulopathy in individuals without previously recognized liver disease. The outcomes of patients with ALF vary greatly according to etiology, and the etiology of ALF varies markedly by geographical region. In Korea, about 90% of ALF are associated with etiologies that usually result in poor outcomes, including hepatitis B virus (HBV) infection and herbal remedies. The main causes of death in patients with ALF are increased intracranial pressure, systemic infection, and multi-organ failure. Recent advances in the intensive care of patients with ALF have contributed to a marked improvement in their overall survival. Emergency adult to adult living-donor liver transplantation (LDLT) can be performed expeditiously and safely for patients with ALF, and greatly improves survival rate as well as deceased-donor transplantation. As the window during which transplantation is possible is limited, emergency adult LDLT should be considered to be one of the first-line treatment options in patients with ALF, especially in regions in which ALFs are caused by etiologies associated with poor outcome and the supply of organs is very limited. (Korean J Hepatol 2010;16:5-18)

Citations

Citations to this article as recorded by

Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation
Dong-Sik Kim, Young-In Yoon, Beom Kyung Kim, Ashok Choudhury, Anand Kulkarni, Jun Yong Park, Jongman Kim, Dong Hyun Sinn, Dong Jin Joo, YoungRok Choi, Jeong-Hoon Lee, Ho Joong Choi, Ki Tae Yoon, Sun Young Yim, Cheon-Soo Park, Deok-Gie Kim, Hae Won Lee, Wo
Hepatology International.2024; 18(2): 299. CrossRef
Epidemiology of liver failure in Asia‐Pacific region
Ankur Jindal, Shiv K. Sarin
Liver International.2022; 42(9): 2093. CrossRef
Bleeding complications associated with the molecular adsorbent recirculating system: a retrospective study
Seon Woo Yoo, Min-Jong Ki, Dal Kim, Seul Ki Kim, SeungYong Park, Hyo Jin Han, Heung Bum Lee
Acute and Critical Care.2021; 36(4): 322. CrossRef
Analysis of Medical Use and Costs of Liver Transplant Patients Using National Patients Sample Data
Hye-Lin Kim
Korean Journal of Clinical Pharmacy.2018; 28(1): 57. CrossRef
Hemostasis based on a novel ‘two-path unifying theory’ and classification of hemostatic disorders
Jae C. Chang
Blood Coagulation & Fibrinolysis.2018; 29(7): 573. CrossRef
An Aggressive Natural Killer Cell Lymphoma Presenting as Acute Liver Failure with Ascites
Jong Ho Lee, Tae-Hoon Oh, Ji Young Park, Tae Joo Jeon, Seung Suk Baek, Tae Hwan Ha, Sung Eun Park
The Korean Journal of Medicine.2016; 90(1): 32. CrossRef
Living Donor Liver Transplantation in a Hepatitis B Patient with Acute on Chronic Liver Failure Accompanying Hepatocellular Carcinoma
Hee Jin Hong, Joo Ho Lee, Yun Bin Lee, Hana Park, Seong Gyu Hwang, Kyu Sung Rim
The Ewha Medical Journal.2016; 39(3): 76. CrossRef
Understanding Acute Liver Failure– A Basic Overview of Definition and Treatment
Yeonjung Ha, Young-Suk Lim
The Korean Journal of Medicine.2015; 89(6): 672. CrossRef
The Analysis of Prognostic Factors Affecting Survival in Liver Transplantation: A Single Institution Experience
Sung Won Park, Gil Jae Lee, Sang Tae Choi, Yeon Ho Park, Jung Nam Lee, Keon Kuk Kim
Korean Journal of Transplantation.2014; 28(4): 211. CrossRef
Perioperative risk factors for prolonged mechanical ventilation after liver transplantation due to acute liver failure
Serin Lee, Hyun Sik Jung, Jong Ho Choi, Jaemin Lee, Sang Hyun Hong, Sung Hyun Lee, Chul-Soo Park
Korean Journal of Anesthesiology.2013; 65(3): 228. CrossRef
Massive hepatic necrosis with large regenerative nodules
Haeryoung Kim, Young Nyun Park
The Korean Journal of Hepatology.2010; 16(3): 334. CrossRef

7,947 View
140 Download
Crossref

Original Article

Clinical features of patients with fulminant hepatitis A requiring emergency Liver transplantation: comparison with acute Liver failure due to other causes: Jin Dong Kim, M.D., Jong Young Choi, M.D., Chung-Hwa Park, M.D., Myeong Jun Song, M.D., Jeong Won Jang, M.D., Si Hyun Bae, M.D., Seung Kew Yoon, M.D., Young Sok Lee, M.D., Young Kyoung You, M.D.1, Dong Goo Kim, M.D.1; Korean J Hepatol 2010;16(1):19-28.
Published online March 26, 2010; DOI: https://doi.org/10.3350/kjhep.2010.16.1.19

Abstract
PDF

Background/Aims
According to recent prevalence of hepatitis A virus (HAV) infection, acute liver failure ALF) due to HAV infection is observed frequently in parallel. The aim of this study was to elucidate the clinical, laboratory, and pathologic features of patients who have undergone emergency liver transplantation (LT) due to fulminant HAV infection. Methods: Clinical, laboratory, and pathologic data of 11 transplant recipients with anti-HAV IgM-positive ALF between December 2007 and May 2009 were analyzed, and compared with data of 10 recipients who underwent LT for the management of ALF due to other causes. Results: The median age of the patients with HAV-related ALF was 34 years (range: 15-43 years). The levels of hemoglobin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine were higher and the level of bilirubin was lower in the HAV-related ALF group than in the other group (P=0.005, 0.001, 0.001, 0.010, and 0.003, respectively). The time from the onset of initial symptoms to the development of encephalopathy was shorter in the HAV-related ALF group than in the other group (median 5 days, range: 4-13 days; P<0.001). In patients with HAV-related ALF, laboratory findings and clinical prognostic parameters including the Acute Liver Failure Study Group prognostic index, King`s College criteria, and model for endstage liver disease (MELD) and Child-Pugh scores were not associated with the grade of hepatic encephalopathy or time of progression to encephalopathy. Conclusions: The results of this study indicate that the clinical condition of patients with HAV-related ALF requiring emergency LT aggravates rapidly. Prognostic parameters are not sufficient for discriminating transplant candidates in patients with fulminant hepatitis A. (Korean J Hepatol 2010;16:19-28)

Citations

Citations to this article as recorded by

Severity of the clinical presentation of hepatitis A in five European countries from 1995 to 2014
Ettore Severi, Leonidas Georgalis, Roan Pijnacker, Lamprini Veneti, Iulia Adelina Turiac, Flaminia Chiesa, Caterina Rizzo, Domenico Martinelli, Line Vold, Bernardo Guzman Herrador, Carmen Varela Martinez, Elena Vanessa Martinez Sanchez, Jan C. Semenza, Pi
International Journal of Infectious Diseases.2022; 118: 34. CrossRef
Epidemiology of liver failure in Asia‐Pacific region
Ankur Jindal, Shiv K. Sarin
Liver International.2022; 42(9): 2093. CrossRef
Hepatitis A in children: evaluation of atypical manifestations
Derya Kalyoncu, Nafiye Urganci, Seda Geylani Gulec
Paediatrica Indonesiana.2020; 60(5): 239. CrossRef
Challenges in Management of Hepatitis A Virus Epidemiological Transition in Mexico
Jorge L. Trujillo-Ochoa, Oliver Viera-Segura, Nora A. Fierro
Annals of Hepatology.2019; 18(1): 14. CrossRef
Update on Clinical and Epidemiological Features of Viral Hepatitis A
Nada Lahmidani
Gastroenterology & Hepatology: Open Access.2016;[Epub] CrossRef
Usefulness of B-mode and doppler sonography for the diagnosis of severe acute viral hepatitis A
Sang Wook Shin, Tae Yeob Kim, Woo Kyoung Jeong, Yongsoo Kim, Jinoo Kim, Young Hwan Kim, Hwan Cheol Park, Joo Hyun Sohn
Journal of Clinical Ultrasound.2015; 43(6): 384. CrossRef
Prognostic Indicators for Acute Liver Failure Development and Mortality in Patients with Hepatitis A: Consecutive Case Analysis
Hye Sun Shin, Sae Pyul Kim, Sang Hoon Han, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Chae Yoon Chon, Jun Yong Park
Yonsei Medical Journal.2014; 55(4): 953. CrossRef
Genotypic shift of the hepatitis A virus and its clinical impact on acute hepatitis A in Korea: a nationwide multicenter study
Ji Hoon Kim, Jong Eun Yeon, Soon Koo Baik, Young Seok Kim, Hong Soo Kim, Sang Hoon Park, Myung-Seok Lee, Joo Hyun Sohn, Jin-Woo Lee, Sung Kyu Choi, So Young Kwon, Jong Young Choi, Ju Hyun Kim, Soon Young Kang, Hyonggin An, Yeon Seok Seo, Hyung Joon Yim, J
Scandinavian Journal of Infectious Diseases.2013; 45(11): 811. CrossRef
Comparative analysis of disease severity between genotypes IA and IIIA of hepatitis A virus
Young Kyung Yoon, Jong Eun Yeon, Ji Hoon Kim, Hee Sun Sim, Jeong Yeon Kim, Dae Won Park, Jang Wook Sohn, Byung Chul Chun, Min Ja Kim
Journal of Medical Virology.2011; 83(8): 1308. CrossRef

7,107 View
113 Download
Crossref

Current status of hepatic surgery in Korea: Kyung Sik Kim; Korean J Hepatol 2009;15(60):60-64.
Published online December 31, 2009; DOI: https://doi.org/10.3350/kjhep.2009.15.S6.S60

Citations

Citations to this article as recorded by

Surgical treatment of hepatocellular carcinoma: an expert consensus-based practical recommendation from the Korean Liver Cancer Association
Min-Su Park, Jai Young Cho, Eunju Kim, Hee Young Na, YoungRok Choi, Na Reum Ki, Young-In Yoon, Boram Lee, Eun Sun Jang, Yun Kyung Jung, Kyung Sik Kim
Annals of Surgical Treatment and Research.2025; 109(3): 123. CrossRef
Surgical treatment of hepatocellular carcinoma: an expert consensus-based practical recommendation from the Korean Liver Cancer Association
Min-Su Park, Jai Young Cho, Eunju Kim, Hee Young Na, YoungRok Choi, Na Reum Kim, Young-In Yoon, Boram Lee, Eun Sun Jang, Yun Kyung Jung, Kyung Sik Kim
Journal of Liver Cancer.2025; 25(2): 140. CrossRef
A Comparative Analysis of Hepatocellular Carcinoma after Hepatic Resection in Young versus Elderly Patients
Cho Rok Lee, Jin Hong Lim, Sung Hoon Kim, Sang Hoon Ahn, Young Nyun Park, Gi Hong Choi, Jin Sub Choi, Kyung Sik Kim
Journal of Gastrointestinal Surgery.2012; 16(9): 1736. CrossRef

5,548 View
26 Download
Crossref

Current status of Liver diseases in Korea: Toxic and alcoholic Liver diseases: Kyung Ah Kim; Korean J Hepatol 2009;15(60):29-33.
Published online December 31, 2009; DOI: https://doi.org/10.3350/kjhep.2009.15.S6.S29

Citations

Citations to this article as recorded by

Understanding exosomes: Part 2—Emerging leaders in regenerative medicine
Richard J. Miron, Nathan E. Estrin, Anton Sculean, Yufeng Zhang
Periodontology 2000.2024; 94(1): 257. CrossRef
The potential diagnostic and therapeutic applications of exosomes in drug-induced liver injury
Lanlan Zhao, Yuezhi Wang, Yu Zhang
Toxicology Letters.2021; 337: 68. CrossRef
Harmful algal blooms and liver diseases: focusing on the areas near the four major rivers in South Korea
Seungjun Lee, Jinnam Kim, Boseung Choi, Gijung Kim, Jiyoung Lee
Journal of Environmental Science and Health, Part C.2019; 37(4): 356. CrossRef
Complications Requiring Hospital Admission and Causes of In-Hospital Death over Time in Alcoholic and Nonalcoholic Cirrhosis Patients
Hee Yeon Kim, Chang Wook Kim, Jong Young Choi, Chang Don Lee, Sae Hwan Lee, Moon Young Kim, Byoung Kuk Jang, Hyun Young Wo
Gut and Liver.2016; 10(1): 95. CrossRef
Genetic variants in ERBB4 is associated with chronic hepatitis B virus infection
Yao Liu, Qun Zhou, Xiao-Shun He, Li-Ming Song, Lin Chen, Wei-Juan Jiao, Tong Shen, Su Yao, Hua Wu, Zhi-Bin Hu, Tian-Ming Gao, Jian-Ming Li
Oncotarget.2016; 7(4): 4981. CrossRef
Improvement of liver function by the administration of oyster extract as a dietary supplement to habitual alcohol drinkers: A pilot study
KENJI OSAKI, YOSHIO SHIMIZU, TETSURO YAMAMOTO, FUMIHARU MIYAKE, SUMIO KONDO, HIDEYO YAMAGUCHI
Experimental and Therapeutic Medicine.2015; 10(2): 705. CrossRef
Iron deficient erythropoiesis might play key role in development of anemia in cancer patients
Silvia Park, Chul Won Jung, Kihyun Kim, Seok Jin Kim, Won Seog Kim, Jun Ho Jang
Oncotarget.2015; 6(40): 42803. CrossRef
Non-invasive diagnosis of alcoholic liver disease
Sebastian Mueller
World Journal of Gastroenterology.2014; 20(40): 14626. CrossRef
Elevated post‐transfusion serum transaminase values associated with a highly significant trend for increasing prevalence of anti‐Vesivirus antibody in Korean patients
Heetae Lee, You‐Hee Cho, Jeong Su Park, Eui‐Chong Kim, Alvin W. Smith, GwangPyo Ko
Journal of Medical Virology.2012; 84(12): 1943. CrossRef
Use of Oral Hypoglycemic Agents in Type 2 Diabetic Patients with Hepatic Dysfunction
Ki Young Lee
Journal of Korean Diabetes.2011; 12(4): 190. CrossRef
Prevalence of Alcoholic Liver Disease Among Korean Adults: Results From the Fourth Korea National Health and Nutrition Examination Survey, 2009
Seung Ha Park, Chang Hoon Kim, Dong Joon Kim, Jong Ha Park, Tae Oh Kim, Sung Yeun Yang, Young Soo Moon, Tae Nyun Kim, Hyun Kuk Kim, Ha Young Park, Jung Goo Lee, Heon Young Lee
Substance Use & Misuse.2011; 46(14): 1755. CrossRef
Genetic polymorphism at codon 10 of the transforming growth factor-β1 gene in patients with alcoholic liver cirrhosis
Jong Joon Lee, Soo Kyung Park, Oh Sang Kwon, In Sik Won, Dong Kyu Kim, Young Kul Jung, Yang Suh Ku, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim
The Korean Journal of Hepatology.2011; 17(1): 37. CrossRef

6,740 View
63 Download
Crossref

Case Reports

Four patients with hepatitis A presenting with fulminant hepatitis and acute renal failure and who underwent Liver transplantation: Se Hoon Oh , Joon Hyoek Lee , Ji Won Hwang , Hye Young Kim , Chang Hoon Lee , Geum Youn Gwak , Moon Seok Choi , Kwang Chul Koh , Seung Woon Paik , Byung Chul Yoo; Korean J Hepatol 2009;15(3):362-369.
Published online September 30, 2009; DOI: https://doi.org/10.3350/kjhep.2009.15.3.362

Abstract
PDF

Hepatitis A is generally known as a mild, self-limiting disease of the liver, but in rare instances it can progress to fulminant hepatitis, which may require liver transplantation for recovery. Such cases are known to be related to old age and underlying liver disease. We report four cases of hepatitis A in which patients presented with fulminant hepatitis and acute renal failure and underwent liver transplantation. The following common features were observed in our cases: (1) occurrence in relatively old age (≥39 years old), (2) association with acute renal failure, (3) presence of hepatomegaly, and (4) microscopic features of sub-massive hepatic necrosis. (Korean J Hepatol 2009;15:362-369)

Citations

Citations to this article as recorded by

Case Report for Severe Hepatitis A Treated in a Korean Hospital
Sul-Ki Kim, Cheon-Hoo Jeon, Nam-Heon Lee, Jung-Hyo Cho, Chang-Gue Son
Journal of Korean Medicine.2020; 41(4): 100. CrossRef
Hepatitis A in children: evaluation of atypical manifestations
Derya Kalyoncu, Nafiye Urganci, Seda Geylani Gulec
Paediatrica Indonesiana.2020; 60(5): 239. CrossRef
Rhabdomyolysis and Mild Kidney Injury in a Patient with Acute Hepatitis A
Gu-Min Cho, Chang Wook Kim, Hyeonjin Seong, Joon Hur, Bu Seok Jeon, Jonghwan Lee, Eun-hui Sim, Seok Jong Lee, Chang Don Lee
Yeungnam University Journal of Medicine.2012; 29(1): 28. CrossRef
Acute Hepatitis A Complicated with Acute Kidney Injury
Ja Kyung Kim, Yong Han Paik, Kwan Sik Lee
The Korean Journal of Gastroenterology.2010; 56(6): 391. CrossRef
Clinical Features and Predictive Factors of Acute Hepatitis A Complicated with Acute Kidney Injury
Jin Hee Lee, Moon Seok Choi, Geum Yeon Gwak, Joon Hyoek Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo
The Korean Journal of Gastroenterology.2010; 56(6): 359. CrossRef
Epidemiology and clinical features of acute hepatitis A: from the domestic perspective
Young Kul Jung, Ju Hyun Kim
The Korean Journal of Hepatology.2009; 15(4): 438. CrossRef

5,569 View
40 Download
Crossref

Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation: Byung Kook Kim, M.D., So Young Kwon, M.D., Soon-Young Ko, M.D., Won Hyeok Choe, M.D., Chang Hong Lee, M.D., He-Seong Han, M.D.1, Seong-Hwan Chang, M.D.2; Korean J Hepatol 2008;14(4):519-524.
Published online December 31, 2008; DOI: https://doi.org/10.3350/kjhep.2008.14.4.519

Abstract
PDF

Fibrosing cholestatic hepatitis (FCH) is the most devastating manifestation of recurrent hepatitis C in transplant recipients with hepatitis C virus (HCV), possibly leading to death or retransplantation. Although FCH was first described as a complication of hepatitis B, this manifestation has been well documented in association with HCV in the setting of liver transplantation, bone marrow transplantation, heart transplantation, and end-stage human immunodeficiency virus infection. We report the clinical course and antiviral response in a patient with FCH due to recurrent hepatitis C after cadaveric liver transplantation who was treated with pegylated interferon α-2a and ribavirin. (Korean J Hepatol 2008;14:519-524)

Citations

Citations to this article as recorded by

Folate-Polyethylene Glycol Conjugated Near-Infrared Fluorescence Probe with High Targeting Affinity and Sensitivity for In Vivo Early Tumor Diagnosis
Fei Liu, Dawei Deng, Xinyang Chen, Zhiyu Qian, Samuel Achilefu, Yueqing Gu
Molecular Imaging and Biology.2010; 12(6): 595. CrossRef

5,759 View
23 Download
Crossref

Original Article

Clinical Outcome after Living Donor Liver Transplantation in Patients with Hepatitis C Virus-associated Cirrhosis: Jeong-Ik Park, M.D.1, Kun-Moo Choi, M.D.2, Sung-Gyu Lee, M.D.1, Shin Hwang, M.D.1, Ki-Hun Kim, M.D.1, Chul-Soo Ahn, M.D.1, Deok-Bog Moon, M.D.1, Young-Hwa Chung, M.D.3, Yung-Sang Lee, M.D.3, Dong-Jin Suh, M.D.3; Korean J Hepatol 2007;13(4):543-555.
Published online December 20, 2007; DOI: https://doi.org/10.3350/kjhep.2007.13.4.543

Abstract
PDF

Background/Aims
Hepatitis C virus (HCV)-associated cirrhosis is an increasingly frequent indication for liver transplantation (LT). However, HCV recurrence is universal and this immediately occurs following LT, which endangers both the graft and patient survival. We investigated the frequency of posttransplant recurrence of HCV infection and the patient-graft survival, and we analyzed the responses to ribavirin and interferon therapy in the patients with recurrent HCV infection after living donor liver transplantation (LDLT). Methods: We retrospectively reviewed the clinical outcomes of 39 HCV-associated cirrhosis patients who underwent LDLT at Asan Medical Center between August 1992 and June 2006. In this study, the diagnosis of recurrent HCV was made on the basis of increased transaminases and serum HCV RNA levels greater than 10 million IU/mL because protocol liver biopsy was not performed. Results: HCV recurrence was seen in 26 of the 39 LDLT patients (66.7%). 86.7% of recurrence occurred within the first postoperative year. Antiviral treatment was used for all patients with recurrence of HCV. None of the 10 patients receiving ribavirin alone and 9 of 16 patients who received combination therapy with pegylated interferon alpha-2a plus ribavirin became HCV RNA negative and they remained persistently negative during the median follow-up of 24.9 months. Our data indicates that there is no significant factor influencing HCV recurrence except for the recipient`s age. The 2-year patient survival for the HCV patients with HCC and those patients without HCC were 81.2% and 81.3%, respectively (P=0.85) and the 2-year graft survival rates were 81.2% and 68.2%, respectively (P=0.29). No patient died from HCV recurrence during the follow-up period. Conclusions: Combination therapy with ribavirin and interferon appears to improve the outcome of recurrent HCV infected patients after LDLT. (Korean J Hepatol 2007;13:543-555)

Citations

Citations to this article as recorded by

Current Status and Perspectives of Living Donor Liver Transplantation
Shin Hwang, Deok-Bog Moon, Sung-Gyu Lee
Journal of the Korean Medical Association.2008; 51(8): 700. CrossRef
Review: Clinical Outcome after Living Donor Liver Transplantation in Patients with Hepatitis C Virus-associated Cirrhosis
Hyung Joon Kim
The Korean Journal of Hepatology.2007; 13(4): 489. CrossRef

5,931 View
17 Download
Crossref

First

Page of 2

Last

Page Path

"Liver transplant"

Article category

Keywords

Publication year

Article category

Keywords

Publication Year

Funded articles

"Liver transplant"

Research Letter

Correspondences

Liver Transplantation

Liver Transplantation

Editorial

Liver Transplantation

Letter to the Editor

Liver Transplantation

Review

Liver Transplantation

Original Article

Liver Transplantation

Review

Original Article

Liver Transplantation

Editorial

Steatotic liver disease

Reviews

Hepatic neoplasm

Steatotic liver disease

Snapshot

Review

Liver fibrosis, cirrhosis, and portal hypertension

Original Article

Review

Snapshot

Liver Transplantation

Review

Hepatic neoplasm

Editorial

Hepatic neoplasm

Original Articles

Liver Transplantation

Liver Transplantation

Liver Transplantation

Review

Liver fibrosis, cirrhosis, and portal hypertension

Editorial

Liver fibrosis, cirrhosis, and portal hypertension

Reviews

Liver Transplantation

Hepatic neoplasm

Original Article

Liver Transplantation

Review

Alcohol-related liver disease

Original Article

Liver Transplantation

Editorial

Liver Transplantation

Reviews

Alcohol-related liver disease

Autoimmune liver disease

Original Article

Liver Transplantation

Case Report

Benign liver tumors and cystic disease of liver

Original Article

Liver Transplantation

Liver Imaging

Liver fibrosis, cirrhosis, and portal hypertension

Original Article

Viral hepatitis

Reviews

Alcohol-related liver disease

Liver development and regeneration

Viral hepatitis

Original Article

Liver Transplantation

Case Reports